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Summary
Pregnancy-induced hypertension (PIH) is still a major cause of obstetrical and 
perinatal morbidity and mortality, and no breakthrough has yet been achieved in the 
understanding of its pathogenesis. The present in vitro work studied the 
pathogenesis of PIH in three aspects: immunology, antioxidants and prostaglandins 
using various immunological, biochemical and molecular genetic methods.
An increased cellular immunological activity was detected in patients with PIH, 
especially in those with proteinuria, as the proliferation of peripheral blood 
mononuclear cells (PBMC) with PHA stimulation and without mitogens was 
increased and the IL-2 activity was elevated compared to normotensive pregnant 
women. The hypersecretion of IgG from B lymphocytes was also found in patients 
with PIH. The increased immunological activity is in accordance with some 
important changes seen in PIH, such as an increased intracellular calcium, the 
presence of a blood-borne mitogenic factor and a decreased prostaglandin E series. 
These findings support the hypothesis that PIH may result from the imbalance 
between fetal antigenic load and maternal production of immunological blockage.
Intracellular (lysate thiol, lysate glutathione and lysate superoxide dismutase (SOD) 
in red blood cells) and extracellular (plasma thiol, plasma glutathione and red blood 
cell membrane thiol) antioxidant buffering levels were investigated in patients with 
PIH and both of them were decreased in the patients, suggesting an occurrence of 
increased reactive oxygen species (ROS) activity in this disorder. It was also found 
that there were significant positive correlations between the levels of prostaglandins 
and andoxidant activity. It was possible that the changes of prostaglandin production 
resulted from the imbalance of decreased andoxidant buffering levels and increased 
ROS formation in PIH. The cause of the decreased andoxidant levels in PIH is not 
clear. However the reduced SOD (CuZn) activity seems to be an acquired 
phenomenon since its gene structure and expression in PIH did not differ from that in 
normal subjects.
Production of prostacyclin (PGI2) and thromboxane A2 (TXA2) in mononuclear 
cells was determined in patients with PIH and the effects of PIH serum on this 
production were investigated. The results showed that the imbalance of decreased 
PGI2 and increased TXA2 production occurred in mononuclear cells from PIH 
patients and thus the ratio of TXA2 to PGI2 was increased. Serum from PIH patients 
with proteinuria slightly reduced PGI2 synthesis in normal pregnant women but
X VII
markedly increased TXA2 production, producing a ratio of TXA2 to PGI2 similar to 
that found in PIH. This result suggested that there was a factors) in serum from PIH 
patients with proteinuria to contribute, at least in part, to the imbalance between 
PGI2 and TXA2 seen in PIH.
PIH and essential hypertension in pregnancy have an important clinical feature in 
common, high blood pressure, however, the cause of this remains unclear. The 
immunological markers and the antioxidant agents were evaluated in both diseases. 
The results showed that immunological changes found in PIH did not occur in 
essential hypertension in pregnancy. Antioxidant agents were decreased in both 
diseases, however the types of antioxidants involved were different There results 
suggested that different pathogenetic mechanisms may associated with these two 
disorders.
The effects of antihypertensive drugs (atenolol, labetalol, methyldopa  ^nifedipine and 
nimodipine) on antioxidants were also studied and the results indicated that atenolol 
and labetalol in vitro possessed some antioxidant activity as they can significantly 
raise the levels of plasma thiol and membrane thiol. The other three drugs were not 
found to have any antioxidant property.
Taken together, the work in this thesis suggests that the cause of PIH is complicated 
and multifactorial. The disorder occurred in the immune system might be an 
important factor in triggering the development of PIH. The immunological 
maladaptation could lead to the imbalance between antioxidant levels and ROS 
activity. The balance of PGI2 and TXA2 was shifted to the TXA2 dominance and 
tins change could contribute to many if not all of the pathophysiological features 
found in PIH. The decreased antioxidants and increased ROS activity may damage 
enthothelial cells and cause an imbalance of PGI2 and TXA2 production, and thus it 
forms the link between the immune system and endothelial dysfunction.
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CHAPTER ONE GENERAL INTRODUCTION
1.1 PIH----------A Review
1.1.1 The Early References
It is difficult to say who first discovered pregnancy-induced hypertension (PIH). The 
signs and symptoms of this fascinating disease were mentioned in the ancient 
Egyptian, Chinese, Indian and Greek medical literatures and but were not 
differentiated from epilepsy (Chesley 1974). However, Chesley (1974) believes that 
it was the ancient Greeks (before the time of Hippocrates) who provided the first 
bona fide documentation of recognizing PIH as a separate disease. There are two 
relevant aphorisms in the Cona Prognosis: "In pregnancy drowsiness with headache 
accompanied by heaviness and convulsions is generally bad."; "In pregnancy the 
onset of drowsy headaches and heaviness is bad; such cases are perhaps liable to 
some sort of fits at the same time".
In 1694, Mauriceau (1694) attributed gestational convulsions to irritation of the 
uterine cervix and in cases of fetal death, to noxious vapours arising in the uterus. 
He did not make a clear distinction between epilepsy and PIH, but his specification 
of causes suggests that he had recognized a difference. He also set forth several 
quotations dealing with convulsion in pregnancy. Among them were: No. 229, 
"Primigravidas are at far greater risk of convulsions than are multiparas."; No. 230, 
"convulsions during pregnancy are more dangerous than those beginning after 
delivery.". Mauriceau (1694) observed that the convulsions often cease with 
delivery and he recommended prompt termination of pregnancy as the best 
treatment.
It was not until 1739 that De Sauvages differentiated epilepsy from convulsions of 
acute cause, which he called "eclampsia" (Chesley 1978). However, it was soon 
followed by the confusion of PIH with nephritis, which lasted for more than a 
century. Lever (1843) discovered the proteinuria of PIH when he looked for it 
because the clinical picture of PIH resembled that of glomerulonephritis. He also 
noted that eclamptic proteinuria abated quickly after delivery and concluded that PIH 
was a different disease, but others were not so astute. To them, PIH still meant renal 
disease which was confused with essential hypertension at that time. Corwin & 
Herrick (1927) made a major contribution in recognizing essential hypertension as a 
frequent component of the hypertensive disorders in pregnancy and as the usual form
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of hypertension found at follow-up. Herrick and Tillman (1936) wrote: "When 
these are fully delineated it is our opinion that we shall find nephritis concerned in 
but a small fraction of the toxemias; that the larger number, including the eclampsia, 
the preeclampsia, and the variously designated milder types of late toxemia will be 
found to have unit characteristics based upon cardiovascular disease with 
hypertension.". Since then, obstetricians gradually realized that PIH is often
mistaken for essential hypertension and renal disease.
1.1.2 Incidence and Epidemiology
The incidence of PIH has been variously given as 2.6% to 15% by different centres 
(Roberts 1984; Saftlas et al. 1990; DHSS 1991). However, it is believed that in the 
Western world, PIH affects 5% to 10% of all pregnancies.
PIH is predominantly a disease of primigravid patients (about 75% of all cases). 
When PIH affects multiparous patients it is usually superimposed upon essential 
hypertension, or less often is associated with one of the features described below.
1. Twin pregnancies: Twin pregnancies are especially prone to be complicated 
by PIH, the incidence being increased by two or three times, or even more 
(Scholtes 1975).
2. Diabetes: Diabetic women are at increased risk for developing PIH during 
pregnancy. A study by Gamer et al. (1990) concluded that PIH is twice as 
common in diabetic pregnancies compared with normal controls. The 
incidence of PIH in diabetic patients is even higher if the glycemic levels are 
not well controlled (Siddiqi et al. 1991).
3. Hydatidiform mole: The greatest increase in incidence occurs in cases of 
hydatidiform mole, in which up to 50% of pregnancies may show evidence of 
PIH (Studd 1977).
Race seems to be a significant factor associated with PIH. Black women have been 
shown to be at greater risk for developing PIH (Chesley et al. 1984). They have a 
higher incidence of essential hypertension than white women and the increased risk 
of PIH in the black may be due to mistaking essential hypertension for PIH and thus 
including those with essential hypertension into the PIH group (Chesly et al. 1984). 
Recently, a case-control study, however, excluded that the increased susceptibility 
for PIH in black women can be explained by the inclusion of patients with essential 
hypertension (Eskenazi et al. 1991).
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Although the incidence of PIH is not related to socioeconomic status (Eskenazi et al.
1991), women working during pregnancy have a significantly higher rate of PIH than 
those not working (Marcoux et al. 1989; Klebanoff et al. 1990). It is postulated that 
pregnant women who work may be more stressed and have different levels of 
physical activities than those who do not work.
Young pregnant women are more susceptible to PIH (Cunningham et al. 1989). 
Saftlas et al. (1990) found that teenagers were at significantly higher risk than 
women 25 to 34 years of age. However, a recent study (Eskenazi et al. 1991) cast 
some doubt on this as it was observed that the increased incidence of PIH in 
teenagers disappeared when parity was controlled for.
Cigarette-smoking is hazardous to the fetus, however, it is paradoxically associated 
with a reduced incidence of PIH, as is alcohol consumption (Eskenazi et al. 1991). 
Adelstein and Fedrick (1980) found that smokers had a lower average pre-pregnant 
weight than the non-smokers. This difference in weight might account for the 
different observed incidences of PIH in different smoking status because heavy-set 
women tend to develop PIH (Chesley 1984). Another explanation for this is that 
smoking and drinking women appear to have lower blood pressure than abstainers 
(Friedman et al. 1982). Although tobaco and alcohol consumption may tend to 
protect against PIH, the well-known risk of both of these agents to the fetus 
outweighs the slight benefit
1.1.3 Classification, Definition and Diagnosis
In reviewing the literature on hypertension in pregnancy, one often faces two 
problems. One is the inconsistency in the classification used to categorize it  
Another is that there are different criteria used to define PIH or the degree of it
1. Classification
There are a multitude of classifications used to categorize high blood pressure during 
gestation. It is reported that there are more than 60 names in English and 40 in 
German to describe PIH (Davey & MacGillivray 1986). For example, gestational 
hypertension, gestational proteinuric hypertension, gestosis, pregnancy-associated 
hypertension, pregnancy-induced hypertension and toxemia are among the terms 
used to describe PIH. The National High Blood Pressure Working Group (1990) 
recommended the approach proposed in 1972 by the American College of
3
Obstetricians and Gynecologists (Hughes 1972), which is still the most concise and 
practical of all current classifications. This schema classifies the following four 
categories of hypertension associated with pregnancy.
1. Pregnancy-induced hypertension
1. Preeclampsia
a. mild
b. severe
2. Eclampsia
n. Chronic hypertension (of whatever cause)
m . Chronic hypertension with superimposed PIH
1. Superimposed preeclampsia
2. Superimposed eclampsia 
IV. Late, or transient hypertension
2. Definition
In the above classification, PIH falls into two categories: preeclampsia and 
eclampsia. Preeclampsia is defined as hypertension induced by pregnancy after 20 
weeks' gestation, concurrent with proteinuria or edema or both. It defines 
hypertension as a diastolic pressure of at least 90 mmHg, a systolic pressure of at 
least 140 mmHg, or a rise from baseline of 15 mmHg diastolic pressure or 30 mmHg 
systolic pressure. The elevated blood pressure reading must occur on at least two 
occasions at least 6 hours apart Eclampsia, a severe complication of PIH, is defined 
as the occurrence of convulsions unrelated to coincidental neurologic disease in a 
woman with PIH.
3. Diagnosis
The diagnostic criteria used by Klonoff-Cohen et al. (1989), which is based on the 
American College of Obstetricians and Gynecologists (1986) (Table 1.1) is more 
pratical and better one.
1.1.4 Pathophysiology
1. Hypertension
Blood pressure readings in women with PIH are characteristically labile and are 
often associated with a reversal of the circadian blood pressure rhythms that 
normally occur in pregnant and non-pregnant populations, i.e. morning peaks and 
nocturnal nadirs. In PIH, the rhythm may be abolished or even reversed, with the 
highest levels occuring at night (Mumaghan et al. 1980; Cunningham & Lindheimer
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1992). This labile blood pressure reflects the intense sensitivity of the vasculature to 
endogenous pressor hormones and autacoids and represents a reversal of the marked 
refractory state to the pressor effects of angiotensin II characteristic of normal 
pregnancy (Aalkjaer et al. 1985). The increased vascular sensitivity is all the more 
remarkable because it occurs while circulating catecholamines remain unaltered and 
angiotensin II levels may even decrease (Aalkjaer et al. 1985; Davision & 
Lindheimer 1988).
The cause of the increased pressor responsiveness in PIH is obscure, but research in 
two areas show promise. One popular hypothesis is the imbalance between 
vasoconstrictor prostaglandins (mainly TXA2) and vasodilating prostaglandins 
(mainly PGI2). A relative or absolute decrease in prostagladin I or E series results in 
the development of hypertension in pregnancy (Walsh 1985; Friedman 1988). 
Another hypothesis is vascular endothelial cell dysfunction (Roberts et al. 1991). 
Endothelial cell injury can cause alterations of several circuiting substances 
including mitogenic factors, endothelin and serotonin, which lead to vasoconstriction 
and hypertension (Musci et al. 1988; Weiner 1990; Schiff et al. 1992).
2. Renal Dysfunction
Glomercular filtration rate (GFR) decreases in women with PIH, but because GFR is 
normally higher in pregnancy, values may still be at or above non-pregnant levels. 
Decrease in GFR is partly due to a characteristic renal lesion that involves swelling 
of the intracapillary glomerular cell termed glomerular endotheliosis (Fisher et al.
1981; Gaber et al. 1987). The increased protein excretion almost always
accompanies glomerular endotheliosis. Urate clearance also decreases, and often to 
a greater degree than does GFR; thus, hyperuricemia can be an early indication of 
PIH. The ability to excrete sodium is also decreased, but the degree to which this
occurs varies and severe disease can occur in the absence of edema "dry PIH"
(Lindheimer & Katz 1992). The underlying pathophysiology responsible for these 
changes may be vasospasm and an increased permeability to large molecules such as 
albumin.
3. Cardiovascular and Hematologic Changes
a. Blood Volume
One of the most significant pathophysiologic changes in PIH is substantial 
hemoconcentration (Lindheimer & Katz 1992). By approximately 34 weeks, the 
normal pregnant woman has expanded her blood volume by about 40% to 50%
6
above the non-pregnant level (Pritchard 1965). In contrast, women with PIH 
manifest a decrease in blood volume (Cunningham & Pritchard 1978).
b. Cardiac
A wide variety of hemodynamic changes has been noted in women with PIH. Before 
treatment, it appears that cardiac output ranges from normal to a hyperdynamic state, 
that systemic vascular resistance is increased, and that both central venous pressure 
and pulmonary capillary wedge pressure are normal to low (Cunningham et al. 
1989).
c. Hematologic
The major hematologic change seen in some women with PIH is thrombocytopenia 
(Cunningham et al. 1989). Other relatively uncommon hematologic abnormalities 
include overt hemolysis, elevated fibrin-degradation products, decreased plasma 
fibrinogen, and a protracted thrombin time. Intense vasospasm may induce 
endothelial damage (Pritchard et al. 1976). The endothelial injury exposes the
underlying vascular basement membrane, resulting in platelet adherence and fibrin
deposition. Platelets are decreased and red blood cells are tom and fragmented in 
these fibrin plugs. This process has termed "microangiopathic hemolytic anemia" 
(Cunningham & Pritchard 1978).
d. Placental Perfusion
A major pathophysiological event in PIH is a decrease in uteroplacental perfusion 
(Kaar et al. 1980; Lunell et al. 1984). Worley et al. (1975) reported that the 
placental clearance rate of dehydroisoandrosterone sulfate was initially increased in 
women who were destined to develop hypertension, but perfusion was uniformly 
decreased by the time overt hypertension developed. Others (Everett et al. 1980; 
Fritz et al. 1985) confirmed that the placental clearance rate of this hormone 
accurately reflected maternal placental perfusion. The causes of poor uteroplacental 
perfusion in PIH are unclear. However, it is believed that the causes have a key role 
in the pathogenesis of PIH (Stirrat 1987; Walsh 1990).
e. Calcium Metabolism— Hypocalciuria
Although research on calcium metabolism in PIH has attracted less attention than on 
the other fields, some recent findings (Belizan et al. 1988; Belizan et al. 1991; 
Sanchez-Ramos et al. 1991) have suggested that calcium may have a role in the 
development of gestational hypertension. Calcium metabolism during pregnancy is 
characterized by minor changes in the serum levels of total and ionized calcium; 
whereas urinary calcium excretion increases markedly during normal pregnancy 
(Gertner et al. 1986). Serum calcium levels in PIH appear no different from the 
values in normotensives, but urinary calcium excretion is considerably reduced 
(Sanchez-Ramos et al. 1991). Intracellular calcium concentrations in erythrocytes
7
and platelets were reported to be higher in women with PIH (Haller et al. 1989; 
Sowers et al. 1989). The cell's responsiveness to pressure stimuli is increased by a 
high concentration of intracellular calcium (Belizan et al. 1991). Thus, the increased 
intracellular calcium could be a factor which contributes to the high blood pressure 
seen in PIH.
There is evidence that hypocalciuria in PIH may be due to increased distal tubular 
reabsorption of calcium (Taufield et al. 1987). Belizan et al. (1991) observed that a 
decreased incidence of PIH occurred in pregnant women who received calcium 
supplements. They postulated that a high calcium intake increased levels of serum 
calcium, lowered parathyroid hormone concentrations, decreased renal calcium 
reabsorption (i.e. increased urinary calcium excretion), therefore, reduced 
intracellular calcium levels, and finally diminished cell responsiveness to pressure 
stimuli and lowered blood pressure.
1.1.5 Clinical Aspects
PIH occurs most often in nulliparous women, almost always after 20 weeks' 
gestation and more commonly towards term. It is associated with hypertension, 
proteinuria, edema, and at times, coagulation and/or liver function abnormalities 
(Sibai et al. 1982). Eclampsia is characterized by these abnormalities along with 
generalized convulsions. The signs and symptoms of PIH usually become apparent 
at a relatively late stage in pregnancy, often in the third trimester, whereas the 
underlying cause of the pathophysiologic mechanisms that are thought to be 
responsible for the disease process appears to occur much earlier in pregnancy, 
between 8 and 18 weeks' gestation (Robertson & Khong 1987). The occurrence of 
the signs and symptoms listed in Table 1.2 is particularly ominous.
Preeclampsia can progress rapidly to eclampsia, one of the most dramatic and life- 
threatening complications of pregnancy. Convulsions are usually preceded by 
premonitory symptoms and signs, including severe frontal or occipital headaches, 
epigastric pain, hyperreflexia, hemoconcentration and/or visual disturbance, but 
occasionally convulsions appear suddenly and without warning in an asymptomatic 
woman known only to have mild hypertension. There is also a variant of the disease 
whose clinical appearance may be misleading, because patients begin with minimal 
elevations in blood pressure and liver enzymes, a small decrease in platelet counts, 
and little or no renal dysfunction. Such patients, however, may progress rapidly to a 
life-threatening syndrome characterized by hemolysis and marked signs of liver
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dysfunction, as well as coagulation abnormalities. This uncommon form of PIH, 
called HELLP syndrome (Hemolysis, Elevated liver enzymes, and Low Platelet 
count), requires prompt termination of the pregnancy (Killam et al. 1975; Sibai et al. 
1986).
PIH typically regresses rapidly after delivery, and its signs and symptoms usually 
abate within 48 hours. Occasionally, late postpartum eclampsia, characterized by 
hypertension, proteinuria, and convulsions, occurs within 10 days after delivery 
(Brown et al. 1987; Sibai 1988).
1.1.6 Treatment
The aims of treatment should be to protect the mother from an excessive rise in 
blood pressure, and prevent the disease progressing to eclampsia or other maternal 
complications. Risks to the fetus should be minimised and it should be delivered by 
the easiest, safest way when the risks of continuing the pregnancy outweigh the risks 
of delivery. Undue delay for fetal reasons has been criticised as a cause of maternal 
mortality (DHSS 1991).
1. Prophylaxis
Although prophylaxis of PIH is difficult since there is currently no suitable 
predictive test for it, several approaches to preventing PIH have been recommended, 
including salt restriction, prophylactic diuretic therapy, calcium supplements and 
low-dose aspirin (Brown 1990).
It is questionable if restriction of salt or diuretic therapy has any beneficial effect on 
the prevention of PIH and some researchers have suggested that dietary salt 
restriction or prophylactic use of diuretics is unnecessary (Zuspan 1978; Collins et 
al. 1985).
The idea of supplemental calcium results from the facts that there is an inverse 
relation between calcium intake and the degree of PIH and calcium supplementation 
lowers blood pressure in both pregnant and non-pregnant women (Villar et al. 1983 
and 1987). Furthermore, several studies have demonstrated that pregnant women 
who receive calcium supplemantation after the 20th week of pregnancy have a 
reduced risk of PIH (Lopez-Jaramillo et al. 1990; Villar & Repke 1990; Belizan et 
al. 1991).
10
The use of aspirin in prevention or treatment of PIH was first proposed by Goodlin et 
al. (1978). He reported that a patient with recurrent PIH seemed to benefit from 
aspirin. Since then growing evidence has demonstrated that low-dose aspirin (60 to 
81 mg per day) reduces the incidence of PIH (Wallenbury et al. 1986; Bcnigni et al. 
1989; Walsh 1990). Aspirin irreversibly acetylates cyclooxygenase, reducing cyclic 
endoperoxide synthesis from arachidonic acid, and decreasing production of both 
PGI2 and TXA2. Interestingly, if aspirin is used in lower doses, it only selectively 
inhibits platelet cyclooxygenase, reducing TXA2 synthesis without inhibiting 
endothelial cell synthesis of PGI2. An alternative explanation for this selective 
inhibition of cyclooxygenase is related to the pharmoldnetics of low-dose apsirin. 
Absorption of non-ionized aspirin occurs in the stomach. Aspirin is then hydrolysed 
to salicylic acid in the liver so that platelets passing through the portal circulation are 
exposed to a higher concentration of aspirin than endothelial cells in the systemic 
circulation. The lower concentration of aspirin in the systemic circulation may be 
insufficient to inhibit endothelial cell cyclooxygenase activity. Recently, Walsh et 
al. (1992) proposed another hypothesis for the selective inhibition of aspirin. 
Platelets, which are the main productive site of TXA2, have a limited life span of 
only 8 to 10 days and do not have a nucleus. Therefore once platelet cyclooxygenase 
is inhibited, it is inhibited for the life span of the platelet On the other hand, 
endothelial cells, which are the main productive site of PGI2 do have a nucleus and 
so can resynthesize cyclooxygenase after inhibition by aspirin. After a single dose of 
aspirin platelet TXA2 production is suppressed for 2 days and only gradually 
recovers (Burch et al. 1978), but endothelial cell production of PGI2 completely 
recovers within 36 hours (Jaffe & Weksler 1979).
2. Management
If the diagnosis of PIH is suspected, hospitalization should be considered 
(Cunningham et al. 1989) and the intervention required depends upon stage of 
gestation and disease severity. Management is outlined in Table 1.3.
The antihypertensive agents most frequently used in the management of PIH are 
listed in Table 1.4. At present there is no good evidence that any one of these drugs 
is preferable to another (Collins & Wallenburg 1989). The drug of choice is the one 
with which the obstetrician is most familiar and of which the maternal and fetal side 
effects are best understood.
11
Table 1.3 The management of PIH*
Clinical Condition Therapy
A. PIH when the fetus is mature Definitive:
1. Prevent convulsions
2. Control blood 
pressure
3. Deliver
B. PIH when the fetus is pre­ Definitive:
mature but there is 1. Prevent convulsions
1. Severe preclampsia or superim- 2. Control blood
pressure posed preclampsia 3. Deliver
2. Fetal growth retardation
3. Fetal jeopardy
4. Thrombocytopenia, liver
dysfunction, progressive renal 
dysfunction and premonitory 
signs of eclampsia
C. Eclampsia, whether the fetus Definitive:
is mature or premature 1. Treat convulsions
2. Control blood 
pressure
3. Stabilize mother
4. Deliver
D. PIH when the fetus is pre­ Expectant:
mature 1. Ambulatory
2. Hospitalization
* Modified from Gant N.F. & Worley R.J. (1980) . 
Hypertension in Pregnancy: Concepts and Management. New 
York: Appleton-Century-Crofts.
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1.1.7 Theories of Aetiopathogenesis
Outside the Chicago Lying-in Hospital the pedestal reserved for the person who 
establishes the cause of PIH remains vacant in spite of many avenues of research 
investigated by obstetricians and other scientists. Too many hypotheses or factors 
concerning the aetiology of PIH have been produced over the past century. In fact, 
the theories became so numerous that PIH was termed "the disease of theories", as 
Chesley (1971) has pointed out: "Everyone from allergist to zoologist has proposed 
hypotheses and suggested rational therapies based upon them, such as mastectomy, 
oophorectory, renal decapsulation, trephination, alignment of the patients with the 
earth's magnetic field with her head pointing to the earth's pole, and all sorts of 
medical regimens.".
A rational aetiologic hypothesis should develop from epidemiological, clinical or 
experimental observations. Here, some important facts associated with aetiologic 
considerations are listed in Table 1.5.
Taken together, it seems likely that PIH results from multiple aetiologic factors 
and/or interactions among them rather than a single one. The five most promising 
areas are immunological factors, antioxidant or reactive oxygen species (ROS) 
factors, eicosanoid factors, genetic factors and placental factors. Each of these is 
discussed in detail in the appropriate following section.
1.2 Immunological Factors
The concept that PIH may be an immunological disorder was first proposed in 1902. 
The hypothesis suggested that PIH reflected either a partial breakdown of the 
mechanisms responsible for the normal exemption of the immunological response 
directed against tissue- or organ-specific antigens associated with the placenta (Beer 
1988). Since then increasingly sophisticated investigations that have parallelled new 
developments in immunology have furthered our understanding of immunobiology 
in the maternal-placental interface and thereby this condition.
1.2.1 Evidence
The evidence supporting the concept that immunological components may play a 
role in the development of PIH is listed in Table 1.6.
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Table 1.6. Evidence supporting the Implication of Immune 
mechanisms In the pathogenesis of PIH
I. Conditions associated with increased incidence
1, Primigravid state
2, Increased trophoblastic mass
3, Pregnancies with a different partner
4, Previous use of a barrier contraceptive method
5, Pregnancies after oocyte donation
II. Conditions associated with decreased incidence
1, Previous pregnancy by same partner
2, Previous abortion
3, Previous frequent exposure to seminal fluid
4, Pregnancies after previous blood transfusions
5, Pregnancies after leucocyte immunization
6, Pregnancies in consanguineous marriages
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The demographic and epidemiologic studies indicate that the degree of unprotected 
coital exposure experienced by the mother-to-be prior to the first pregnancy may 
relate to her risk of developing PIH (Klonoff-Cohen et al. 1989). The greater the 
exposure to same semen (an allogeneic antigen for women), the less the likelihood 
that she will develop PIH. This type of reasoning is also supported by data that 
parity has a protective effect against the development of PIH (MacGillivray 1958; 
Campbell et al. 1985; Seidman et al. 1989), whereas, the risk of PIH increases when 
a multiparous woman is exposed to new or different paternal antigens (Feeney 1980; 
Serhal & Cragt 1987). A study of inbred communities also found that PIH was 
commoner when mother/conceptus immunogenetic disparity was greatest (Need 
1975). Feeney et al. (1977) studied the incidence of PIH in women who previously 
received blood transfusions and discovered that previous blood transfusions 
protected against its development, suggesting that it might be analagous to the 
beneficial effect of blood transfusions on renal allograft survival. Studies also 
indicated that the incidence of PIH was significantly lower after an induced abortion 
(1.70%) but not after a previous spontaneous abortion (2.33%) (Seidman et al. 1989). 
Taken together, there has been sufficient demographic and epidemiologic evidence 
to propose that immunological mechanisms are involved in the pathogenesis of PIH.
1.2.2 Immunological Maladaptation
Reproduction in an outbred population normally involves the mating of genetically 
different members of the same species. This results in intimate contact between cells 
which are allogeneic to one another. The maternal genital tract is exposed to male 
semen which contains spermatozoa and some mononuclear leukocytes bearing 
antigens of the male (Alexander & Anderson 1987; Wolff & Anderson 1988; 
Anderson & Hill 1989; Jassim 1990) and the conceptus which implants in the uterus 
expresses male-derived histocompatibility antigens against which the maternal 
immune system can react (Smith et al. 1978; Zuckermann & Head 1986; Billington 
& Burrows 1989). These alloantigens are particularly important during the first 
trimester and the early second trimester when uteroplacental vascular circulation is 
being established.
Extensive morphologic and physiologic changes take place in the uteroplacental 
vasculature which is necessary for the development of hemochorial placentation, 
characteristic of human pregnancy. These vascular changes are thought to be 
induced by the interaction of the fetal-derived trophoblasts with maternal tissues at 
the time of implantation. The human placenta receives its blood supply from
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numerous uteroplacental arteries which are developed by the action of migratory 
interstitial and endovascular trophoblasts into the walls of spiral arteries (Gerretsen 
et al. 1983; Hustin et al. 1983; Althabe et al. 1985). During normal pregnancy the 
arteries are eroded by the invading trophoblasts to such a great extent that entire 
portions of the spiral arteries in the endometrium and even into the myometrium are 
eliminated (Ramsey & Donner 1980). As a result of these trophoblast-induced 
changes, foreign fetal antigens that are expressed on these various trophoblast cells 
are directly exposed to maternal blood that contains both cellular and humoral 
immune factors. Therefore, the maternal ability to mount immune responses and 
react against non-self antigen, ie, the immunological tolerance between maternal and 
fetal tissues, is important and necessary for normal conception and placentation.
In PIH a state of imbalance between the ratio of maternal blocking antibodies 
(alloantibodies) and fetal antigenic load may occur. The antigenic dose presented by 
the trophoblast overwhelms the maternal immune system to such an extent that 
adequate immunological coexistence between host and graft is not achieved or, 
alternatively, that the immune-response genes governing the mother's immunological 
reactivity are not sufficiently stimulated to produce an adequate and effective 
immunological blockade to the fetal antigens presenting. Factors responsible for 
placental immunoprotection may be produced in insufficient levels to camouflage 
the invasive trophoblast and to restrain the reactivities of effector lymphocytes 
(effector blockade). This process can be termed 'immunological maladaptation'. It is 
tempting to propose that such immunological maladaptation results in a disturbance 
of trophoblast invasion in the spiral arteries, which are left with a non-pregnant 
architecture and fail to dilate (Robertson & Khong 1987).
Since the morphologic and physiologic changes in the maternal-placental interface 
occur at the time of the first trimester (Roberts et al. 1989; Zeeman et al. 1992), 
much earlier than the overt disease, the development of mutual immunological 
tolerance in the first and early second trimesters of pregnancy is thought to have a 
decisive effect on whether or not PIH occurs.
1.2.3 Major Histocompatibility Complex (MHQ and Cytokines
In fact, pre-implantation embryos and villous syncytiotrophoblasts do not express 
class I or class IIMHC antigenic determinants and syncytiotrophoblasts are covered 
by a highly charged sialomucin coat (Desoye et al. 1988; Lata et al. 1990). The 
covering of the syncytiotrophoblast surface with a sialomucin coat results in many of
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the other surface antigens being either hidden from recognition or impervious to 
immune attack. Only cells of the extravillous/spongiform trophoblast, which 
eventually come in direct contact with decidua, express a novel HLA (human 
leucocyte antigen), HLA-G (Ellis 1990). HLA-G is probably involved in some way 
in interactions with the cells in the decidua. Although the function of HLA-G is not 
completely understood, it may have another role in allowing recognition by maternal 
graft rejection effector cells. The lack of classical HLA expression by the 
trophoblasts precludes the possibility that maternal T cells, cytotoxic or helper, can 
respond directly to the trophoblasts, however, it may increase the susceptibility of the 
trophoblasts to nonadaptive immunity, for example, mediated by natural killer cells 
(Lijunggren & Kane 1990). Thus it is likely that the immune interaction between 
mother and fetus is more analogous to that of a host-tumor than host-graft 
relationship.
Placental cells especially decidua and placental villi have been found to be a source 
of several cytokines (Jaattela et al. 1988; Casey et al. 1989; Kauma 1989; Romero et 
al. 1989b, 1989c and 1990; Beikowitz et al. 1990; Dudley 1990). So far there is 
little knowledge on the direct implication of cytokines in the development of PIH. 
However, in view of the fact that some cytokines have the ability to stimulate local 
prostacyclin production (Romero et al. 1989a and 1989b; Mitchell 1991), it is 
reasonable to believe that cytokines may be involved in the development of PIH.
It is believed that the maternal decidua constitutes a distinct immunological 
microenvironment (Dudley 1990). Decidual cells have been shown to be a source of 
several cytokines such as IL-1, IL-3, TNF and granulocyte-macrophage colony 
stimulating factor (GM-CSFC) (Athanassakis et al. 1987; Wegmann 1987; Casey et 
al. 1989; Romero et al. 1989b; Dudley et al. 1990; Vince 1992). Cytokines could 
exert immunotrophic effects on the maternal-placental interface by acting to 
stimulate trophoblast growth (Wegmann 1988). According to this model, a deficient 
immune response could lead to subnormal levels of growth factors and in turn reduce 
the ability of trophoblasts to destroy the muscular layer and the autonomic 
innervation of the spiral arteries. Consequently, the spiral arteries are thicker, their 
lumens are narrower, their vascular tone is higher than the vessels of normal 
pregnancy, and blood flow through the uterus and into the intervillous space of the 
placenta is thus reduced (DeWolf 1975; Ramsey 1980; Gerretsen 1983; Lunell 
1984).
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1.2.4 Autoimmunity
While a major focus of the development of PIH has been on the maternal ability to 
mount immune responses and react against non-self antigens, autoimmunity needs to 
be considered. In fact, a number of investigators have suggested that some cases of 
PIH are associated with clinical autoimmune phenomena (Griffin & Wilson 1979; 
Foidart et al. 1986; Kochenour et al. 1987; Rote et al. 1987). Since the syncytial 
trophoblast is an immunologically privileged tissue, the focus of the immune attack 
by the effector cells or their products appears to be the placental cytotrophoblastic 
component of the arterioles that are physiologically and morphologically altered 
during placentation (Labarrere 1988). This autoreactive process may result in 
immune vasculitis pathognomonic of PIH and thus may play a role in contributing to 
the well-defined consequences: choriodecidual damage and liberation of tissue 
thromboplastin, fibrin, fibrinogen and the vasoactive mediators (including 
prostaglandins). To date abnormal levels of autoantibodies towards trophoblast 
antigens (Hytten & Brinton 1963; Bieglmayer et al. 1986), amniotic glycoprotein, 
placental and renal antigens (Gaugas & Curzen 1974), lymphocytes (Mekori et al. 
1981), laminin (Foidart et al. 1986), and endothelial cells (Rappaport et al. 1990) 
have been reported in the sera of women with PIH.
1.2.5 Complement and Immune Complexes
Circulating immune complexes may have some relevance in the tissue injury that 
occurs in PIH. Unfortunately, there is no agreement between different investigators 
on this issue (Masson et al. 1977; Stirrat et al. 1978; Gleicher and Theofilopoulos 
1979). Some workers have not detected immune complexes in either normal 
pregnant or PIH sera, whereas others have found increased concentrations in 
association with PIH (Redman & Sargent 1986; Haeger et al. 1991). The increase in 
immune complexes may have a role in stimulating macrophages and platelets to 
synthesize prostaglandins and also in inducing the release of cytokines and the 
production of ROS from monocytes (Hansch et al. 1987). Although there is some 
suggestions that complement activation and immune complexes are involved in the 
preeclamptic process, there is no direct evidence that any of these factors actually 
cause this condition. Clearly, more detailed investigations are needed.
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1.3 Reactive Oxygen Species (ROS)
ROS are also known as oxygen free radicals. However, because some biologically 
important oxidants are not radicals, for example, hydrogen peroxide, hypochlorous 
acid, ozone, singlet oxgen, it is appropriate to speak of ROS instead of oxygen free 
radicals.
ROS have played an essential role in the origin of aerobic life forms and radical 
reactions are an integral part of the homeostasis in cellular processes. The catalytic 
action of many cellular enzymes and energy producing electron transport processes 
involve one-electron transfers that produce reactive intermediate oxygen species. 
Molecular oxygen, present in all aerobic organisms, readily accepts electrons, 
resulting in the formation of ROS. ROS can become highly destructive to cells and 
tissues if their production is not tightly controlled.
1.3.1 Chemistry of Reactive Oxygen Species
The molecule of ROS has one or more unpaired electrons. Molecular oxygen (O2 ) 
has two unpaired electrons, each located in different orbitals. The reactivity of 
molecular oxygen is increased by the addition of a single electron, forming the 
superoxide anion (0 2“). Addition of a second electron produces the peroxide ion 
(0 22"). At physiologic pH, the peroxide ion will immediately be protonated to form 
hydrogen peroxide (H20 2). Hydrogen peroxide is also generated in aqueous 
solution by the spontaneous dismutation of the superoxide anion. While the 
superoxide anion and hydrogen peroxide are both ROS and are able to cause direct 
cellular damage, they are weak oxidants in aqueous solution. Their 
pathophysiologic significance relates to their ability to serve as substrates for the 
formation of the very reactive hydroxyl radical (*OH) (Wispe & Roberts 1987).
Fenton first proposed the existence of the hydroxyl radical in 1894 and suggested 
that it was formed as a product of oxidation of Fe2+ or other metals (Ti^+, Cu*+, 
Co2+) by hydrogen peroxide (Reaction 1.1):
Fe2+ + H20 2 ------------- > Fe3+ + • OH + OH" (Reaction 1.1)
The modified Fenton reaction includes the reduction of Fe3+ by superoxide anion in 
the two-step Haber-Weiss reaction (Reactions 1.2 and 1.3):
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Fe3* + 0 2" » Fe2+ + 0 2 (Reaction 1.2)
Fe2+ + H20 2 » Fe 3+ + *OH + OH ' (Reaction 1.3)
The Fenton or Haber-Weiss reactions are important because they provide 
mechanisms by which the limited reactivity of superoxide anion and hydrogen 
peroxide can be increased. The hydroxyl radical is highly reactive and capable of 
reacting with almost every type of cellular molecule.
ROS broadly have the following properties:
1. High reactivity with a consequent extremely short life span (measured in fis).
2. Self-perpetuating (autocatalytic) and diverse chemical reactivity.
3. Low chemical specifity.
4. Generated both in vivo and in vitro.
1.3.2 Possible Sources of ROS
It is now well established that ROS are continuously produced in vivo. There are two 
main sources of ROS: cellular and environmental (Table 1.7). Increased ROS levels 
have been documented in various diseases including PIH (Ishihara 1978; Maseki et 
al. 1981; Wickens et al. 1981; Dekker & Kraagenbrink 1991; Wang et al. 1992). 
There are several fundamental pathological changes in PIH which may contribute to 
the increased production of ROS.
1. Placental hypoxia
The spiral arteries in PIH fail to undergo a physiological change and can not become 
refractory to vasomotor agents (Brosens 1977; Ramsey & Donner 1980; Cooper et 
al. 1988). In addition, many vessels are occluded by fibrinoid material and exhibit 
adjacent foam cell invasion (atherosis) (Robertson & Khong 1987). The placental 
maladaptations would result in poor perfusion, placental hypoxia and concomitant 
placental damage. This concept is supported by the observations that a decrease in 
uteroplacental blood flow occurs in PIH (Kaar et al. 1980; Lunell et al. 1984) and 
that many of the ultrastructural changes of PIH placental tissue closely resemble 
alterations seen in placental tissue when placed in hypoxic organ culture (Tominaga 
& Page 1966; Fox 1970). Tissue hypoxia appears to be a promoting factor for ROS 
production (Figure 1.1). Poor perfusion or ischemia can lead to a rapid decrease in 
tissue ATP (Hems & Brosnan 1970) and a rise in the ATP degradation products
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Table 1.7 Sources of ROS in biological systems*
Sources Examples
Cellular Auto-oxidation Adrenaline
Dinucleotide
Flavin
Flavin adenine 
Melanin thiols 
Mononucleotide 
Reduced riboflavin
Metabolism Cell proliferation 
and activation
Eicosanoid metabolism
Endoplasmic reticulum 
oxidation
Enzymic activity
Mitochondrial electron 
transport
Phagocytosis
NADPH oxidase 
Xanthine oxidase
Environmental Cytotoxics Bleomycin
Doxorubicin
Drugs Halothane
Paracetamol
Pesticides
Photochemical air 
pollutants
Paraquat
Radiation 
Tobacco smoke
X-ray
Light
* Modified from Sinclair et al. (1990).
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Xanthine
dehydrogenase
Ca2+ protease
Xanthine oxidase
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Figure 1.1 Generation of ROS during tissue hypoxia and ischemia
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adenosine, inosine and hypoxanthine (Osswald et al. 1977; Miller et al. 1978). The 
loss of adenosine from cells by degradation during poor perfusion or ischemia is 
believed to result in the depletion of adenine nucleotides. The enzyme xanthine 
dehydrogenase normally catalyses the reaction (Reaction 1.4):
Hypoxanthine + H20  + NAD+ ----------> Xanthine + NADH + H+ (Reaction 1.4)
But in conditions of hypoxia, activation of a calcium-dependent protease induces a 
transformation of the enzyme leading to predominantly oxidase activity (Parks & 
Granger 1986). During hypoxia, xanthine oxidase will use any available oxygen as 
an electron acceptor and convert xanthine or hypoxanthine to uric acid, with the 
production of the superoxide radical. Superoxide radical and its reduction products, 
hydrogen peroxide and hydroxyl radical, can produce cellular injury through lipid 
peroxidation of mitochondrial, lysosomal and plasma membranes (Kellogg & 
Fridovich 1975). A role for the participation of ROS in injury during hypoxic insult 
has been found in the brain, heart and intestine of experimental animals (Flamm et 
al. 1978; Guamieri etal. 1980; Granger if  al. 1981; Kogure et al. 1982).
2. Arachidonic acid metabolism
Arachidonic acid metabolism through eicosanoid biosynthesis is accompanied by the 
generation of ROS (Figure 1.2). The first step in the biosynthesis of prostaglandins 
is the oxygenation of arachidonic acid to the hydroperoxy endoperoxide PGG2 
(Crawford 1983). This reaction is catalyzed by a heme-containing oxygenase, called 
cyclooxygenase, that requires no external source of electrons (Hemler et al. 1976; 
Miyamoto et al. 1976; Van der Ouderaa et al. 1977). The hydroperoxy group of 
PGG2 is reduced to a hydroxy group (PGH^ by a peroxidase that utilizes a wide 
variety of compounds to provide the requisite pair of electrons (Miyamoto et al. 
1976; Ogino et al. 1978) and this process produces a radical species (Ox) which has 
many of the properties of the hydroxyl radical, although it is known not to be this 
species.
An alternative pathway of arachidonate metabolism is an oxidation controlled by 
lipoxygenase enzymes. The fatty acid is converted into hydroperoxy derivatives 
(hydroperoxy eicosatetraenoic acids; HPETEs) which can readily be reduced to the 
corresponding hydroxy acids (HETEs) by glutathione peroxidase. The conversion of 
hydroperoxy derivatives to the hydroxy fatty acid yields oxygen radicals (Ox) 
(Figure 1.2), such as peroxy radical (Taylor & Morris 1983).
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Figure 1.2 Generation of ROS during eicosanoid metabolism
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There is evidence suggesting that both cyclooxygenase and lipoxygenase activities 
are changed in patients with PIH (Saeed & Mitchell 1983; Ogbum et al. 1984; Satoh 
et al. 1991; Walsh et al. 1992). Therefore, it is reasonable to consider eicosanoid 
metabolism as a possible source of ROS production in PIH.
3. Leukocytes
The superoxide anion is produced by activated neutrophils and macrophages. 
Oxygen uptake in activated neutrophils and macrophages is due to the action of a 
NADPH-oxidase complex associated with the plasma membrane, the electrons 
released on oxidation of NADPH reducing oxygen to superoxide radical as part of 
the "respiratory burst" (Babior 1978). During the respiratory burst, myeloperoxidase 
is released into the phagocytic vacuole and reacts with hydrogen peroxide to produce 
reactive byproducts including hypochlorous acid (Reactions 1.5 & 1.6), which can 
oxidise many biological molecules, especially reduced thiol groups (Babior 1978; 
Marietta 1989). For example, hypochlorous acid in low concentrations has been 
shown in vitro to inactivate rapid al-antiproteinase, the main inhibitor of proteolytic 
enzymes in extracellular fluids. The extent to which inactivation could occur in vivo 
depends on the environment of the neutrophil, as in plasma, hypochlorous acid reacts 
preferentially with albumin.
2H+ + 2 0 a' --------— ------ > H20 2 + O 2 (Reaction 1.5)
H20 2 + C f ) HOCl + OH~ (Reaction 1.6)
It has now been estabilshed that the development of PIH is associated with 
neutrophil activation as indicated by the increasing plasma levels of neutrophil 
elastase (Greer 1989 and 1991). The concentration of neutrophil elastase in human 
plasma is normally very low and independent of neutrophil count, thus, elevated 
levels reflect neutrophil activation and degranulation in vivo (Weissman et al. 1980; 
Janoff 1985).
1.3.3 Injury to Cells and Tissues
Among the major cellular and extracellular targets for ROS are proteins, unsaturated 
fatty acid components of lipids and lipoproteins, and DNA constituents including 
carbohydrates, as depicted in Table 1.8.
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Table 1.8 The major cellular targets for ROS
TARGET DAMAGE CONSEQUENCE
DNA scission on mutations;
deoxyribose ring; translational errors;
base damage; inhibition of
strand breaks; 
cross-linking.
protein synthesis.
PROTEIN aggregation & cross- modified ion
lonking; transport;
fragmentation increased calcium
Sc breakdown; influx; modified
modification of 
thiol groups.
enzyme activity.
POLY­ loss of unsaturation; altered lipid; flui­
UNSATURATED formation of reactive dity and membrane
metabolites (MDA and permeability;
4-HNE). effects on membrane- 
bound enzymes.
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1. Lipids
The phospholipid component of the cellular membrane is a highly vulnerable target 
due to the susceptibility of its polyunsaturated fatty acid sidechains to oxidative 
damage termed lipid peroxidation. This can lead to changes in the membrane 
permeability characteristics and its ability to maintain transmembrane ionic gradients 
(Slater 1984). The initiating ROS extracts a hydrogen atom from the carbon chain 
generating a lipid carbon-centered radical (L* Reaction 1.7). This lipid radical 
reacts with molecular oxygen to yield a hydroperoxyl radical (LOO*, Reaction 1.8) 
that can propagate the oxidizing chain reaction by abstracting electrons from other 
susceptible fatty acids to form another lipid radical and lipid hydroperoxide (LOOH, 
Reaction 1.9).
LH + *OH------------- > H20  + L* (Reaction 1.7)
L* + O2  ------------- > LOO* (Reaction 1.8)
LOO* + LH ------------- » LOOH + L* (Reaction 1.9)
In the presence of transition metals and metal complexes, particularly iron (Fe2+, 
Fe3*), hydroperoxides yield another series of reactive lipid species including alkoxyl 
radicals (LO*, Reaction 1.10) and peroxyl radicals (LOO*, Reaction 1.11). (O'Brien 
1969; Davies & Slater 1987).
LOOH + Fe2+-com p lex » LO* + Fe3+-com plex + OH* (Reaction
1. 10)
LOOH + Fe3+-com p lex  > LOO* + Fe2+-com plex + H+ (Reaction
1. 11)
Alkoxy and peroxyl radicals can initiate new rounds of lipid peroxidation and 
propagate further radical chain reactions thus amplifying the initial damage. 
Cleavage of the carbon bonds during lipid peroxidation reactions results in the 
formation of (Figure 1.3):
1), Alkanals, such as malondialdehyde, which interact with protein thiols, cross 
link amino groups of lipids and proteins and give rise to chromolipids and 
aggregated proteins (Tappel & Dillard 1981).
2), Alkenals, such as 4-hydroxy nonenal, which are very biologically active. 
They inhibit platelet aggregation, modify adenyl cyclase activity and are a 
substrate for glutathione transferases (Esterbauer 1985).
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3), Alkanes e.g. pentane, produced by this mechanism as an end-product of the 
oxidation of linoleic and arachidonic acid, and ethane from linolenic acid 
(Tappel & Dillard 1981).
The production of ROS leads to primary reactions (lipid peroxidation) which are 
close to the site of formation. Secondary products of such peroxidative events such 
as lipid peroxyl radicals and lipid hydroperoxides may diffuse in the plane of the 
membrane before reacting further, thereby spreading the biochemical lesion. Such 
processes therefore not only affect the structural and functional integrity of the 
membrane, its fluidity and permeability, but also the breakdown products of lipid 
peroxidation can further damage cellular function. Some lipid peroxidation products 
can escape from the membrane and cause disturbances at a distance. Therefore a 
reaction that originally produces a radical which interacts within its 
microenvironment may produce a sequence of later events that direct disturbances 
throughout the cell, its membrane and, in some instances into the extracellular 
domain.
Therefore, these lipid peroxidation reactions, once initiated, can result in chain 
reactions, with injuries at sites distant from the initial site of ROS generation (Wispe 
& Roberts 1987).
2. Protein
Proteins are susceptible to ROS injury through oxidation of their sulphydryl groups, 
which may alter protein structure or inactivate catalytic sites (Wolff et al. 1986). 
Oxidation reactions may also cause degradation or cross-linking of proteins into 
large aggregates. Oxidative modification of proteins also renders them more 
susceptible to proteolytic attack and enzymic hydrolysis (Davies 1987; Wolff et al. 
1986). Reactions of ROS with proteins also generate protein radical byproducts that 
can propagate the initial damage. Extracellular proteins with a large proportion of 
disulphide bridges (e.g. IgG or albumin) appear to be particularly vulnerable to 
hydroxyl and peroxy radical attack.
3. Nucleic acids
Nucleic acids are also susceptible to ROS-mediated alterations. It seems to be 
generally accepted to date that the hydroxyl radical is the main source of damage to 
DNA. Hydroxyl radical may penetrate the cell, thereby gaining access to DNA 
(Cochrane 1991). The hydroxyl radical damages DNA by hydroxylating the purine 
and pyrimidine bases and by scission, nicking, and cross-linking of DNA strands.
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Injury to cellular DNA (ROS-induced chromosomal aberrations) subsequently causes 
mutations, alterations in growth, and inhibition of protein synthesis (Schraufstatter et 
a l  1988).
1.3.4 Defence against ROS Antioxidants
Biological systems are continuously challenged by pro-oxidants which are either 
exogenously generated {e.g. directly from xenobiotics) or generated from 
endogenous sources such as phagocytes. In the normal course of events cells have 
adequate anti-radical defence mechanisms, both those synthesised in vivo and those 
taken up in the diet (Halliwell 1990). Thus oxidative stress occurs when the balance 
between pro-oxidants and antioxidants is shifted in favour of pro-oxidants (Sies 
1986), or, alternatively, when a measurable shift occurs in one or more redox couples 
to a more electron deficient (oxidised) steady state or equilibrium (Smith 1991). Any 
situation which increases the turnover of the antioxidant cycle whether increased 
oxidative stress or modified anti-radical defences can lead to progressive cellular and 
membrane damage. There is some evidence to show that ROS activity is increased 
in PIH (Ishihara 1978; Maseki et a l  1981; Wickens et a l  1981; Dekker & 
Kraagenbrink 1991; Wang et a l 1992). However, knowledge regarding the 
antioxidant status in PIH is limited.
The antioxidants synthesised in the body include a range of proteins, enzymes and 
other molecules (bilirubin and urate). The range of antioxidants in the different 
locations in the body, which are located either intracellular, extracellular or bound to 
the membranes, is shown below.
1.3.4.1 Extracellular Antioxidant Defences
1. Transferrin
Oxidant damage to cell organelles and membranes is markedly potentiated by the 
presence of iron (Halliwell & Gutteridge 1984; Weiss & LoBuglio 1982). 
Apotransferrin binds iron (m) for transport and delivery to cells. It is its capacity as 
an iron binding protein which enables it to function as an antioxidant by making iron 
(HI) unavailable for participation in iron-catalysed radical reactions.
2. Caeruloplasmin
This copper-containing protein is regarded as a physiological inhibitor of lipid 
peroxidation (Gutteridge 1978). In this one of its many roles, it acts as an
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antioxidant by virtue of its ferroxidase activity, converting iron (II) to iron (HI) by 
electron transfer.
3. Albumin
Albumin, one of the most important proteins in human plasma, is able to bind copper 
(II) tightly and iron weakly. Copper (II) bound to albumin is still effective in 
generating ra'ical species in the presence of hydrogen peroxide. Thus 
macromolecules functioning by this mechanism are called sacrificial antioxidants 
since the hydroxyl radical is generated locally on the protein and reacts at the 
specific site (Halliwell 1988). The binding of copper ions to albumin may represent 
a protective mechanism overall, since not only can the damaged albumin be quickly 
replaced but it can also absorb hypochlorous acid (Halliwell 1988). Another aspect 
of the antioxidant action of albumin may be its ability to scavenge some hydroxyl 
and peroxy radicals (Wayner et al. 1985; Gutteridge 1986), which may partly 
account for its reported ability to decrease lipoxygenase activity (Duniec & Robak 
1984).
4. Haptoglobin/Haemogopexin
These proteins bind free haemoglobin/haem, thus protecting delocalised 
haemoglobin from influences which might otherwise activate the protein or 
destablise the haem ring and promote iron release (Gutteridge & Smith 1988).
5. Urate
Urate has the potential for chelating iron and copper rendering them unreactive and 
thus inhibiting lipid peroxidation. It also reacts with singlet oxygen, peroxy radicals 
and hydroxyl radicals (Ames et al. 1981; Grootveld & Halliwell 1987).
6. Vitamin E (a-Tocopherol)
This is a membrane-bound (lipid soluble) chain-breaking antioxidant which reacts 
with peroxyl and other reactive radicals (Esterbauer et al. 1989; MaCay 1985). Its 
lipid-soluble nature allows it to concentrate preferentially within the phospholipid 
bilayer of cell membranes and within blood lipoproteins (Lambert & Mourot 1984). 
Therefore, vitamin E is one of the major lipid-soluble chain-breaking antioxidants 
which protect membrane fatty acids from oxidant-induced lipid peroxidation (Ozawa 
etal. 1978).
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7. Vitamin C (Ascorbic acid)
Although at relatively low levels in human plasma, many tissues contain ascorbate in 
millimolar concentrations. This antioxidant nutrient scavenges singlet oxygen and 
reacts rapidly with the hydroxyl radical, the superoxide anion and the hydrogen 
peroxide. It has also been proposed that it acts synergistically with vitamin E 
(MaCay 1985). Reaction of vitamin C with superoxide, peroxide and hydroxyl 
radicals forms, via a semidehydroascordate intermediate, dehydroascorbic acid 
(Bates 1981). Vitamin C is reported to be the most effective aqueous-phase 
antioxidant in human plasma, protecting against oxidants released from 
polymorphonuclear leukocytes and against lipid soluble peroxyl radicals (Levine 
1986; Frei et al. 1990).
8. P-Carotene
This carotenoid scavenges singlet oxygen and peroxyl radicals (Burton & Ingold 
1984; Vile & Winterboum 1988).
9. Lycopene
Lycopene is a low concentration, core carotenoid antioxidant in lipoproteins 
(DiMascio et al. 1989; Esterbauer et al. 1989).
10. Metallothionein
The metallothioneins are generated in response to high concentrations of certain 
metal ions. They bind these ions extremely efficiently such that they are rendered 
harmless and can be removed from the body (Halliwell & Gutteridge 1984).
11. Bilirubin
Bilirubin has been proposed to be an effective antioxidant in terms of its capacity to
protect albumin-bound polyunsaturated fatty acid (Stocker et al. 1987).
1.3.4.2 Intracellular Antioxidant Defences
1. Superoxide dismutase (SOD)
SOD is the major intracellular antioxidant enzyme in aerobic cells and there are two
forms of SOD (Weisiger & Fridovich 1973). One is a cytosolic copper-zinc enzyme 
(CuZn-SOD) and the other a manganese-centred enzyme (Mn-SOD) found in the 
mitochondria. These two dismutases are structurally very different proteins, 
however, they both catalyze the dismutation of superoxide radical to hydrogen 
peroxide and oxygen very rapidly and specifically, and with equal efficiency
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(Reaction 1.12) (Fridovich 1978). Its antioxidant activity is about 350000 times 
more effective than caeruloplasmin (Markland 1980). SOD activity is high in tissues 
with high oxygen utilization.
2 0 2 + 2H+
SOD
■> H2 O2 + O 2 (Reacton 1.12)
2. Thiols
Thiol-containing compounds, such as cysteine, glutathione (GSH) and proteins with 
sulphydryl groups, stop ROS reactions by donating electrons from their sulphydryl 
group (Freeman & Crapo 1982) and they play an important role in scavenging ROS 
and in suppressing oxidative injury in cells and tissues exposed to hypoxia 
(Weinberg et al. 1987). The tripeptide glutathione (-Glu-Cys-Gly) is widely 
distributed in most mammalian cells (Meister & Anderson 1983). It is typically 
present in high (0.1-10 mM) levels and is thus the pivot in various protective 
systems (Meister 1988). In the GSH redox cycle, GSH is used by glutathione 
peroxidases (GSH-px) to reduce hydrogen peroxide and organic peroxides and form 
innocuous end products and oxidized glutathione (GSSG) (Reactions 1.13 & 1.14). 
To protect cells and tissues from ROS-mediated damage, high concentrations of 
GSH are essential for maintaining the GSH redox cycle. Cells are thus equipped 
with NADPH-dependent glutathione reductase (GSH-rd) to reconvert GSSG to the 
reduced GSH (Reaction 1.15).
2GSH + H2e>2 GSH pi -> GSSG + 2H (Reaction 1.13)
2GSH + LOOH-------------- >GSSG + LOH + H20  (Reaction 1.14)
3. Catalase
Catalase reacts very rapidly with hydrogen peroxide, converting it to water and 
oxygen (Reaction 1.16). It is located in the cytosol, mitochondria and other 
subcellular organelles, such as peroxisomes. Normally, the low concentrations of 
hydrogen peroxide production are efficiently reduced in cells by glutathione 
peroxidase. However, if the concentration of hydrogen peroxide is raised, catalase 
becomes important (Southom & Powis 1988).
rafalag/*
2 H2 O2 --------------------> 2H 20  + O 2  (Reaction 1.16)
GSSG + NADPH + H+
GSH-rd
* 2GSH + NADP (Reaction 1.15)
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4. Coenzyme Q (Ubiquinone)
As well as its function as a transporter in the mitochondrial electron transfer chain 
and in energy conservation, coenzyme Q has been reported to function as an 
antioxidant in its hydroquinone form (the majority of tissue coenzyme Q molecules 
exists in the reduced state) (Baum 1991; Beyer 1990). The mechanism of action is 
unclear, but several studies in subcellular systems, intact animals and human subjects 
in a clinical context all support one of the functions of coenzyme Q as a membrane, 
and possibly LDL, protectant against ROS damage.
1.3.4.3 Secondary Protection
In addition, cells contain mechanisms for repairing DNA after attack by ROS, 
systems for degrading proteins damaged by ROS (Marcillat et al. 1988) and 
erythrocytes contain oxyhaemoglobin which is capable of protecting the cell 
membranes against peroxidative damage (Rice-Evans et al. 1985).
In general, intracellular antioxidants are systems for removing ROS, whereas among 
the extracellular components are those which additionally serve the essential 
function of keeping the transition metal catalysts under control.
1.4 Eicosanoid System
The increasing interest in the eicosanoid system in PIH reflects a growing 
recognition of its importance in the process of this disease. The functional 
imbalance between vasodilator and vasoconstrictor eicosanoid products may play an 
important role in the pathophysiologic mechanisms involved in the development of 
the various signs and symptoms of PIH (Dekker 1989, Friedman 1988). Two of the 
most important eicosanoids are prostaglandins and leukotrienes.
1.4.1 Biosynthesis
Neither the prostaglandins nor the leukotrienes are stored in tissues but are 
biosynthesized from fatty acid precursors upon cell stimulation. Arachidonic acid is 
the common precursor for products of both the cyclooxygenase (prostaglandins, 
prostacyclin and thromboxanes) and lipoxygenase (leukotrienes) pathways. The 
amount of free arachidonic acid within cells is very low but there is a comparatively 
large amount esterified in cell membrane phospholopids and glycerides. Therefore,
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the initial and rate limiting step in the biosynthesis of eicosanoids is the enzymic 
liberation of free arachidonic acid from the ester pools. The main source of this 
precursor acid is the phospholopids. Arachidonic acid is located predominantly at 
the position of phospholipids and its release is controlled either by phospholipase A2 
or the combined action of phospholipase C and a diglyceride lipase (Van den Bosch 
1980; Irvine 1982; Flower & Blackwell 1983). Arachidonic acid released from the 
phospholipids reacts with oxygen, and cyclizes in a cyclooxygenase-catalysed 
reaction to give the prostaglandin endoperoxide PGG2. This endoperoxide is 
converted into a second endoperoxide, PGH2, in a peroxidase-catalysed reaction. 
Various synthetases then catalyse and convert PGH2 into other prostaglandins, 
prostacyclin and thromboxanes. Arachidonic acid may also be converted by 
lipoxygenase into a hydroperoxy derivative from which leukotrienes are 
biosynthesized (Figure 1.4).
The critical factor that determines the particular arachidonic acid metabolites 
produced by a given cell type is which enzymes of the arachidonic acid cascade are 
present in that cell type (Stenson & Parker 1984). Thus platelets, which contain 
cyclooxygenase and thromboxane synthetase, produce TXA2 and endothelial cells, 
which contain cyclooxygenase and prostacyclin synthetase, produce PGI2, whereas 
neutrophils, which contain lipoxygenase, leukotriene A synthetase, and leukotriene A 
hydrolase, produce leukotrienes.
1.4.2 Prostaglandins
The prostaglandins are a groups of 20-carbon unsaturated fatty acids that are similar 
in structure, yet varied in function. The term prostaglandin was introduced by early 
investigators who discovered the compounds in human semen and believed the 
prostate gland to be a major source. This suggestion is now known to be incorrect 
but the name has been retained. There are four most relevant prostaglandins, that is 
prostaglandin E (PGE), prostaglandin F2 (PGF2), prostacyclin (PGI2) and 
thromboxane A2 (TXA2). Their functions and main sites of production places are 
listed in Table 1.9.
1.4.2.1 Prostacyclin
PGI2 is a potent vasodilator and inhibitor of platelet aggregation (Goodman et al. 
1982; Walsh et al. 1985; Schiff et al. 1989). It is the most abundant arachidonic acid 
metabolite and is synthesized primarily in the endothelium but other tissues such as
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myometrium and placenta also produce some PGI2 (Omini et al. 1979; Jogee et al. 
1983; Rakoczi et al. 1983; Walsh & Parisi 1986; Walsh 1987). Trophoblastic 
production of PGI2 might function to prevent platelet-clumping in the intervillous 
space, whereas vascular PGI2 would maintain (placental) vasodilation. PGI2 is 
chemically unstable, with a half-life of three minutes at physiological pH and 
temperature (Dusting et al. 1978). Because its instability, PGI2 is frequently 
quantified by measuring its stable degradation product 6-keto-PGFla.
Studies examining PGI2 levels in normal pregnant and preeclamptic women have 
yielded conflicting results and there seems to be no general agreement about how 
prostaglandin production is best assessed. In studying the maternal compartment, 
including plasma, urine and blood vessels, the evidence weakly suggests that the 
levels of PGI2 may be increased in normal pregnancy and decreased in PIH 
(Goodman et al. 1982; Walsh et al. 1985; Walsh 1985; Yamaguchi & Mori 1985; 
Friedman 1988; Schiff et al. 1989). Walsh et al. (1985) reported that the production 
of PGI2 in placental tissue obtained from women with PIH was significantly lower 
than that from normotensive women. Ylikoikala et al. (1981) also reported 
decreased levels of prostacyclin in amniotic fluid obtained from women with PIH, as 
compared with normotensive pregnant women.
Other investigators have preferred to study prostaglandin production in fetal rather 
than maternal tissues. The justification for this point of view is that fetal tissues are 
apparently capable of synthesizing greater amounts of prostacyclin than maternal 
tissues (Kawano & Mori 1983; Remuzzi et al. 1979). The literature on the 
fetoplacental unit largely agree about the decrease in PGI2 production in PIH 
(Friedman 1988).
1.4.2.2 Thromboxane A2 (TXA2)
TXA2 opposes the action of PGI2. It is a potent vasoconstrictor and a stimulant of 
platelet aggregation (Ellis 1976; Bhagwat 1985). TXA2 is primarily produced by 
platelets in nonpregnant patients (Fitzgerald et al. 1987; Reilly & Fitzgerald 1987). 
Like PGI2, TXA2 is too unstable for isolation and measurement Its biologic half- 
life in the blood at 37°C is approximately 30 seconds (Moncada & Vane 1979), and 
it is therefore usually measured as its stable hydration product TXB2 (Granstrom et 
al. 1982). TXA2 synthesis is increased in normal pregnant women; this is likely due 
to increased production by either the placenta (Walsh et al. 1985) or platelets 
(Fitzgerald et al. 1987).
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1.4.2.3 Imbalance between PGI2 and TXA2
Since both prostacyclin and thromboxane A2 are increased during normal pregnancy, 
it has been thought that a major mechanism involved in the pathophysiology of PIH 
is a change in the ratio of prostacyclin to thromboxane production (Ylikorkala et al. 
1981; Walsh 1985), with a change in "the direction of thromboxane A2 dominance." 
(Ylikorkala et al. 1981). In fact, Walsh (1985) reported that the placentae of women 
with PIH produced seven times more thromboxane A2 than prostacyclin. The 
selective inhibition of thromboxane A2 and sparing of prostacyclin by low-dose 
aspirin administration has led to several clinical trials attempting to prevent or 
forestall the development of PIH (Wallenburg et al. 1986; Wallenburg & Rotmans 
1988; Benigni et al. 1989; Schiff etal. 1989).
The cause of the imbalance of TXA2 and PGI2 is still unclear. Walsh and Coulter 
(1989) indicated that progesterone, either alone or in combination with estradiol, 
could suppress PGI2 production by the human placenta, but it did not affect placental 
TXA2 production. However, this can not explain the decreased PGI2 found in the 
maternal circulation in PIH because the circulating concentrations of progesterone do 
not differ from those found in normal pregnancy (Parker et al. 1979; Pedersen et al. 
1983). It has been suggested that ROS may cause the imbalance of TXA2 and PGI2. 
Lipid peroxides can activate cyclooxygenase and impair endothelial PGI2 synthetase 
(Higgs & Vane 1983). Therefore the increased lipid peroxide levels in PIH favor 
production of platelet-derived TXA2 above vascular PGI2 production. There is 
evidence showing that 12-HPETE can inhibit PGI2 synthesis (Turk et al. 1980; El 
Tahir & Williams 1981). Ogbum et al. (1982 & 1984) also speculated that elevated 
production of lipoxygenase products by the uteroplacental unit could be responsible 
for the inhibition of PGI2 production.
1.4.3 Leukotrienes
Studies have suggested that PGI2 is not the only physiologic vasodilator in 
normotensive pregnancy. Spitz et al. (1988) reported that treatment of normotensive 
pregnant women, who exhibit an increased vascular sensitivity to angiotensin-II, 
with low-dose aspirin did not completely restore vascular refractoriness to 
angiotensin-H. The incidence of PIH in pregnant women using high doses of 
prostaglandin systhetase inhibitors is not increased (Dekker 1989; Briggs et al.
1990). It has been suggested that PGI2 production merely functions as a rescue
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mechanism, especially during periods of ischemia and hypoxia (Spokas et al. 1983). 
Vasodilatory prostaglandin is evoked locally in an attempt to re-establish normal 
function by regulating tissue perfusion and metabolism. It might be that other 
autocoids such as leukotrienes are involved in the physiologic vasodilation in 
pregnancy. Those considered the most important physiologically are leukotriene B4, 
leukotriene C4 and leukotriene D4. In general, leukotriene B4 causes chemotaxis 
and increased vascular permeability (in the presence of neutrophils). Leukotriene C4 
and leukotriene D4 induce vasoconstriction and increase vascular permeability (Piper 
1984; Stenson & Parker 1984). Saeed and Mitchell (1983) have demonstrated that 
human uterine and intrauterine tissues are capable of producing 5-HPETE and 12- 
HPETE. 5-HPETE is the labile precursor of the leukotrienes and it undergoes 
enzymatic conversion into leukotrienes A4, C4, D4 and E4 (Piper 1984; Stenson & 
Parker 1984). Furthermore, Ogbum et al. (1984) have presented some data 
suggesting that the production of lipoxygenase products, including 12-HPETE is 
elevated in PIH.
1.5 Genetic Factors and HLA system
The discovery of the occurrence of PIH to be familial suggests that susceptibility to 
PIH may be inherited. There is, therefore, an important genetic component in the 
disease. However, the exact mode of inheritance has not yet been understood. In 
principle, susceptibity could be controlled by the maternal genetype alone, or the 
fetal genotype alone, or by a genotype-by-genotype interaction between the mother 
and her fetus.
Most of the simple pedigree data point to a major role for the single maternal 
genotype in the recessive inheritance. Sutherland et al. (1981) compared the 
frequency of PIH in mothers versus mothers-in-law of PIH index cases and found 
that the incidence of severe PIH was much higher among the former than the latter. 
Subseqently, Chesley and Cooper (1986) studied the incidence of PIH in 147 sisters, 
248 daughters, 74 granddaughters, and 131 daughters-in-law of women who had 
eclampsia. The authors observed an increased frequency of PIH in the daughters and 
granddaughters, but not in daughters-in-law, of women who themselves had a history 
of eclampsia.
Some evidence does suggest a fetal genetic contribution to PIH as shown in the 
following references.
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1. Discordance of PIH in identical twin sisters has been found (Thornton & 
Sampson 1990).
2. There is a higher incidence of PIH with male fetuses and in pregnancies 
conceived by partners of dissimiliar race (Alderman et al. 1986; James 1987).
3. The fetal chromosomal abnormalities of triploidy and trisomy 13 can be 
associated with PIH (Toaff & Peyser 1976; Bower et al. 1987; Feinberg et al.
1991).
4. It has been reported that there are various kinds of association between 
susceptibility and HLA types and this also implicates the fetal genetic 
contribution (Redman ef al. 1978; Kilpatrick et al. 1987 & 1989a).
Amgrimsson et al.(1990) postulated that a dominant gene with incomplete 
penetration may contribute to the development of PIH. It now seems likely that 
susceptibility depends on a combination of maternal and fetal genotypes involving a 
single recessive gene shared by mother and fetus. This gene may be associated with 
HLA-DR4 (Kilpatrick et al. 1989a), but the association needs to be further confirmed 
(Wilton et al. 1990).
HLA may be a marker for a closely linked gene (or genes) that predispose to or cause 
PIH and account for its familial incidence. It has been reported that there is an 
association between the presence of HLA-DR4 and increased incidence of PIH ( 
Simon et al. 1988; Kilpatrick et al. 1989a). This finding suggests that the genetic 
susceptibility to PIH is associated with HLA-DR4. The association probably also 
indicates an underlying tendency to autoimmune disease with which HLA-DR4 is 
linked. However, subsequent studies by others have make this association remain in 
some doubt (Hoff et al. 1990; Wilton et al. 1990). It has also been suggested that 
there is a defective genetic coding for normal placental prostacyclin and/or 
thromboxane production in women with PIH from the time of conception (Walsh 
1990).
1.6 Placental Factors
The facts that the symptoms and lesions of PIH disappear soon after termination of 
pregnancy (Chesley 1978; Roberts 1984) and that the disease can occur in abdominal 
and molar (without a fetus) pregnancy (Page 1939; Rote 1985) suggest that uterine 
and fetal factors are not required and that the placenta is a very important component 
and can provide key information relating to the pathogenesis of PIH.
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During the establishment of uteroplacental maternal circulation, the denervation of 
spiral arteries and the production of eicosanoids take place. The uterine vasculature 
is richly supplied with adrenergic nerves (Owman et al. 1967), so erosion of the 
spiral arteries in normal pregnancy decreases the uterine content of sympathetic 
neurotransmitters, producing a functional denervation (Thorbert et al. 1979; 
O'Shaughnessy et al. 1983; Robertson & Khong 1987). At the same time the inner 
lining, endovascular trophoblast and endothelium, of these so-called uteroplacental 
arteries, produce vasodilating prostaglandins (Friedman 1988) and perhaps other 
vasodilating autocoids, such as endothelium-derived relaxing factor (EDRF) 
(Klebanoff 1988; Hubei et al. 1989). As a result of these morphologic and 
physiologic changes, the uteroplacental blood vessels have markedly decreased 
vascular tone and are maximally dilated. Consequently a low-resistance, low- 
pressure, high flow syspem is formed. Immunological mechanisms are also believed 
to involved in the development of poor placentation in PIH (see Section 1.2.2).
In PIH, the maladaptation at the maternal-placental interface results in the 
trophoblast failing to destroy the spiral arteries and results in placentation with poor 
uteroplacental circulation, which in turn leads to placental ischemia. Histopathologic 
and epidemiologic data have shown a decrease in uteroplacental blood flow in PIH 
(Dixon et al. 1963, Kaar et al. 1980, Lunell et al. 1984). In addition, experimental 
animal models of PIH also indicated that reduction of placental and uterine perfusion 
was a common feature (Chesley 1978). Many of the ultrastructural changes of PIH 
placental tissue closely resemble alterations seen in placental tissue when it is placed 
in hypoxic organ culture (Tominaga & Page 1966; Fox 1970). The poor placentation 
has been correlated with the increased incidence of placental infarction, fetal distress 
and fetal growth retardation that often accompany PIH (Chesley 1978; Ramsey & 
Donna 1980; Gerretsen et al. 1983; Sibai 1984; Redman 1987). Therefore, 
fundamental defects of placentation and uteroplacental vascular development in PIH 
may relate to poor perfusion and placental hypoxia, which are the earliest and most 
consistent changes in PIH (Chesley 1978; Roberts etal. 1989).
Placental hypoxia is thought to cause an increased production of ROS ( Klebanoff 
1988; Hubei et al. 1989; Roberts et al. 1990). ROS, which are increased in PIH 
(Ishihara 1978; Maseki et al. 1981; Wickens et al. 1981; Dekker & Kraagenbrink 
1991; Wang et al. 1992), have several adverse effects which set in motion a 
dysfunction cascade of coagulation, vasoconstriction, and intravascular fluid 
redistribution that results in the clinical syndrome of PIH (see Section 1.3).
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The precise cause of poor placentation and the effects of poor placentation on the 
pathogenesis of disease are still not completely understood, but there is enough 
evidence to regard poor placentation as a final common step resulting in PIH. PIH is 
primarily a placental disease.
Several lines of studies have suggested that human placental cells have an 
immunoregulative function by the production of cytokines and other immunological 
substances (Wolf 1988; Pockley & Bolton 1990; Kettel et al. 1991; Vince et al.
1992) (see Section 1.2.3). Considering that ROS are able to damage cell membranes 
(Hubei et al. 1989; Croustein 1991) and they have an important role in the immune 
response (Gallaghen & Curtis 1984; Fidelus 1988; Sekkat et al. 1988), placental 
hypoxia which leads to production of ROS will undoubtedly affect the immune 
system, at least the local immune response in maternal-placental interface. Although 
the research on the immunolocical changes at the local maternal-placental interface 
in PIH is limited, an exciting discovery by Greer and his coworkers (1990) has 
shown that neutrophil activation in PIH is localized in part to the placental bed. 
Activated neutrophils are capable of destroying the integrity of endothelial cells, 
vascular basement membranes and subendothelial matrix by releasing neutrophil 
granules such as elastase and other proteases (Harlan 1987; Greer et al. 1990). In 
addition, activation of neutrophils also produce ROS and leukotrienes, both of which 
may contribute to the necrotizing arteriopathy seen in PIH (Sacks et al. 1978; Weiss 
et al. 1981; Pelusi et al. 1990).
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CHAPTER TWO IMMUNOLOGICAL FACTORS
2.1 Introduction
2.1.1 Why are immune mechanisms involved in the pathogenesis of PIH
Immunological components may play a role in the development of pregnancy-
induced hypertension (PIH). This conclusion arises from the following facts:
1, The greater the exposure to semen (an allogeneic antigen for women), the 
less the likelihood that PIH will occur (Klonoff-Cohen et al. 1989).
2, PIH is most likely to arise in a woman who changes partners (Feeney 1980).
3, Previous blood transfusion protects against PIH development (Feeney et al. 
1977).
2.1.2 Cell-mediated immunity
Immunological reactions are conveniently divided into two mechanistically different 
types: humoral (or antibody-mediated), and cellular (or cell-mediated) immunity. 
The former type is mediated by specific antibodies and the latter by immune 
lymphocytes. There are two lymphocyte populations: T lymphocytes, responsible 
for cell-mediated immunity and B lymphocytes, concerned in the synthesis of 
circulating antibodies. Approximately 80% of normal blood lymphocytes are T 
cells. They emerge from a period of development and differentiation in the thymus 
as cells capable of 1), undergoing blast transformation in response to certain 
mitogenic substances; 2), producing many soluble mediators of immune reactivity; 
3), serving as memory cells of previous antigenic exposure; 4), being helper and 
suppressor cells in many B-cell responses; and 4), having the special capacity to kill 
foreign cells through direct cytotoxic mechanisms (Roitt et al. 1989).
There are a number of publications describing the changes in cell-mediated 
immunity in PIH. Moore et al. (1983) studied the various lymphocyte subsets and 
showed a significant increase in helper T cells. However, others found a 
significantly lower proportion of helper T cells (Bardeguez et al. 1991) or a 
proportional decrease in both helper and suppressor T cells (Sridama et al. 1983). 
Although the findings of T cell subset analysis are inconsistent, the results do suggest 
that abnormalties of T cell function might exist
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2.1.3 Immunoglobulins
Antibody activity is associated with the classical y-globulin fraction of serum. With 
the recognition of heterogeneity in the types of molecules which can function as 
antibodies, it has now become customary to use the general term 'immunoglobulin'. 
In each species, the immunoglobulin (Ig) molecules can be subdivided into different 
classes on the basis of the structure of their *backbone' (rather than on their 
specificity for given antigens). Thus, five major structural types or classes in the 
human can be distinguished: IgG, IgM, IgA, IgD and IgE. The ability to secrete Igs 
is the distinguishing functional characteristic of B lymphocytes. Therefore, B 
lymphocyte function or activity can be monitored by its ability to produce and 
secrete Igs.
Clinical autoimmune phenomena in patients with PIH are manifested by production 
of autoantibodies toward lymphocytes, endothelial cells, trophoblast antigens and 
placental and renal antigens (Rappaport et al. 1990; Sibai 1991). As stated above, 
the main function of B lymphocytes is to produce antibodies (Igs). The appearance of 
these abnormal antibodies suggests that it is very likely that B cell function or 
activity is altered. So far, the production of Igs from lymphocytes has not yet been 
studied in patients with PIH.
2.1.4 Cytokines
There are two ways in which T lymphocytes can influence the activities of other 
cells. One involves cell contact, recognition and the subsequent destruction by T 
lymphocytes with cytotoxic properties. The other, more versatile way in which T 
lymphocytes communicate and influence other cells is by the production and 
secretion of a variety of potent mediator molecules, termed lymphokines or more 
generally 'cytokines'. T lymphocytes are a particularly rich source of cytokines. At 
the last count they are able to produce over 10 cloned products, such as IL-1, IL-2, 
IL-3, IL-4, IL-5, IL-6, IL-8, IL-9, IL-9, EL-10, IL-13, TNF, IFN, GM-CSF and 
TGFp. It appears that the majority of T cell effects are mediated by the production 
of cytokines.
As stated in Sections 2.1.2 and 2.1.3, PIH might be associated with T and B 
lymphocyte abnormalties. If this is true, one possible mechanism involved is the 
roles of cytokines. Among cytokines, IL-2 acts as an activating factor and a growth 
factor for T, B and NK (natural killer) cells (Smith 1984). Studies on IL-2 activity
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have been carried out in several kinds of diseases associated with T and 8  
lymphocyte disorders (Huang et al. 1988; Kahaleh & LeRoy 1989). However, this 
issue has not been investigated in PIH previously.
2.1.5 Cytokines and prostaglandins
The generation of immune responses involves a complex series of cellular events, 
each of which may be regulated by antigen-specific and nonspecific signals. One of 
the antigen nonspecific immunoregulatory mechanisms results from the action of 
prostaglandins. The effects of prostaglandins on T lymphocyte function and 
cytokines have been well studied (Kingston et al. 1985; Hwang 1989). Conversely, 
there is only limited information on the role of cytokines in the production of 
prostaglandins especially PGI2 and TXA2, which play an important role in the 
development of PIH (Friedman 1988; Walsh 1990). Increasing our understanding of 
the interaction between cytokines and prostaglandins (PGI2 and TXA2) could help 
us to understand how and why PIH develops.
2.1.6 Aims of the study
The aims of the study were to determine the following parameters in women with 
PIH and normotensive pregnant women.
1, T lymphocyte function (mitogenic activity).
2, B lymphocyte function (IgG and IgM production).
3, IL-2 production from PBMC (peripheral blood mononuclear cells).
4, The effects of IL-1, IL-2 and TNF on the production of PGI2 and TXA2 from
PBMC.
2.2 Materials and Methods
2.2.1 Study Population
Three groups of subjects were included in the study of T and B lymphocyte function 
and IL-2 production. 1, 37 normotensive pregnant women; 2, 19 PIH women 
without proteinuria; 3, 9 PIH women with proteinuria. None of the pregnant 
women were taking any anti-hypertensive drugs before sampling. Clinical data is 
shown in Table 2.1.
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Table 2.1 Demographic Characteristics of Study
Population
Group N Age
(year)
Gestational 
Age (weeks)
Diastolic Blood 
Pressure (mmHg)
Normotensive
Pregnancy
37 27.9±4.9 35.213.7 73.119.5
(n=24)
PIH without 
Proteinuria
19 2 6.514.3 35.213.7 93.914.7*
PIH with 
Proteinuria
9 25.814.1 35.415.2 110.019.3
All data were expressed as mean± SD. 
*p<0.001 versus PIH with proteinuria.
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The study of the effect of cytokines (IL-ip, IL-2 and TNFa) was carried out in 7 
normal non-pregnant women.
PIH was defined by the standard recommended by the American College of 
Obstetricians and Gynecologists (For details see Chapter 1).
2.2.2 Major reagents
Fetal calf serum (FCS) was supplied by Northumbria Biologicals Ltd., Cramlington, 
UK. PBS and lymphoprep™ were purchased from Oxoid Limited, England and 
Nyegaard and Co., Oslo, Norway respectively. RPMI1640 (lOx) was obtained from 
Gibco, BRL., UK. 3H-thymidine (TRK418, specific activity 40-60 Ci/mM) was 
supplied from Amersham International pic., UK.
Three distinct mitogens were used in study of mitogenic lymphocyte activity, 
phytohaemagglutinin (PHA), Concanavalin A (ConA, Type IV) and pokeweed 
mitogen (PWM) and all of them were purchased from Sigma Chemical Company 
Ltd., UK. PWM for Ig production was obtained from Gibco Ltd., UK and PHA for 
IL-2 production from Wellcome Diagnostics, UK. Human IgG/IgM, anti-human 
IgGAgM, anti-human IgG (y-chain specific)AgM (jt-chain specific) alkaline 
phosphatase conjugate and PNP were from Sigma Chemical Company, USA.
Purified recombinant human TNFa and human IL-1(3 were products of Cistron 
Biotechnology, Pine Brook, NJ07058, USA. TNFa had specific bioactivity of 5.6 x 
107 Units of TNFa per mg of protein. The specific activity of IL-lp is 1 unit per 
nanogram of IL-ip. Human IL-2, with specific activity of lxlO6 U/mg, was 
obtained from Cell Biology Boehringer Mannheim GmBH, Germany. 1 unit is 
defined as the amount of IL-2 that is required to support half-maximal 3H-thymidine 
incorporation into CTLL-6 cells.
The enzyme immunoassy (EIA) systems for TXB2 and 6-keto-PGFla (the stable 
metabolites of TXA2 and PGI2, respectively) were purchased from Amersham 
International pic., Amersham, U.K.
2.2.3 Culture medium and mitogen preparation
The culture medium (completed RPMI 1640) was prepared according to the 
manufacturers instructions. Distilled/deionised water (cff^O) was autoclaved for 20
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minutes at a temperature of 120 °C and a pressure of 1.2/cm2. The d H ^  was 
allowed to cool before the RPMI 1640 (lOx) was added. Sodium bicarbonate (7.5%, 
Gibco, BRL) was added to give a final concentration of 2 g/1 where it is to act as a 
CO2  buffer as well as a nutrient or to give a final concentration of 0.85 g/1 where N- 
[2-Hydroxyethl] piperazine-N-[2 ethanesulphonic] acid (HEPES) was the CO2  buffer 
of choice. HEPES (1M, Gibco, BRL) was added to the media to give the 
concentration of choice (usually 10 mM). Finally the various supplements as 
detailed elsewhere in the text, were added prior to use. The bottle of medium was 
then adjusted to the correct pH (between pH 1 2  and pH 7.4) by addition of either 
HQ or NaOH. Glutamine (200 mM) was added to the bottle of medium 
immediately prior to use. The reason for this is that glutamine has a half-life in the 
order of 19 days at 4°C. Therefore it is important to replenish the glutamine lost 
After 7 days at 4 °C only 80% of the original glutamine will remain. It is for this 
reason that glutamine was added every week to bottles of media in use for longer 
than a week to make up for this shortfall. Glutamine is an essential nutrient and 
energy source for the growing cell. Stock glutamine was for this reason stored at - 
20°C.
PHA (for lymphocyte mitogenic activity) was resuspended in sterile distilled water 
to give a stock solution of 1000 pg/ml. PHA stock was aliquoted and stored at -20 
°C. Prior to use an aliquot of stock PHA was further diluted in completed RPMI 
1640 to give a working concentration of 10 pg/ml (a 100-fold dilution).
ConA was resuspended in sterile distilled water to give a stock solution of 5 mg/ml. 
ConA stock was aliquoted and stored at -20 °C. Before use an aliquot of the stock 
was further diluted in completed RPMI 1640 to produce a working stock of 100 
pg/ml (a 50-fold dilution).
PWM (for lymphocyte mitogenic activity) was prepared at a concentration of 50 
pg/ml in completed RPMI 1640, aliquoted and stored at -20 °C. Prior to use an 
aliquot of the stock was further diluted to give a working concentration of 0.2 |ig/ml 
(a 250-fold dilution) in completed RPMI 1640.
PWM (for Ig production) was made up as the manufacturers instructionson by 
adding 10 ml of PBS. This solution was then aliquoted and stored at -20 °C. Prior to 
use an aliquot of the stock was diluted in completed RPMI 1640 containing 20% 
FCS at 1:250 as the working concentration.
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PHA (for IL-2 production) was resuspended in sterile distilled water to give a stock 
solution of 1000 pg/mL PHA stock was aliquoted and stored at -20 °C. Prior to use 
an aliquot of stock PHA was further diluted in completed RPMI 1640 to give a 
working concentration of 2 pg/ml
2.2.4 PBMC preparation
Venous blood was added as aseptically as possible to a universal container with 
preservative-free heparin such that the final concentration was 30 units/ml. PBMC 
were separated by density gradient centrifugation over lymphoprep™, washed three 
times in PBS and resuspended in 1 ml RPMI 1640 media. The cells were counted 
and adjusted to the required concentration.
2.2.5 Lymphocyte mitogenic activity assay
The lymphocyte culture was set up in 96 well, U-shaped microtiter plates (Greiner 
Labortechnik Ltd., UK). All cultures were set up in triplicate and in a final volume 
of 200 pi. Each well contains 100 pi of cells and 100 pi of mitogen (in control wells 
RPMI 1640 instead of mitogen). Cells were used at the concentration of 1 xl0*> 
cells/ml for PHA and ConA stimulation. When PWM was the mitogen, the cells 
were resuspended to the concentration of 2 x 106 cells/ml. The culture were 
incubated at 37 °C in a humidified atmosphere of 5% CO^air for a total of 72 hours. 
All mitogens were used at optimal concentrations (Wilson et al. 1989).
The most commonly used method of detecting lymphocyte activation is the 
incorporation of 3H-thymidine into DNA, which correlates well with the number of 
lymphocytes in the S-phase of the cell cycle. The working stock contains 50 pQ  3H- 
thymidine, 50 pM 'cold1 thymidine (stock 5 mM) (Sigma Chemical Company, UK) 
and completed RPMI 1640. The equivalent of 1 pCi was added to each well (20 pi)
at the time of completing 68-hour incubation. The cultures were incubated in the
presence of the label for further four hours.
After 72 hour incubation, the microtiter plates were harvested on a Titertek Cell 
Harvester (Row Laboratories). The cell harvester transfers the cells from the wells 
to clearly defined discs on a glass-fibre filter mat (Skatron Ltd., UK) and unbound 
3H-thymidine passes through the filter into the reservoir. The discs containing the 
radioactivity were removed from the filter mats and placed in clearly labelled 
minivials (Pony Vials, Canberra Packard International S.A., Switzerland) and
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allowed to dry. The scintillation fluid was prepared by added 4 grams of 2.5 
diphenyloxazole (PPO, Scintillation Grade, United Technologies Packard, UK) to 
one litre of methylbenzene (Pronalys A.R. (toluene), May & Baker, UK). Three mis 
of scintillation fluid were added to each vial, the vials were then counted on a LKB 
1216 Rackbeta II liquid scintillation counter (Phamacia, UK). The counter was 
programmed to measure low energy beta emissions. The results were expressed as 
cpm.
2.2.6 Ig production and ELISA for IgG and IgM
Ig production from lymphocyte was set up in 24 well microtiter plates (Greiner 
Labortechnik Ltd., UK). All cultures were set up duplicate wells and at a final 
volume of 2 ml. Each well contains 1 ml of cells (1 x 106) and 1 ml of PWM (1:250 
dilution). Control wells consisted of cells and culture media which replace PWM. 
This control was set up for each sample to account for spontaneous release of Igs. 
The plate was incubated at 37°C in a humidified atmosphere of 5% C 02/air for a 
total of 7 days. After culture, the medium was pipetted off into 10 ml plastic conical 
tubes and centrifugated at about 700 x g for 10 minutes. The supertanants were 
obtained and stored at -20°C until assay.
The amount of IgG and IgM was determined by ELISA (Wilson et al. 1988). A 96 
well microtitre plate was coated with 200 pi (1:1000 dilution) goat anti-human 
IgG/IgM and incubated for one hour at 37°C. The plate was then washed four times 
with washing buffer (0.5% BSA, 0.05% Na Azide and 0.05% Tween 20 in PBS), 
using a plate washing machine (Ultrawash II, Dynatech Laboratories Ltd., England). 
200 pi of diluted buffer (0.5% BSA and 0.05% Na Azide in PBS) was then added 
and incubated for further 30 minutes at 37°C. The plate was then shaken out and 
blotted dry. 100 pi samples and standard IgG/IgM (3.125, 6.25, 12.5, 25, 50, 100 
and 200 ng/ml) were added to the plate and incubated for two hours at 37°C. The 
plate was washed four times as before. 100 pi (1:1000 dilution) of the anti-human 
IgG/IgM conjugate was now added to the plate and incubated for another two hours 
at 37°C. The plate was washed four times again as before. 100 pi of PNP substrate 
was added to the plate and incubated for final 30 minutes at 37 °C. The substrate was 
prepared beforehand by dissolving 4 tablets (5 mg/tablet) of P-nitrophenyl phosphate 
substrate (PNP) in 20 ml substrate buffer (2.2 ml of 0.2 M Na2 CC>3 , 2.8 ml of 0.2 M 
NaHCC>3 , 2.0 ml of 0.01M MgCC>2 , 14 ml of CIH2 O). The reaction was stopped 
by adding 100 pi of 3 M NaOH. The plate was now read at 490 nm on a Dynatch 
MR 700 microplate reader (Dynatech Laboratories Ltd., England).
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2.2.7 IL-2 production and assay
The method for IL-2 production and assay has previously been described by Wilson 
et al (1989) and Smith et al. (1990).
The lymphocyte culture for IL-2 production was set up in 24 well microtiter plates 
(Greiner Labortechnik Ltd., UK). The culture system was carried out at a final 
volume of 1 ml completed RPMI 1640 with 4% FCS. Each well contains 4 x 106 
cells and 2 pg of PHA. The control well for each sample was set up to examine the 
spontaneous release of IL-2 and therefore it contained cells without PHA. The plate 
was incubated at 37 °C in a humidified atmosphere of 5% COyair for a total of 48 
hours. After incubation, the culture medium was centrifuged at 700 x g for 10 
minutes. The supernatants were obtained and stored at -20°C until assay.
The IL-2 assay is a bioassay which relies on measuring the increase in proliferation 
of a dependent cell line, HT-2 cells. This cell line is derived from murine T-helper 
cells and requires IL-2 for continuous growth. HT-2 cells are maintained in RPMI 
1640 containing 10% FCS and 2 x 10‘5M 2-mercaptoethanol (conditional medium). 
Cell cultures are fed every 48 hours with the conditional medium, this corresponds to 
a concentration of approximately 20 international units of IL-2 per ml (Cell Biology 
Boehringer Mannheim GmBH, Germany). After two days when the cell density is 
approximately 2 x 105 cells, cultures are split to 2 xlO4 cells per ml and re-fed with 
IL-2.
The protocol for bioassay for IL-2 and calculation of unitage is as follows:
1, Harvest the HT-2 cells 2 or 3 days after feeding with IL-2. Wash the cells 
twice by centrifugation in RPMI 1640.
2, Determine viability of the cells by Trypan Blue dye exclusion (cells should 
be > 80% viable) and resuspend cells to a final concentration of 1.5 x 10s 
cells/ml in RPMI 1640 containing 20% FCS
3, Titrate the IL-2 standard in triplicate in a 96 well microtitre plate. Start the 
titration at 100 Unit/ml IL-2 and then make serial twofold dilutions down to 
0.195 unit/ml IL-2. Prepare dilutions of the samples (twofold serial dilutions) 
in triplicate. The negative control is culture medium without IL-2. Each well 
should contain a volume of 100 pL
4, Add 100 pi of the cell suspension to each well and incubate the plates for 20 
hours at 37 °C in a humidified CO2  incubator.
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5, Add 1 |iCi of tritiated thymidine to each well and return the plates to the 
incubator for further 4 hours.
6, Harvest the contents of each well onto filter mats, using MicroMate™ 196 
Cell Harvester (Packard Instrument Company, CT, USA), and determine the 
radioactivity incorporated into DNA by a computer-programmed Matrix 
96™  Direct Beta Counter (Packard Instrument Company, CT, USA).
7, The raw data for proliferation (cpm) is first transformed to a percentage of 
maximum counts. A rough estimate of relative potency can be obtained for 
comparing the dilution at which 50% maximum counts are obtained for each 
sample.
8, Transformed counts are then converted to log values, as are the dilutions for 
each sample, and plotted graphically.
9, The unitage of each sample, relative to the standard, is calculated from the 
distance between the straight line portions for each sample. These straight 
lines should be parallel if the molecule responsible for the activity in 
samples/standards is the same.
2.2.8 Cell culture for the effects of cytokines on prostaglandin production
and EIA for PGI2 and TXA2
To assess the effects of cytokines on TXB2 and PGI2 biosynthesis, 2 x 105 PBMC 
were placed in 96 well, U-shaped microtitie plates (Greiner Labortechnik Ltd., UK) 
and incubated at 37 °C in a humidified atmosphere of 5% COyair for 30 minutes to 
24 hours with the specified cytokine dilution. After incubation, the supernatants 
were obtained and stored at -20°C until assay.
Control samples consisted of PBMC processed in the same manner as those treated 
with cytokines. Controls were set up at each time point to account for spontaneous 
release of TXA2 and PGI2. The culture medium was tested for interference with the 
assay system and found to contain 6-keto-PGFla and TXB2 concentrations of less 
than 5% and 4% respectively of the concentrations detected in supernatants of the 
background PBMC culture.
The levels of 6-keto-PGFla and TXB2 in supernatants were determined by the EIA 
method and performed as outlined in the protocol supplied with the system (for 
details see Chapter 4). Briefly, 50 pi of sample was added to a 96-well plate which 
was coated with donkey anti-rabbit IgG and then 50 pi of rabbit anti-6-keto-PGF 1 a  
or rabbit anti-TXB2 was added. After incubation by shaking, the samples were
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reacted with 6-keto-PGFla- or TXB2-horseradish peroxidase for 1 hour. The wells 
were washed four times with washing buffer by a plate washing machine (Ultrawash 
n, Dynatech Laboratories Ltd., England) and then 150 \si enzyme substrate (TMB) 
dispensed into the wells. The reaction was stopped by 1.0 M sulphuric acid and read 
at 450 nmona Dynatch MR 700 microplate reader (Dynatech Laboratories Ltd., 
England) within 30 minutes. The assay sensitivity, defined as the amount of TXB2 
or 6-keto-PGFla needed to reduce zero dose binding by two standard deviations was
3.6 pg/ml and 3.0 pg/ml respectively. The intra and inter-assay variations for TXB2 
assays were 2.5% and 9.9% respectively and for 6-keto-PGFla 4.5% and 14.8%.
2.2.9 Statistics
Data for prostaglandins are expressed as medians and ranges since prostaglandin 
levels are not normally distributed (Moodley et al. 1984). Kruskal-Wallis analysis 
was performed to determine whether comparisons among groups were valid and 
differences between groups were analyzed for by Mann-Whitney test Other data are 
expressed as mean±SD. Differences between groups were tested for by Student's t 
test All statistical analyses were done by using Minitab Statistical Software. A p 
value of less than 0.05 was considered to indicate statistical significance.
2.3 Results
2.3.1 Lymphocyte mitogenic activity
Figure 2.1 shows mitogenic activity. In the absence of mitogenic stimulation 
thymidine uptake was significantly greater in PBMC from PIH women without 
proteinuria compared to normotensive pregnant women and PIH women with 
proteinuria (Figure 2. ID). There was no significant difference between the latter 
two. In the presence of mitogenic stimulation, PBMC from patients suffering from 
PIH with or without proteinuria showed enhanced 3H thymidine uptake when 
stimulated by PHA (Figure 2.1A) but not by ConA (Figure 2.1B) and PWM (Figure
2. IQ  compared to normotensive pregnant women. 3H thymidine uptake in 
stimulated PBMC of PIH did not differ significantly between women with and 
without proteinuria (Figure 2.1 A to 2.1C).
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Figure 2.1. continuing
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PMBC were incubated at 37°C for 72 hours in the presence of mitogens (A: PHA; B : 
ConA; C: PWM) or in the absence of mitogens (D). At the time of 68 hour 
incubation, 3H-thymidine was added. The incorporation of 3H-thymidine into DNA 
was measured after incubation. The data are represented as mean of samples with 
standard deviation. Statistical significance is given by asterisks and crosses: *p<0.05 
compared with normal pregnant women; +p<0.05 compared with PIH women without 
proteinuria.
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2.3.2 IgG and IgM Production
The amount of immunoglobulins (IgG and IgM) produced by PWM mitogen- 
stimulated PMBC is shown in Figure 2.2. Compared with normotensive pregnant 
women, IgG production was significantly raised in PIH women with proteinuria, but 
not in those without proteinuria. There was no significant difference in IgG 
production between PIH women with proteinuria and those without proteinuria. IgM 
production did not differ significantly amongst the three tested groups.
2.3.3 IL-2 activity
The results are shown in Figure 2.3. IL-2 activity was significantly higher in PIH 
patients with proteinuria than normal pregnant women (p<0.01) and PIH patients 
without proteinuria (p<0.05). There was no significant increase in IL-2 production in 
PIH patients without proteinuria (p=0.087).
2.3.4 Effects of TNFa on 6-keto-PGFla and TXB2 production
The results are illustrated in Figure 2.4. The effects of various concentrations of 
TNFa on 6-keto-PGFla and TXB2 production were studied in four PBMC 
preparations. The effects of TNFa on 6-keto-PGFla and TXB2 generation were 
tested at various doses of TNFa (0.2 to 20 ng/ml) and in all cases a bell-shaped dose 
response curve were obtained. PBMC synthesized the largest amount of 6-keto- 
PGFla (mean: 544, range: 506-618 pg per 106 cells) at 2 ng/ml of TNFa and TXB2 
(mean: 694, range: 652-768 pg per 106 cells) at 0.2 ng/ml of TNFa. It was found 
that PBMC produced a mean of 189 (range: 159-225) pg 6-keto-PGFla per 106 cells 
in the conditioned media of the control sample and a mean of 420 (range: 398-440) 
pg 6-keto-PGFla per 106 cells in the tested medium treated with 0.2 ng/ml of TNFa, 
representing a 2.2-fold enhancement whereas PBMC produced a mean of 544 (range: 
506-618) pg TXB2 per 106 cells in the conditional media of sample control and a 
mean of 694 (range: 652-768) pg TXB2 per 106 cells in the tested medium with 0.2 
ng/ml of TNFa representing only 1.3-fold enhancement, which was much less than 
that of 6-keto-PGFla (p<0.05). TNFa at the concentration of 20 ng/ml inhibited 
both 6-keto-PGFla and TXB2 generation from PBMC.
59
Figure 2.2. B lymphocye function (Ig production)
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PMBC were incubated at 37°C for 7 days at the presence of
PWM and culture supernatants were obtained for the 
determination of Igs. IgG and IgM were measured by ELISA. 
The data are represented as mean of samples with standard 
deviation. Statistical significance is given by asterisks: *p<0.05 
compared with normal pregnant women
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Figure 2.3 IL-2 activity
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IL-2 containing supernatants were obtained by culturing PBMC 
in the presence of PHA for 48 hours. IL-2 activity was 
determined by a bioassay using HT-2 cells as IL-dependent cell 
lines. The data are represented as mean of samples with 
standard deviation. Statistical significance is given by asterisk: 
*p<0.01 compared with normal pregnant women, +p<0.05 
compared with PIH patients without proteinuria
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Figure 2.4. Effects of TNFa on 6-keto-PGFla
and TXB2 production
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PBMC weie incubated with vaiying concentrations of TNFa for 24 hours. 
The levels of 6-keto-PGFla and TXB2 in the conditional meda were 
determined by EIA after incubation. Each point represents medan of samples 
(n=4). Statistical significance of a point versus no TNFa is given by 
asterisks, *p<0.05, **p<0.01. TNFa significantly affects both 6-keto- 
PGFla and TXB2 synthesis, both p<0.01, Kruskal-Wallis analysis for the 
effects of different concentrations of TNFa.
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2.3.5 Effects of IL-1(3 and IL-2 on 6-keto-PGFla and TXB2 production
The production of 6-keto-PGFla from PBMC was increased by both IL-ip and IL-2. 
IL-lp significantly enhanced 6-keto-PGFla production at the concentration ^ 0.025 
ng/ml (Figure 2.5A). IL-2 appeared to be less effective, as 25 ng/ml of IL-2 was 
required to produce a significant increase in 6-keto-PGFla production. IL-2 had no 
effects on TXB2 production although IL-lp significantly increased its production at 
the concentrations £ 0.25 ng/ml (Figure 2.5B).
2.3.6 The time course study of 6-keto-PGFla and TXB2 production
induced by TNFa, IL-lp and IL-2
Generally, enhancement of both 6-keto-PGFla and TXB2 by the three cytokines 
was time-related. It was noted that the stimulation by TNFa reached a significant 
increase after only a 30-minute incubation. Both IL-ip and IL-2 also increased 6- 
keto-PGFla and TXB2 production but this did not reach a statistical significance 
until 8 hours after the start of the incubation (Figure 2.6).
2.3.7 The ratio of TXB2 to 6-keto-PGFla
Figures 2.7 shows the changes in the ratio of TXB2 to 6-keto-PGFla during the 
formation of prostaglandins stimulated by TNFa, IL-ip and IL-2 respectively. Apart 
from TNFa at the concentration of 20 ng/ml (Figure 2.7A), the ratio of TXA2 to 
PGI2 gradually decreased in PBMC treated with cytokines (TNFa: Figure 2.7A; IL- 
lp  and IL-2: Figure 2.7B) compared with untreated controls.
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PBMC weie incubated with varying concentrations of IL-lp or IL-2 for 24 
hours. The levels of 6-keto-PGFla and TXB2 in the condtional meda were 
determined by EIA after incubation. Each point represents median of samples 
(n=4). Statistical significance of a point versus no IL-lp or IL-2 is given by 
asterisks, *p<0.05, **p<0.01. IL-lp significantly affects both 6-keto- 
PGFla and TXB2 synthesis, both p<0.01, Kruskal-Wallis analysis for the 
effects of different concentrations of IL-1 p. IL-2 significantly affects 6-keto- 
PGFla synthesis, p<0.05, Kruskal-Wallis analysis for the effects of different 
concentrations of IL-2.
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Figure 2 .6  The levels o f 6 -keto-P G F la (A) and 
TXB2 (B) in PBMC conditional media 
after different incubation times
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PBMC were incubated with 0.2 ng/ml of TNFa, 2.5 ng/ml of IL-ip and 25 ng/ml 
of IL-2 respectively. The supernatants weie obtained after dfferent incubation 
times and the levels of 6-keto-PGFla and TXB2 weie determined Each point 
represents result (medan) of three PBMC preparations. Statistical significance of 
a point versus 1/6-hour incubation is given by asterisks, *p<0.05, **p<0.01. 
The effects of TNFa and IL-lp on the production of 6-keto-PGFla and TXB2 at 
the dfferent incubation times weie significantly dfferent, all pcO.Ol, Kruskal- 
Wallis analysis for the effects of TNFa and IL-lp at the different time point The 
effects of IL-2 on the production of 6-keto-PGFla at the different incubation 
times were significantly dfferent, p<0.05, Kniskal-Wallis analysis for the effects 
of IL-2 on the production of 6-keto-PGFla at the dfferent time point.
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PBMC were incubated with varying concentrations of TNFa (A), IL-lp or 
IL-2 (B) for 24 hours. The levels of 6-keto-PGFla and TXB2 in the 
conditional media were determined by EIA after incubation and the ratio of 
TXB2 to 6-keto-PGFla was calculated Each point represents result 
(median) of four PBMC preparations. Statistical significance of a point 
versus no cytokines is given by asterisks, *p<0.05, **p<0.01. TNFa, IL- 
ip and IL-2 significantly affects the ratio, p<0.001, p<0.001 and p<0.01 
respectively. Kruskal-Wallis analysis for the effects of different 
concentrations of cytokines.
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2.4 Discussion
The results of this study have demonstrated that lymphocyte activity or its response 
to the mitogen PHA was increased in some groups of patients with PIH. This 
increased activity did not seem to be affected by the status of patients' proteinuria 
since lymphocyte response to PHA was not different between PIH patients with and 
without proteinuria. The reason why increased PBMC proliferation in the absence of 
mitogenic stimulation was observed only in PIH patients without proteinuria and not 
in those with proteinuria remains unclear. Increased mitogenic activity in PIH may 
result from intrinsic lymphocyte abnormalities. A number of facts, however, suggest 
it may be due to some intracellular and extracellular mechanism associated with the 
disease. Firstly, increased intracellular calcium has been noted in patients with PIH 
(Haller et al. 1989; Sowers et al. 1989). The increase in intracellular calcium is an 
essential signal for T cell activation (Tsien et al. 1982). Secondly, changes of 
prostaglandin pattern can greatly affect lymphocyte activity or proliferation. It is 
reported that the PGE series and PGI2 have a suppressive effect on the immune 
system (Goodwin & Webb 1980, Kingston et al., 1985) whereas TXA2 is suggested 
to have a positive effect (Kelly et al. 1979). The imbalance of increased TXA2 and 
decreased PGI2 and PGE has been well documented in PIH (Friedman 1988; 
Lindheimer & Katz 1989; Walsh 1990). Thirdly, a blood-borne mitogenic factor 
from patients with PIH has recently been discovered (Taylor et al. 1990). Although 
the patient serum was separated from PBMC in this study, the possibility that the 
mitogenic factor could have been secreted from PBMC cannot be excluded. 
Fourthly, studies have indicated that ROS are able to activate lymphocytes and 
subsequently to enhance lymphocyte proliferation (Fidelus 1988; Sekkat et al. 1988) 
and the acitivity of ROS is increased in PIH (Dekker et al. 1991; Wickens et al. 
1981). Lastly, an increase in IL-2 activity has been shown in PIH by this study. It is 
well known that IL-2 can stimulate lymphocyte proliferation via the activation of 
PKC (Watson & Mochizuki 1980; Smith 1984).
Previous investigators have found some alterations in the human immune system 
during PIH. Among the changes are elevated levels of circulating immune 
complexes (Haeger et al. 1991) and the presence of antibodies to trophoblast 
antigens, amniotic glycoprotein, placental and renal antigens, and endothelial cells 
(Rappaport et al. 1990; Sibai 1991). Here, we demonstrated that the amount of IgG 
secreted from PBMC in culture was elevated, suggesting an increased B lymphocyte 
function in PIH. The B lymphocyte hyperactivity could contribute to increased 
antibodies toward fetal or maternal tissues seen in PIH. Some of the factors which
71
favour the increase of PBMC in response to mitogens, may also affect B lymphocyte 
activity. Most autoantibodies belong to the IgG class and this may explain why the 
production of IgM is not altered in POL However, at present it is unclear why 
increased IgG production was only observed in PIH women with proteinuria but not 
in those without proteinuria. A very recent study has shown that the IgG fraction 
prepared from plasma containing antiphospholipid antibody can cause increased 
placental TXA2 production without altering PGI2 production (Peaceman & 
Rehnberg 1992). It appears that the TXA2 level is increased and antiphospholipid 
antibody occurs frequently in PIH (Branch et al. 1988; Friedman 1988; Kilpatrick et 
al. 1989b; Triplett 1989; Walsh 1990). It is therefore plausible that the observation of 
increased IgG production is one of the factors which may result in increased TXA2 
in PIH.
IL-2 plays a pivotal role in the study of lymphocyte function in vitro (Morgan et al. 
1976; Smith 1984). It is produced after T lymphocytes are activated by an antigen or 
mitogen and IL-2 binding to its receptors leads to T-lymphocyte proliferation and 
expansion in an antigen-independent manner. Although the cause of PIH is still not 
fully understood, it is likely to be an immunologically mediated process (Redman
1991). Endothelial cell damage has been deemed to have such a key role in the 
pathogenesis of PIH that it is regarded as final common pathway in the development 
of PIH (Roberts et al. 1989 & 1991). Endothelial cell injury has been closely linked 
with IL-2-mediated mechanisms. Firstly, IL-2 administration is associated with 
vascular changes, especially the capillary leak syndrome (Rosenstein et al. 1986; 
Klausner et al. 1989a). Endothelial compromise and damage may result from IL-2 
stimulating lymphocytes directly or indirectly. IL-2, in a dose-dependent manner, 
induces lymphocytes to adhere to vascular endothelium but not to other cell types. 
Activated lymphocytes (cytokine activated killer cells) are highly cytotoxic to 
endothelial cells (Damle et al. 1987). Damage is probably mediated by the release of 
soluble mediators such as lymphotoxin, TNFa and INFy (Fletcher & Goldstein 1987; 
Nedwin et al. 1985). Secondly, IL-2 is able to induce ROS production and ROS are 
known to be toxic to endothelium (See Chapter 3). Lymphocfes, neutrophils and 
macrophages can respond to IL-2 stimulation and generate ROS (Nathan 1987; Staub 
1988). Endothelial cells, although not directly affected by IL-2 (Klausner et al. 
1989a), can produce and secrete ROS in response to other cytokines such as IL-1 and 
INF-y (Matsubara & Ziff 1986), which are known to be released after IL-2 
administration (Damle et al. 1987). Thirdly, IL-2 is also known to induce TXB2 
production. This was demonstrated by the present study (See below) and others 
(Klausner et al. 1989b; Welboum et al. 1990 & 1991). TXB2 can adversely affect
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endothelial cells (Welles et al. 1985; Klausner et al. 1988) and is responsible in a 
large part for IL-2-induced the early increase in permeability of endothelial cells 
(Klausner et al. 1989b). On the other hand, TXB2 itself is a potent vasoconstrictor 
and its level in PIH is increased (Friedman 1988). Thus it plays an important role in 
the pathophysiology of PIH (See Chapter 4).
A explanation has long been sought for survival of the fetus without immunological 
rejection in normal pregnancy. A major focus of this issue has been on the female's 
ability to mount an immune response and react against non-self antigens. A change 
in the balance of maternal immunoregulatory cells towards greater suppression of 
immune responses would contribute to the immunoregulation of normal pregnancy. 
As a result, there is a balance between fetal antigenic load and maternal production 
of blockage (alloantibodies). The immunological suppression in normal pregnancy 
is evident by the fact that the response of maternal lymphocytes to PHA and mixed 
lymphocyte reactions are depressed (Petrucco et al. 1976; Tomoda et al. 1976; 
Stankova & Rola-Pleszczynski 1984). Conversely, in PIH as in recurrent 
spontaneous abortions (Christiansen et al. 1990; Redman 1991) the immune 
mechanism may not be able to adjust the balance of immunoregulatory cells in favor 
of immune suppressive function. Therefore, an excessive fetal antigenic load or 
inadequate production of immunological blockade to the fetal antigens presenting 
might lead to development of PIH (Zeeman & Dekker 1992). Fetal antigens are 
immunological and can induce a typical cell-mediated response. Locally, the 
decidual cellular immunity is stimulated to limit the trophoblastic invasion and this 
results in the failure of the endovascular trophoblast to destroy the muscular layer 
and the autonomic innervation of the spiral arteries (Zeeman et al. 1992). 
Consequently, the spiral arteries are left with a non-pregnant architecture and fail to 
dilate. Systemically, the immune system could be activated to a certain degree. It 
has been reported that the activities of neutrophils, macrophages and T-cell 
lymphocytes are increased in women with PIH (Greer et al. 1991; Zeeman & Dekker
1992). The findings of increased PBMC response to PHA, increased IL-2 activity 
and elevated IgG production from PBMC are the further evidence of this hypothesis.
Previous blood transfusion protects against PIH development (Feeney et al. 1977), 
suggesting PIH may be analagous to the beneficial effect of blood transfusion on 
renal allograft survival. Blood transfusions could lead to the presence of immune- 
blocking factors in the host and thus develop mutual immunological tolerance 
between the host and fetal or renal allograft (Persijn et al. 1979; Proud 1980). 
Interestingly, the findings of increased immune responses in PIH are also noted in
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renal allograbt (Kirkpatrick & Rowlands 1992), suggesting that a similar 
immunological mechanism might exist in both conditions.
Recent developments in the study of pathogenetic aspects of PIH seem to suggest 
that this enigmatic disease is mulitifactoral (Hubei et al. 1989; Walsh 1990; Redman 
1991), involving the immune, eiscosanoid and ROS systems. From the systemic 
point of view, it is important to understand the relationship between them. We have 
demonstrated that there is an imbalance of increased TXA2 and decreased PGI2 (See 
Chapter 4) as well as an increased IL-2 activity in PIH. Therefore, it is important to 
study the effect of immune mediators such as IL-ip, IL-2 and TNFa on the 
production of PGI2 and TXA2 in normal persons. Although IL-ip and TNFa have 
not yet been investigated in PIH, the close link between IL-2 and other cytokines 
including IL-lp and TNFa was the reason that their effects on prostaglandins were 
also studied.
It has been documented that cytokines are able to stimulate prostaglandin production 
from several kinds of cells (Kawakami et al. 1986; Akahoshi et al. 1988; Frasier- 
Scott et al. 1988; Raz et al. 1988). However, there is little data available regarding 
the effects of cytokines on the formation of prostaglandins from PBMC. This 
experiment has demonstrated that TNFa, IL-lp and IL-2 could stimulate the 
synthesis of PGI2 and TXA2 in a time- and dose-dependent manner. The induction 
of prostaglandin production was exquisitely sensitive to the concentrations of IL-lp; 
as little as 0.025 ng/ml and 0.25 ng/ml produced a clear stimulation of PGI2 and 
TXA2 syntheses respectively. The effects of TNFa on prostaglandin synthesis was 
biphasic. Culture of PBMC with 0.2 to 2 ngAnl of TNFa up-regulated the 
production of prostaglandins while at the concentration of 20 ng/ml, TNFa exerted 
down-regulation of prostaglandin production. The stimulatory activity of TNFa was 
rapid. It was observed that both PGI2 and TXA2 production increased after only 30- 
minute incubation of PBMC with TNFa. This is quite different from the effect of 
IL-lp and IL-2, in which no significant effects on PGI2 and TXA2 synthesis were 
recorded after 30-minute incubation but were present after a 8-hour incubation. This 
observation suggests that the effect of TNFa and interleukins on prostaglandin 
production is somewhat different The regulatory effects of TNFa is unlikely to 
involve protein biosynthesis, at least at the early stage of the prostaglandin synthesis.
Regulation of prostaglandin synthesis can be obtained by either increasing the supply 
of arachidonic acid or altering the cyclooxygenase activity or the specific 
prostaglandin synthetases. Our findings raise a number of possibilities. Firstly, the
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content of arachidonic acid in membrane lipid of PBMC is very high and more 
importantly the release of arachidonic acid from PBMC is increased when the cells 
are activated (Hwang 1989). As cytokines are able to activate PBMC, one putative 
role of the cytokines on the up-regulation of prostaglandin production in this study 
might be through their activation of PBMC and increasing arachidonic acid release. 
Secondly, cytokine-induced augmentation of cell activation is associated with 
generation of ROS (Meier et al. 1989). Although the high concentrations of ROS 
can be damaging to cyclooxygenase, it is believed that a lower levels of ROS 
activate the enzymes (Taylor et al. 1983). On this basis, it is possible that cytokines 
may increase the production of prostaglandins by inducing the activity of ROS. 
Thirdly, the production of cyclooxygenase and specific prostaglandin synthetase 
have been reported to be increased by the stimulation of cytokines in several cell 
systems. Frasier-Scott et al. (1988) proved that IL-2 induced de novo synthesis of 
the 70-KD subunit of prostaglandin H synthase in endothelial cells and Raz et al. 
(1988) reported that IL-1 could enhance cyclooxygenase synthesis in a time- and 
dose-dependant fashion in dermal fibroblast. However, there is, so far, no data 
available to demonstrate whether this is the case in PBMC. Since the significant 
actions of IL-ip and IL-2 were observed at a quite late stage of incubation (8th 
hour), it is believed that the increase of cyclooxygenase or other related enzyme 
synthesis in PBMC induced by interleukins could be considered to be a possible 
mechanism. Finally, as the time of action between the TNFa and interleukins (IL-1 (3 
and IL-2) differs, as stated above, the mechanism of TNFa induction of 
prostaglandin production may differ, at least in part, from that of the interleukins. 
Unlike TNFa, it is impossible that the increased release of arachidonic acid from cell 
membrane or the induction of cyclooxygenase activity by the increase of ROS is a 
major mechanism of IL-1 P and IL-2.
It has been established that TNFa has an immunoregulatory activity on PBMC 
(Balkwill 1989). Paradoxically, it is also a potent cytotoxin for cells. In addition to 
generation of ROS, there is now evidence that TNFa can interfere with the 
intracellular antioxidant buffering capacity such that cells or enzymes become more 
sensitive to oxidant-mediated injury (Ishii et al. 1992). Although the biphasic effect 
of TNFa can not be directly explained by the present experimental data, 
overproduction of ROS or damage of antioxidant ability could be one of explanations 
for this interesting phenomenon. Increased ROS levels or deficient antioxidant 
ability have been known to occur in PIH (See Chapter 3). However, whether there is 
an elevated TNFa level in PIH to account for these changes remains an interesting 
question.
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Both PGI2 and TXA2 are derived from arachidonic acid through the action of 
cyclooxygenase. It is worth noting that the increasing rate of prostaglandins induced 
by cytokines is quite different between the PGI2 and TXA2 and it depends on the 
type and concentration of cytokines involved. At lower concentrations of TNFa 
(0.02 to 2 ng/ml), the enhancement of PGI2 is much greater than that of TXA2, 
resulting in a decreasing ratio of TXA2 to PGI2 (Figures 2.7A). Conversely, at 
higher concentrations of of TNFa (more than 2 ng/ml), the increase in TXA2 is more 
obvious than that in PGI2 and this leads to a increasing ratio of TXA2 to PGI2. IL- 
lp  at the concentrations of 0.025 to 2.5 ng/ml and IL-2 at 25 ng/ml decrease TXA2 
to PGI2 ratio (Figure 2.7B). The mechanisms for these complicated effects are 
unclear. It is contradictory that there is an increased IL-2 activity (about 32 units/ml) 
and an elevation of TXA2 to PGI2 ratio in PIH and that IL-2 at the concentration of 
> 25 ng/ml (about 30 units/ml) can reduce this ratio in an in vitro experiment 
However, this may suggest that IL-2 itself is not a major factor contributing to the 
prostaglandin changes in PIH. Nevertheless, IL-2 may affect this ratio indirectly via 
its effects on other cytokine release such as TNFa.
Evidence has shown that PGI2 inhibits immunological function in a manner 
analogous to PGE2 (Kingston et al. 1985), a well known immunosuppressant, 
whereas TXA2 has been suggested to have an action on lymphocyte activation 
opposite to that of PGE2 (Kelly et al. 1979). From this point of view, the increased 
IL-2 activity and lymphocyte hyperactivity in PIH are in accordance with the 
imbalance of increased TXA2 and decreased PGI2. The interactions between the 
cytokines and prostaglandins need to be further investigated and should be 
considered to be of potential importance in the development of PIH.
2.5 Conclusions
1. PIH is associated with increased B lymphocyte function including the 
hypersecretion of IgG and increased T lymphocyte function such as hyper- 
response to mitogenic stimulation and elevation of IL-2 activity.
2. Increased IL-2 activity together with other cytokines such as TNFa may 
partially contribute to the imbalance of increased TXA2 and decreased PGI2 
found in PIH.
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CHAPTER THREE ANTIOXIDANTS
3.1 Introduction
3.1.1 Reactive oxygen species and antioxidants
The role of reactive oxygen species (ROS) in the pathogenesis of PIH has recently 
attracted attention (Hubei et al. 1989; Zeeman et al. 1992). Produced by most 
human cells, ROS may act as mediators in the development of hypertension in 
pregnancy by producing various noxious effects due to the changes in cell membrane 
phospholipids, with consequent changes in cell integrity, fluidity and permeability 
(Cronstein 1991; Rice-Evans & Bruckdorfer 1992). Other toxic effects include 
damage to nucleic acids and proteins. Lipid peroxidation production and glutathione 
peroxidase activity are increased suggesting an active role of ROS activity in PIH 
(Hubei et al. 1989), although the mechanism responsible is unclear.
The body has a multilayered antioxidant system including enzymatic and 
nonenzymatic components to cope with elevated or adventitious ROS production. 
This enables the body to use ROS biochemistry without the risk of uncontrolled 
reactions affecting physiology. However, when balance between ROS generation 
and the protective mechanisms is shifted in favour of pro-oxidants, then excessive 
ROS can be damaging.
Antioxidant buffers are essential in the protection against the deleterious effects of 
ROS, but to date knowledge about antioxidant buffering level in PIH is limited. 
Since red blood cells (RBC) can synthesize thiols and have only a limited ability to 
repair (Chilles et al. 1990) and since thiols are effective antioxidants, their 
concentrations can reflect any stress which has occurred. Therefore, RBC provide a 
useful model for the in vitro study of antioxidants or ROS.
3.1.2 Reactive oxygen species and prostaglandins
Research has suggested that the activity of ROS is closely associated with the 
production of prostaglandins. One important phenomenon which has been noted is 
the selective inhibition of PGI2 synthetase by ROS. In contrast, TXA2 synthetase is 
not influenced by comparable concentrations of such reactive molecules (Moncada et 
al. 1976; Salomon et al. 1978; Ham et al. 1979; Warso and Lands 1983; Schimke et 
al. 1992). This view is in line with some recent studies dealing with the influence of
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ROS on eicosanoid metabolism in cells. Vercellotti et al. (1991) and Whorton et al. 
(1985) demonstrated a H20 2-induced dose-dependent inhibition of PGI2 formation 
in cultured endothelial cells. PGI2 and TXA2 are involved in the control of vascular 
tone and hemostasis via a reciprocal function in blood-endothelium interactions. The 
production of TXA2 is increased in PIH, while the production of PGI2 is relatively 
or absolutely decreased (Friedman 1988; Walsh 1990; See Chapter Four). This leads 
to an increase in the ratio of TXA2 to PGI2. It has been demonstrated that changes 
in this ratio play an important role in PIH (Friedman 1988; Walsh 1990). If ROS 
change the ratio of TXA2 to PGI2 formation, it would diminish the protective 
function of the endothelium in hemostasis and vascular tone.
Since both ROS activity and prostaglandin levels appear to be changed in patients 
with PIH (Friedman 1988; Hubei et al. 1989; Walsh 1990; Zeeman et al. 1992), it is 
hypothesized that the alterations in the levels of prostaglandins may result from 
increased ROS activity or decreased antioxidant ability in PIH. To our knowledge, 
there is no evidence so far available to link prostaglandin levels and antioxidants in 
PIH.
3.1.3 Aims of the study
The first aim of the present study was to investigate the possible changes of 
intracellular and extracellular antioxidant buffering levels in RBC from patients with 
PIH and to analyse their roles in association with pathological features of PIH. 
Three extracellular antioxidant markers were measured: plasma thiol (PSH), plasma 
total glutathione (GSHp) and membrane thiol (MSH) and three intracellular 
antioxidant markers in RBC: lysate thiol (LSH), lysate total glutathione (GSH1) and 
lysate superoxide dismutase (SOD).
The second aim was to investigate the antioxidant state and the prostaglandin system 
simultaneously and to analyse relations between them. For this reason the 
antioxidant agents, TXA2 and PGI2 were chosen to be measured in the same sample 
of peripheral blood.
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3.2 Materials and Methods
3.2.1 Subjects
Four groups of subjects were studied:
1, 25 healthy nonpregnant women.
2, 36 normotensive pregnant women.
3, 27 PIH women without proteinuria.
4, 8 PIH women with proteinuria.
All pregnant women were in their third trimester of pregnancy. The detailed clinical 
information is listed in Table 3.1.
PIH women were sampled after diagnosis but before any anti-hypertensive therapy 
had been instituted.
PIH is defined as a persistent or recurrent diastolic blood pressure of 90mmHg 
which developed during pregnancy after 20 weeks of gestation, and resolved by six 
weeks post partum. Proteinuria is defined as the persistent presence of protein in the 
urine of > + on urine 'dipstick' testing, or >300 mg excreted in 24 hours. A more 
detailed discussion of these criteria has been given in Section 1.1.3 of Chapter One. 
Patients who had a history of hypertension before the twentieth week of pregnancy 
are designated as essential hypertension and were not included in this study.
3.2.2 Blood sample collection and separation of plasma and RBC
For the measurement of antioxidant markers, 10 ml of heparinized (30 units/ml 
blood) peripheral venous blood was obtained. This was then immediately 
centrifuged at 1200 x g for 10 minutes at 4°C and the plasma and RBC were 
separated.
For measurement of TXB2 and 6-keto-PGFla, 10 ml of peripheral venous blood was 
obtained and anticoagulated with 3.2% trisodium citrate (0.8ml/10 ml blood). This 
was immediately centrifuged at 1200 x g for 10 minutes at 4°C. Plasma was then 
separated and rapidly stored at -20°C until assay.
79
CO4J
Cd
Q
04J
«
M
1h3
cO
CO
O
CO
0)iH
A
cO
f r i
® c
JS ^ 535
X
s 0>
u  <  
S Ol
a)0>
««
VO
-H
o
CN
in
in
o
-H
oo
oo
oo
inr-
CN
-H
oo
o\
CN
00
-Hvo
r~oo
00
-H
(N
rooo
ooo
-H
CN
00
in
o
-H
00
oo
-H
o \o
-H
00
in
+ ^ 
+ r~
co r~ 
Z  ~
CO c-
a  ~
co r- 
Z  ~
co t> 
Z
co t"- 
Z  —
co r- 
Z
♦ t"
*
["•oo
-Hoo
o \
CN
00
00
o
+c
oo
00
00
in
CN
-H
<T>
ov
CN
VO
Mi
-Ho
av
00
00
CN
-Hin
in
00
CN
-H
00
00
00
o
+1in
ov
00
in
+1CTl
o \
-Hin
m
co in 
Z  CN
co in 
Z  CN
co in 
Z  CN
co in 
Z  CN
co in 
Z  CN
co in 
Z  CN
co in 
Z  CN
in
in
-Ho
00
CN
OV
o \
©
-Hin
oo
oo
ov
o \
-H
m i
o
oo
o \
Ml
-H
CN
O
ov
CN
-H
o \
00
VO
< T \
©
-Hin
oo
CN
o
-Hin
oo
m i
oo
in
CN
in
CN
in
CN
in
CN
00
Ml
00
o>—' I—1m -H 00
CN CN 00r-
tH*—* r lin -H 00
CN vo 00■—* H
tH
O
Ml . .• Ml i n  ^ TJMi CO -H co i n -H oo ID
-H Z  0- ov Z  CN oo oo 01cn s—' • 1—- • — 01• vo ID00 CN CN u
CN aid id X•H 01 •H oi IDd P u a  p u
0) 3 •H 0) 3 •H 44 <D
6 d 44 644 d 44 d M
5 -H 0) 0 3 H 01 rH id id
:* <d •H S 0 <D •H d d d,C44 44 rd4-> 44 Etna) <d
X U 0 id W 4 J 0 id fia>6 44
M -H 14 4-) M-HJ-I 44 OMO id0i5P. co q co q ZQ&  q Q
a
co
3
id
a)
6
oi
<d
4-1
2
0
A
4->
•H
c
<DI
X
M
0 i
A
4->
•H
TJ
m
p
idI
u
o•
o
V
a*
*
*
ino
o ,
V
a in* o
„ o
d
31 $60
^  • <D!—1 I)
44 O d
d  • idid o u
d  v •H
o> a 144<D + •H
P + dPi Di& •h
i h  in 01
id o
H *
H  O id
0 V u
d  p . •H+ 44
X! 01
44 - •H
■h id 44
£ -H idU 44
TJ
a>
p
idI
u
COz
80
3.2.3 Preparation of RBC lysate
All steps were carried out at 4°C. 1 ml of RBC pellet was resuspended in 1 ml of 
ice-cold distilled water in a 10 ml glass tube, mixed well and put on ice for 2 hours. 
During this period the sample was stirred occasionally. 800 pi of cooled absolute 
ethanol and chloroform mixture (3:5, v/v) was then added and mixed thoroughly 
with a glass pipette until the mixtures became thicker and the colour turned brick red. 
The mixtures were left on ice for a further 10 minutes and mixed occasionally. 
Three more drops of cooled absolute ethanol and chloroform mixture (3:5, v/v) and 
300 pi of distilled water were then added and mixed thoroughly. The mixtures were 
centrifuged at 1200 x g for 10 minutes at 4°C. The pale yellow supernatants were 
removed using a pipette and constituted the RBC lysate. If the separated 
supernatants still had pink or brick red colour, one more drop of cooled absolute 
ethanol and chloroform mixture (3:5, v/v) was added and the pellet was mixed 
thoroughly. The mixtures were centrifuged as above and the supernatants were 
obtained.
3.2.4 PSH and LSH assay
Assays of LSH and PSH concentrations have been described previously by Banford 
et al. (1982a & 1982b). This assay requires the following reagents:
1, Sodium phosphate buffer, 0*1 M, pH 7.6 at room temperature (25* Q .
2, DTNB, 0.01 M, in 0.1 M sodium phosphate buffer (kept in ice and 
used within one hour of preparation).
Cuvettes (3 ml) were set up as follows at room temperature.
A B C
reagent blank plasma blank lysate blank
Al Bl = B2 Cl = C2
reagent test plasma test lysate test
To the reagent blank cuvette (A) are added 3 ml of sodium phosphate buffer and to 
reagent test (Al) 2.5 ml of sodium phosphate buffer and 0.5 ml of DTNB. The 
reaction, which is carried out at room temperature, is started by the addition of
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DTNB and monitored spectrophotometrically by the increase in absorbance at 440 
nm against the reagent blank (A) exactly five minutes after adding DTNB. This 
value is the reagent blank. To plasma and lysate blank cuvettes (B and C) are added 
2.8 ml of sodium phosphate buffer and 0.2 ml of sample (plasma or RBC lysate). To 
plasma and lysate cuvettes (B l, B2 and C l, C2) are added 2.3 ml of sodium 
phosphate buffer and 0.2 ml of the sample (plasma or RBC lysate). The reaction is 
carried out as above except comparison is against the respective blanks (B or C), to 
yield the plasma and RBC lysate test values.
The results are calculated by subtracting the blank value from the average of the test 
value and multiplying by a correction factor to correct for the dilution in cell 
volumes. The correction factor for PSH is 1471 and for LSH 2297 (Banford et al. 
1982a & 1982b). Values are expressed in pmol/L, as follows.
PSHftimol/L) = [(Bl + B2)/2] x 1471 
LSH(pmoVL) = [(Cl + C2)/2] x 2297
The intra and inter-assay variations for LSH assays in our laboratory were 1% and 
7% respectively and for PSH 1.2% and 1.7%.
3.2.5 SOD assay
SOD activity was measured by the method of Misra and Fridovich (1977) based on 
the increase in the rate of photo-oxidation of 0-dianisidine. This assay requires the 
following reagents and materials:
1, Potassium phosphate buffer, 0.01 M, pH 7.5 at room temperature (25°C).
2, Riboflavin solution*, 1.3 x 10"5 M, in 0.01 M potassium phosphate buffer.
3, 0-dianisidine solution*, 0.01 M, in ethanol. 0-dianisidine is obtained from 
Sigma Chemical Company LTD.
4, SOD standard solution. SOD (from bovine RBC) is purchased from Sigma 
and stored at -20°C. It can not be used if the SOD powder turns green.
5, Light box, 8 W Philip fluorescent tubes mounted 6 inches apart, box size: 648
cm2, 38 cm high.
6, 3 ml quartz cuvettes.
*: Riboflavin solution and 0-dianisidine solution are light sensitive and should be 
covered with foil.
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The spectrophotometer was zeroed on air at 460 nm. Cuvettes were covered with 
foil. For the reagent blank, 2.94 ml of riboflavin solution and 0.06 ml of 0- 
dianisidine solution were added to the cuvette and mixed well by inversion. For the 
standard and samples, 2.8*ml of riboflavin solution, 0.06 ml of 0-dianisidine solution 
and 0.06 ml of the standard or sample were added to the cuvette and mixed well by 
inversion. The absorbance at 460 nm was measured. The cuvette was then 
illuminated for exactly 4 minutes in the light box. Absorbance at 460 nm was 
remeasured. Results are calculated by subtracting the blank value from the standard 
or sample value and multiplying by a correction factor (78.125) (Misra & Fridovich 
1977). The amount of SOD was plotted against the corresponding absorbance 
forming a standard curve and used to determine the SOD in the unknown samples. 
The value is expressed in fimol/L. The intra and inter-assay variations in our 
laboratory were 4.6% and 7.0%.
3.2.6 GSH assay
Many worker have used the DTNB-GSSG reductase recycling procedure to measure 
GSH in biologic samples. This was first reported by Owens and Belcher (1965) and 
later modified by Tietze (1969). The modification described here is basically that of 
Anderson (1985). The recycling assay for total GSH (GSH + GSSG, in GSH 
equivalents) is a sensitive and specific enzymatic procedure. As indicated in 
equation 3.1, GSH is oxidized by DTNB to give GSSG with stoichiometric 
formation of TNB. GSSG is reduced to GSH by the action of the highly specific 
glutathione reductase (GSSG reductase) and NADPH (equation 3.2). The rate of 
TNB formation is followed by spectrophotometry at 412 nm and is proportional to 
the sum of GSH and GSSG present.
2 GSH + DTNB---------------- > GSSG + TNB (Equation 3.1)
GSSG reductase
GSSG + NADPH+ H+---------------- >2GSH + NADP+ (Equation 3.2)
This assay requires the following reagents:
1, Stock buffer: 0.143 M sodium phosphate plus 6.3 mM EDTA (pH 7.5 at 
25°C), stored at 4°C.
2, Working buffer: 0.248 mg NADPH per milliliter of stock buffer (prepared 
daily and stored at 4°C).
3, DTNB solution, 6 mM in stock buffer (stored at -20°C).
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4, GSSG reductase, 50 U/ml in stock buffer (Sigma type VII, stored at 4°C).
5, Glutathione standards, diluted to desired concentrations daily from a frozen 
stock solution (1 mM GSH, prepared weekly).
6, Sulphosalicylic acid (SSA) (BDH Chemical Ltd., England), 5% (W/V).
Plasma or RBC lysate was immediately deproteinized by adding one half volume of
10% (W/V) SSA. Before assay, all reagents are warmed up to room temperature 
(25°Q. 700 pi of the working buffer, 100 pi of DTNB solution, 175 pi of distilled 
water and 25 pi of sample or standard (containing the same amount of SSA as the 
samples) were pipetted into a quartz cuvette (1.5 ml). The sample is added with 
mixing by inversion and the assay is initiated by addition of the GSSG reductase 
solution (10 pi, 50 U/ml). The spectrophotometer is set to 0.5 absorbance units full 
scale and zeroed on air at 412 nm. The background rate is determined from a blank 
containing the same amount of SSA as the sample. The amount of GSH is 
determined from a standard curve in which the GSH equivalents present are plotted 
against the rate of change of absorbance at 412 nm. A standard curve for each test is 
prepared. Values are reported in pmol/L. The intra and inter-assay variations were 
5.7% (n=7) and 9.8% (n=8) respectively.
3.2.7 MSH assay
ESSE (5,5'-dithio-bis-(2-nitrobenzoic acid), which was first synthesized by Ellman
(1959), is a reagent widely used for the determination of sulphydryl groups. ESSE 
exchanges with sulphydryl groups and can be used to determine the number of 
sulphydryl groups on the exofacial surface of the intact erythrocytes (Hoey 1987). 
ESSE undergoes a thiol-disulphide exchange reaction with free sulphydryl groups to 
produce a mixed disulphide and an anionic species (equation 3.3 and 3.4). The 
generation of ES-, an intensely chromophoreic product, can be monitored 
spectrophotometrically at 412 nm, while unreacted ESSE absorbs at 325 nm. ESSE 
can induce cell lysis when used at high concentrations and when prolonged 
incubation times are employed. This can be overcome however by careful control of 
experimental conditions.
ESSE + RES---------------- »ES-SR + ESH (Equation 3.3)
ESH---------------- > ES' + H+ (Equation 3.4)
The RBC pellet was washed with PBS three times in 15 ml-centrifuge tube (1000 x
g, 10 minutes, 25°C). 1 ml of the RBC pellet was added to a 15 ml-centrifuged tube
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containing 9 ml of ESSE solution (1(H M). The tube was inverted a number of 
times to ensure sufficient mixing had occurred and then incubated at 37 °C for 30 
minutes. After incubation, the sample was centrifuged at 1000 x g for 10 minutes. 
The supernatant was pipetted into a cuvette. The spectrum of the supernatant was 
recorded over the range of 300 to 600 nm, referencing the sample against PBS. 
Absorbance values were taken at wavelengths of 412 nm and 541 nm respectively. 
Absorbance values obtained at 541 nm was to ensure that cell lysis could be 
monitored. The sample should be discarded if cell lysis occurs. MSH was calculated 
by the following formula and the values were expressed in number of thiols per RBC 
as shown below. The intra and inter-assay variations were 6.6% and 13.5% 
respectively.
[ES"] x volume x Avogadro's No.
MSH(No of thiols/cell)  -----------------------------
RBC number x 1000 x 13600
where [ES-] = Absorbance of ES' at 412 nm.
Volume = 10.
Avogadro's No. = 6.02 x 1023.
1000 = Concentration factor
13600 = Molar absorptivity of (ES') at 412 nm.
RBC number is calculated as follows.
A RBC count was determined by taking an aliquot (10 pi) of freshly 
washed RBC and adding to PBS (90 ill). This suspension was mixed 
thoroughly. Another aliquot (10 pi) was removed from this 
suspension and added to PBS (90 pi) and mixed well. The cells were 
treated in this manner until a 1:100,000 dilution of the cell suspension 
was achieved. This diluted suspension (10 pi) was then transferred 
underneath a microscope slide placed over a haemocytometer. Using 
this method, it was then possible to calculate the number of cells 
present within a 4 x 4 matrix. The calculation was done by using the 
following formula.
Number of cells = 1/dilution factor x lOfyml (104 is the factor due to 
haemocytometer).
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3.2.8 Measurement of 6-keto-PGFla and TXB2
Both TXA2 and PGI2 are extremely labile in the circulation, undergoing rapid 
hydration of the oxange ring to yield more stable prostanoids, thromboxane B2 
(TXB2) and 6-keto-prostaglandin F la  (6-keto-PGFla) respectively. Therefore, we 
monitored TXB2 and 6-keto-PGFla as a measure of the levels of TXA2 and PGI2 
respectively.
6-keto-PGFla and TXB2 concentrations in plasma were measured using an 
enzymeimmunoassay (EIA) system (Amersham International pic, Amersham, U.K.). 
For details see Section 4.2.6 in Chapter 4.
3.2.9 Whole blood counts
Complete whole blood counts including RBC number, hemoglobin, haematocrit 
(PCV), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and 
mean corpuscular hemoglobin concentration (MCHC) and platelet count were 
measured using an automated Coulter Counter.
3.2.10 Statistical analysis
Data for clinical parameters and antioxidants are presented as mean±SD. Statistical 
differences between groups were tested by Student's t test Since 6-keto-PGFla and 
TXB2 levels are not normally distributed (Moodley et al. 1984), their data are 
described by median and ranges and to determine whether comparisons among 
groups were valid, a Kruskal-Wallis analysis was performed. Where permitted, 
differences between groups were tested for by the two-tailed Mann-Whitney (Siegel 
& Castellan 1988).
The relation between variables was assessed using the Pearson coefficient of 
correlation. Variance was compared using the F test A p value of less than 0.05 
was considered to indicate statistical significance. All statistical analyses were done 
by using Minitab Statistical Software.
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3.3 Results
3.3.1 Clincal and laboratory data
Clinical and laboratory data are summarized in Table 3.1. Blood pressure was 
significantly greater in the both PIH groups and the diastolic blood pressure in PIH 
women with proteinuria was higher than in those without proteinuria. RBC number 
count, hemoglobin concentrations, PCV, MCV, MCH and MCHC in the PIH groups 
were not significantly different from those in the normal pregnant controls. Platelets 
did not differ significantly between the PIH women without proteinuria and the 
normal pregnant women. However the levels were much lower in the PIH women 
with proteinuria compared both to those without proteinuria and to normal pregnant 
women as well.
3.3.2 Extracellular antioxidant buffering level
The concentrations of PSH in PIH women with proteinuria were lower than that in 
normal pregnant women (294±67 vs 358±74 fimol/L, p<0.05) (Figure 3.1 A). 
Although the concentrations of PSH in PIH women without proteinuria were also 
lower than that in normal pregnant women, these did not differ significantly (338±79 
vs 358±74 pmol/L, p>0.05). The levels of MSH did not differ significantly between 
the three groups (Figure 3. IB). GSHp in PIH women with proteinuria was 
significantly decreased compared to those without proteinuria (9.3±2.5 vs 18.4±11.3 
pmol/L, p<0.01) and to normal pregnant women (9.3±2.5 vs 16.4±8.1 pmol/L, 
p<0.001) (Figure 3.1C). However, the levels of GSHp between normal pregnant 
women and PIH women without proteinuria did not differ significantly.
3.3.3 Intracellular antioxidant buffering level
The PIH women with proteinuria had a significant reduction in the intracellular 
antioxidant buffering level as compared with the normal pregnant women. This was 
shown by the decreased GSH1 levels (233±42 vs 322±69 pmol/L, p<0.01) and SOD 
activity (31.5±8.7 vs 44.6±20.2 |xmol/L, p<0.05) (Figure 3.2A and 3.2B). However, 
the levels of LSH were unchanged compared to those without proteinuria and to 
normal pregnant women (Figure 3.2C). The concentrations of GSH1 in PIH women 
with proteinuria were also lower than that in those without proteinuria (233±42 vs 
298±80 prnol/L, p<0.05). The levels of LSH and SOD in PIH women with 
proteinuria were not significantly different from that in those without proteinuria.
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The concentrations of all three intracellular antioxidant markers in PIH women 
without proteinuria were not different from those in the normal pregnant women, 
though the levels of GSH1 and SOD tended to be lower (Figure 3.2A, 3.2B and 
3.2C).
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Figure 3.1 Extracellular antioxidant buffering activity in
women with PIH and normal pregnant women
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Plasma and RBC (red blood cells) were separated from peripheral venous 
blood. PSH (A, plasma thiol) and GSHp (C, plasma total glutathione) 
wore measured in plasma and MSH (B, membrane thiol) was measured 
on the membrane of RBC. Results are represented as mean ± SD. 
Statistical significance is expressed as: *p<0.05, **p<0.01, compared 
with normal pregnant women; ++p<0.01, compared with PIH women 
without proteinuria.
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Figure 3.2 Intracellular antioxidant buffering activity in
women with PIH and normal pregnant women
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Figure 3.2 continuing
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Lysate was prepared from RBC of peripheral venous blood and GSH1 
(A, lysate total glutathione), SOD (B, superoxide dismutase) and LSH 
(C, lysate thiol) were measured. Results are represented as mean ± SD. 
Statistical significance is expressed as: **p<0.01, compared with normal 
pregnant women; ++p<0.01, compared with PIH women without 
proteinuria.
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3.3.4 Correlation between the antioxidant buffering levels and the blood 
pressure.
Results were shown in Table 3.2. Blood pressure readings were taken at time of 
sample. None of the pairs showed a significant correlation.
3.3.5 Plasma levels of TXB2 and 6-keto-PGFla
The plasma concentrations of TXB2 and 6-keto-PGFla in PIH patients are shown in 
Figure 3.3 and 3.4 respectively. The levels of TXB2 were increased in normal 
pregnant women (402(216-902) p g/m l) and in PIH women both with (1091(772- 
1370) pg/tril) and without (779(565-1047) p g/m l} proteinuria, as compared 
with nonpregnant women (301(187-397) pg/ m l} • • The increased j>lasi«a 
concentration of TXB2 in PIH women with proteinuria was 262% of nonpregnant 
women, in PIH women without proteinuria 159%, and in normal pregnant women 
34% (Table 3.3). When compared with PIH women without proteinuria (779(565- 
1047) pgJwX)y  . we also found that the levels of TXB2 were much higher in the 
PIH women with proteinuria (1091(772-1370) pg/m t) (p<0.05). Nonpregnant 
women (145(91.6-192) pg/m t} \ produced less 6-keto-PGFla than normal 
pregnant women (217(119-499) pg/m l) (p<0.01) (Figure 3.4). There were, 
interestingly, no significant differences in the concentrations of 6-keto-PGFla 
between the nonpregnant women (145(91.6-192) pg/m t} and PIH women with 
(149(101-185) pg/ftit) . or without (145(52-388) pg/m t) proteinuria (p=0.65 
and 0.99 respectively). However, the levels of 6-keto-PGFla in PIH women both 
with and without proteinuria were significantly lower than that in normal pregnant 
women (217(119-499) p g/n il} (bothp<0.01).
3.3.6 The ratio of TXB2 and 6-keto-PGFla
The ratio of TXB2 to 6-keto-PGFla is an index of the relative activity of the 
opposing stimuli that modulate vascular tone and platelet activation. This ratio was 
markedly elevated in PIH women with (7.75(5.91-8.90)) and without (5.68(2.43-19.9)) 
proteinuria, as compared with normal pregnant women (1.75(1.18-2.63)) (both p<0.01) 
and nonpregnant women (2.08(2.04-2.38)) (both p<0.01) (Figure 3.5). The ratio in 
normal pregnant women did not differ significantly from that in nonpregnant women. 
There was no significant difference in the ratio between PIH women with proteinuria 
and those without proteinuria.
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Figure 3.3 Plasma concentrations of TXB2 in nonpregnant 
women, normal pregnant women and women 
with PIH
PIH women with 
proteinuria n-7
PIH women without 
proteinuria n-27
Normal Pregnant 
women n-32
Nonpregnant 
women n-7
0 200 400 600 800 1000 1200
TX B2 (p fl/m l)
Plasma was separated from peripheral venous blood and TXB2 was 
measured by immunoen zymeas say (EIA). Results were represented 
as the medians with the ranges in parentheses. Statistical significance 
was expressed as: **p<0.01, compared with nonpregnant women; 
••p<0.01, compared with normal pregnant women; Ap<0.05, 
compared with PIH women without proteinuria.
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Figure 3.4 Plasma concentrations of 6-keto-PGFla in 
nonpregnant women, normal pregnant 
women and women with PIH
PIH women with 
proteinuria n-7
PIH women without 
proteinuria n-27
Normal Pregnant 
women n-32
Nonpregnant 
women n-7
(101 -185) *
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(92- 192)
200
6-keto-PG Fla  (pg/ml)
Plasma was separated from peripheral venous blood and 6-keto-
PGFla was measured by immunoenzymeassay (EIA). Results were
represented as the medians with the ranges in parentheses. Statistical 
significance was expressed as: **p<0.01, compared with nonpregnant 
women; ~p<0.01, compared with normal pregnant women.
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Table 3.3 Increasing rate (%)* of TXB2 and 6-keto-
PGFla in PIH patients and normal pregnant women
TXB2 6-keto-PGFla TXB2/6-keto-PGFla
34 50 -16
159 3 173
262 3 273
* Increasing rate (%) = (A-B)/B x 100
where A: value from normal pregnant women or PIH
patient without proteinuria or PIH patient 
with proteinuria.
B: value from nonpregnant women.
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Figure 3.5 The ratio of TXB2 to 6-keto-PGFla in nonpregnant 
women, normal pregnant women and women with 
PIH
20
14 -
10 -
Nonpregnant Normal PIH woman PIH women
women pregnant without with
women proteinuria proteinuria
TXB2 and 6-keto-PGFla in plasma were measured by
immunoemzymeassay and the ratio of TXB2 to 6-keto-PGFla was
calculated. The individual data and the group medians were represented 
as: and " j—h " respectively. Statistical significance was expressed
as: *p<0.01, compared with nonpregnant women and normal pregnant 
women.
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3.3.7 Correlation between the antioxidant buffering level and
prostaglandins.
Correlation and regression adjustment analyses demonstrated that there were 
significant positive correlations between the several pairs of markers. The results of 
the correlations were given in Table 3.4.
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3.4 Discussion
The changes in TXB2 and 6-keto-PGFla levels in patients with PIH have been well 
documented (Friedman 1988; Walsh 1990). However none of the studies carried out 
previously have considered these changes in relation to ROS activity. In this study 
where TXB2 and 6-keto-PGFla levels were measured in the same blood sample at 
one particular point in time, we found the concentrations of TXB2 to be increased 
and 6-keto-PGFla to be decreased in PIH patients. These findings are in agreement 
with previous studies.
A major pathological event in PIH is systemic vasospasm which may lead to 
multiorgan dysfunction in extreme cases. PGI2 is a potent vasodilator and inhibitor 
of platelet aggregation. Conversely, TXA2 opposes the actions of PGI2 being a 
potent vasoconstrictor and platelet aggregator. It is therefore proposed that the most 
likely cause of vasospasm in PIH is an imbalance between TXA2 and PGI2 
(Friedman 1988). This is discussed in detail in Chapter 4 and is not the topic of this 
Chapter.
In the present study, we have also demonstrated that both extracellular and 
intracellular antioxidant buffering levels were decreased in the PIH women with 
proteinuria. While antioxidant buffering levels in PIH women without proteinuria 
were not significantly different to that seen in the normal pregnant women, levels of 
four out of the six antioxidant markers tested tended to be lower in the PIH women 
without proteinuria. This suggests that while the antioxidant buffering level in these 
patients may be sufficient to scavenge ROS, its reserve capacity may be reduced.
Antioxidants function as blockers of radical processes. The intracellular antioxidant 
buffering level is considered to be the mechanism for removal of adventitious ROS, 
whereas the extracellular one serves to control the release of ROS for essential 
functions (Rice-Evans & Bruckdorfer 1992). Among the intracellular antioxidant 
systems, GSH, a non-protein free thiol, is thought to be the most important 
component It works to reduce hydrogen peroxide to water through the action of 
GSH peroxidase (Sinclair et al. 1990) and traditionally, GSH has been viewed as the 
major component responsible for maintaining and regenerating protein-thiol groups 
that are susceptible to disulfide oxidation in RBC. SOD which catalyzes the 
dismutation of the superoxide anion radical to water and oxygen (Sinclair et al.
1990), serves as a major antioxidant enzyme in RBC where superoxide radicals are 
continuously generated by the autoxidation of hemoglobin (Misra & Fridovich
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1972). Therefore, GSH and SOD work together to form a substantial defensive 
network to protect protein and lipid from ROS attack in RBC.
The levels of PSH in PIH women with proteinuria are very low. The thiol group on 
albumin accounts for most of the available thiol in plasma and is one of the most 
likely groups to be attacked by excess ROS. Although most cells are susceptible to 
oxidative injury, RBC seem to be more at risk because of their high iron content and 
exposure to high oxygen tension as well as oxidative xenobiotic agents (Cohen et al. 
1964; Goldberg & Stem 1976; Hebbel et al. 1982). While attack by ROS is likely, a 
more probable route of attack is by membrane damage or even cell lysis. Release of 
GSH into the plasma would make GSH available to react with caeruloplasmin (CP) 
to form oxidized glutathione (GSSG) (Figure 3.6). However the assay for GSH 
which actually measures GSSG + GSH, gave a low result suggesting that some 
glutathione has been removed. If the plasma is oxidized in PIH women with 
proteinuria, as suggested by the low PSH, then it may be that GSH is removed by 
exchange. The levels of SOD were significantly reduced in PIH women with 
proteinuria. Given that ROS are produced continually in RBC (Misra & Fridovich 
1972; Hebbel et al. 1982) and there is a lower level of intracellular GSH, the reduced 
SOD levels may therefore be the result of intracellular attack.
Taken together, a decreased level of antioxidants can mean either an overproduction 
of ROS which produced a decrease in the antioxidant level or an original antioxidant 
deficiency which subsequently leads to increased ROS activity. Whatever the 
mechanism, the balance between antioxidants and ROS is shifted to ROS dominance 
in PIH. Although we have no direct data to show an increased ROS activity in PIH, 
this conclusion is in accordance with the findings of others that the formation of ROS 
and lipid peroxidation were increased in this disease (Maseki at al. 1981; Wickens at 
al. 1981; Hubei at al. 1989; Sane at al. 1989; Roberts at al. 1990; Dekker & 
Kraayenbrink 1991).
Oxidative stress can produce major interrelated derangements of cell metabolism, 
including DNA strand breakage, rises in intracellular "free" calcium, damage to 
membrane transports, cell-surface receptors, and other specific proteins especially 
thiol-containing proteins (for details see Section 1.3 in Chapter 1). These 
abnormalities may associated with the following pathological changes seen in PIH:
1, Elevation of intracellular calcium in RBC (Sowers et al. 1989).
2, Reduced RBC deformability (Cunningham et al. 1985; Anceschi et al. 1992).
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Figure 3.6 Scheme of the glutathione (GSH) and oxidized 
glutathione (GSSG) pathway
I
-SH +n
albumin
GSSG ^ GSH
GSH
CP +1/2 02
increased activity
SOD ?
RBC
-SH, thiol groups; CP, caeruloplasmin, -SSG, compounds that 
react with GSH to form GSSG; SOD, superoxide dismutase; RBC, 
red blood cells.
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3, Inhibition of endothelium-derived relaxing factor (EDRF) (Sarrel et al. 1990;
Pinto et al. 1991).
4, Increased immunological activity (See Chapter 2).
5, Imbalance between decreased TXA2 and increased PGI2 (Friedman 1988;
Walsh 1990).
6, Damage in endothelial cells (Roberts et al. 1989; Zeeman et al. 1992).
The mechanisms for each point listed above are given as follows.
Firstly, the Ca2+-ATPase and hormone receptors involved in maintaining Ca2+ 
homeostasis contain an essential thiol group (Haenen et al. 1989). The impairment 
of this thiol moiety could lead to increased intracellular levels of calcium (Bast et al.
1991). The elevation of intracellular calcium is considered to have a causal role in 
the enhanced vascular reactivity in PIH (Sowers et al. 1989).
Secondly, the composition and organization of biological membranes are important 
factors that determine the fluidity, permeability and deformability of cells. 
Biomembrane phospholipids are composed largely of unsaturated fatty acids. ROS 
attacking the membrane can lead to the oxidative destruction of unsaturated fatty 
acids in the well-documented process termed lipid peroxidation. It is also known 
that ROS can damage membrane proteins by causing fragmentation, cross-linking 
and amino acid modification (Rive-Evans & Bruckdorfer 1992) and furthermore, 
RBC are more likely to be attacked by ROS (Hebbel et al. 1982). Studies have 
shown that the increased ROS activity results in RBC membrane peroxidation and 
reduced RBC deformability (Hirayama et al. 1986; Davies & Goldberg 1987) and on 
the other hand that antioxidant agents are important in maintaining RBC 
deformability (Powell et al. 1989). Decreased RBC deformability may result in 
decreased microcirculatory flow as a result of the RBC, with a normal diameter of 7 
pm, no longer being able to deform and negotiate the capillaries, which have an 
average diameter of 4.5 pm. Thus, in PIH, reduction in RBC deformability may 
contribute to the decreased placental perfusion and inadequate oxygen supply to the 
fetus (Cunningham et al. 1985; Anceschi et al. 1992).
Thirdly, EDRF, released by vascular endothelium, is a potent vasodilator and plays 
an even more prominent role in the regulation of vascular responsiveness and tone 
than PGI2 (Vane et al. 1990). It is reported that EDRF is protected from breakdown 
by SOD and is inactivated by Fe2+ (Gryglewski et al. 1986). Fe2+ can damage
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EDRF by generation of hydroxyl radicals from H2 O2  in the Haber-Weiss and 
Fenton reaction (Freeman & Crapo 1982).
Fourthly, increasing data have been documented to support the hypothesis that 
antioxidants inhibit immunological response whereas ROS activate it via several 
different ways. Research by Gallagher & Curtis (1984) suggested that ROS could 
stimulate lymphocytes mitogenically. Others indicated that antioxidants could 
suppress the expression of receptors for IL-2 and transferrin and production of IL-2 
itself (Chaudri et al. 1986 & 1988; Domand & Gerber 1989). Oxidation of 
lymphocyte surface thiol groups has been shown to result in impairment of 
suppressor cell activity in patients with rheumatoid arthritis (Brown & Hall 1988). 
However, ROS have also been reported to inhibit lymphocyte function (Nishida et al. 
1981; Allan et al. 1987). It seems that effects of ROS or antioxidants on the immune 
system are complicated and the net result depends on their concentrations, types, 
target cells and other related factors such as calcium and cytokines. Nevertheless, an 
increased immunological activity has been found in PIH (See Chapter 2). Although 
there are no direct data yet available to support that decreased antioxidant levels have 
a causive role in it, there is a good theoretical basis for believing some links may 
exist.
Fifthly, increased ROS can change the pattern of prostaglandin production in favour 
of TXA2 synthesis (Moncada et al. 1976; Salomon et al. 1978; Warso & Lands 
1983; Schimke et al. 1992). Although the cyclooxygenase (an enzyme essential for 
PGI2 production) and PGI2 synthase require low levels of hydroperoxides for 
activation and continued catalysis, high concentrations of hydroperoxide are 
inhibiting (Ham et al. 1979; Markey et al. 1987). The activity of cyclooxygenase is 
also limited by a self deactivation (Brotherton & Hoak 1983). Whorton et al. (1985) 
demonstrated a hydrogen peroxide-induced dose-dependent inhibition of the PGI2 
formation in cultured endothelial cells. The role of ROS and antioxidants in 
changing production of TXA2 and PGI2 in PIH is reinforced by a recent study which 
showed increased lipid peroxides and decreased vitamin E levels in PIH maternal 
blood associated with an imbalance between TXA2 and PGI2 (Wang et al. 1991). 
The observations of positive correlation between the ROS scavengers and 6-keto- 
PGFla in the present study is another piece of evidence to support this theory.
Sixthly, it has been well established that the increased intracellular GSH protects 
endothelial cells against oxidative damage whereas decreased intracellular GSH 
sensitizes endothelial cells to oxidative cytolysis (Harlan et al. 1984; Tsan et al.
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1985). Endothelial cell injury is so important in the development of PIH that PIH 
has been characterised as an endothelial disorder (Roberts et al. 1989). RBC 
circulate within the vascular system and it is possible that the change of antioxidant 
levels in RBC reflects an occurrence of such an alteration in the vascular system 
including the vascular endothelial cells. This suggestion is further supported by our 
observation that extracellular antioxidant buffering level is also decreased in patients 
with PIH.
Decreased antioxidant buffers can be associated with several important features of 
PIH. However, what is the exact role played by antioxidants or ROS in the 
development of PIH? Unfortunately, at present, there is not enough evidence to give 
a completely satisfactory answer to this question. However, it seems that increased 
ROS activity or decreased antioxidants may form the link between the placental 
immunological maladaptation and the injury of endovascular trophoblast and 
endothelial cells in PIH. Immunological maladaptation can lead to placental hypoxia 
which occurs in PIH (Kaar et al. 1980; Lunell et al. 1984). As a result of hypoxia, 
ROS formation is increased (See Section 1.3.2 in Chapter 1) and subsequently 
damage to endovascular trophoblasts and endothelial cells occurs. Since PIH is 
primarily a placental disease with disappearance of its symptoms and lesions soon 
after termination of pregnancy (Chesley 1978; Roberts 1984; Redman 1991), the 
placental hypoxia is likely to be the major cause of increased ROS or decreased 
antioxidant levels. Arachidonic acid metabolism and leukocytes can also attribute to 
this changes (See Section 1.3.2 in Chapter 1). Work presented later in this thesis 
(Chapter 6) will indicate that the a reduced SOD activity is an acquired phenomenon 
as its gene structure and expression is normal, but whether there is a genetic factor 
involved in the other defective antioxidant agents still needs further studied (Walsh 
1990).
Although the extracellular antioxidant buffering level is less important in removing 
ROS than the intracellular one, its state can modulate intracellular antioxidant 
capability. Tsan et al. (1989) has reported that exogenous GSH can enhance 
intracellular concentrations of GSH. From this point of view, the decreased 
extracellular antioxidant buffering level in patients with PIH could be regarded as the 
reduction of the reserve capacity of intracellular antioxidant buffering level.
Plasma concentrations of ROS oxidation products are reported to have a correlation 
with the level of the blood pressure in PIH (Zeeman et al. 1992). However, no 
correlation was found between the antioxidant buffering level and blood pressure in
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the present study. This observation could suggest that the decreased antioxidant 
ability may not be the direct cause of raised blood pressure in PIH.
If the reduced antioxidant buffering level and/or the increased ROS activity did 
damage RBC by changing RBC deformability and fragility, it is possible that the 
RBC count could be reduced in patients with PIH. However, the RBC count in PIH 
women either with proteinuria or without proteinuria was found to be no different 
from that in the normal pregnant women in this study, although it has been reported 
by others (Skajaa 1929).
PSH, an extracellular antioxidant agent, is a thiol group located mainly on serum 
albumin. Therefore, one question arises from this fact Does an increment in 
associated protein excretion due to renal dysfunction contribute to the decreased 
antioxidant level found in PIH women with proteinuria? To date, there is no direct 
data to prove or exclude this possibility. However, since the reduced antioxidant 
levels in PIH appear to be both intracellular and extracellular and the decreased 
antioxidant agents are both proteinous and non-proteinous (such as GSH and SOD). 
Thus it is unlikely that the renal protein loss can be attributed to the decreased 
antioxidant state in PIH. However, further studies are needed to clarify this question.
Finally, the emerging appreciation of the role of ROS or antioxidants in the 
pathogenesis of PIH suggests that a possible strategy for therepeudc intervention. A 
wide range of antioxidants, both natural and synthetic (Table 3.5), has been proposed 
for use in the treatment of human disease (Greenwald 1991) and there is clear 
evidence accumulating that the presence of antioxidants such as vitamins E and C in 
the blood may have a protective role against cardiovascular diseases (Rice-Evans & 
Bruckdorfer 1992). Although, until now, antioxidant features have not been a factor 
to be considered by clinicians to choose drugs for treatment of PIH, in fact, some 
anti-hypertensive drugs have been recently found to be antioxidant (Mak & Weglicki 
1988; Nayler & Britnell 1991; See Chapter 5). Whether using those anti­
hypertensive drugs with antioxidant property or other antioxidant agents is more or 
less beneficial to PIH patients remains an interesting question.
107
Table 3.5 Some antioxidants available for
therapeutic use
Naturally-occurring
molecules and Synthetic molecules
related substances
SOD (isolated Thiols (e.g., N-
or recombinant) acetylcysteine,
mercaptopropio-
a-Tocopherol nylglycine)
Ascorbic acid Synthetic chelators
(e.g.,hydroxypyri-
Adenosine dones)
Transferrin Xanthine oxidase
inhibitors (e.g.,
Lactoferrin allupurinol,
oxypurinol,
Glutathione and amf lutizole)
its percursors
Inhibitors of
Carotenoids# other phagocyte
plant pigments activation
Deferoxamine Lipid-soluble
chain-breaking
antioxidants
(e.g., probucol)
Trolox C
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3.5 Conclusions
1, Both extracellular and intracellular antioxidant buffering levels were 
decreased in patients with PIH, especially in those with proteinuria. This 
probably reflects an occurrence of increased ROS activity in this disorder.
2, The reduction of the antioxidant buffering levels may account for several 
important pathological feathers seen in PIH and thus play a role in the 
development of PIH.
3, Plasma PGI2 level was decreased in PIH whereas TXA2 increased, resulting 
in an increased ratio of TXA2 to PGI2. These changes may result from the 
imbalance between decreased antioxidant buffering levels and increased ROS 
formation in PIH.
Postscript to Chapter 3
The concentrations of 6-keto-PGFla and TXB2 found here are much higher than 
others (FitzGeral et al. 1983. Circ 67:1174-1176; Ritter et al. 1983. Lancet 1:317- 
319; McLaren et al. 1985. Thrombosis Res. 37:177-183; Greer et al. 1985. Br J 
Obstet Gynaecol 92:581-585). In the present study an enzymeimmunoassay was 
applied to detect these two substances but most of others used a radioimmunoassay 
method. Although the different methods used may account for the differences, other 
factors could not be completely excluded, such as cross-reaction with other 
substances especially 11-dehydro-thromboxane B2, 6-keto-prostaglandin El and E2 
because the cross-reaction for these prostaglandins has not been checked with the 
enzymeimmunoassay. Therefore a further investigation is needed.
109
CHAPTER FOUR PROSTACYCLIN AND THROMBOXANE
4.1 Introduction
4.1.1 Importance of PGI2 and TXA2 in PIH
PIH is characterized by increased blood pressure, general vasoconstriction, and 
platelet hyperactivity (Pritchard et al. 1976; Lindheimer & Katz 1992). 
Theoretically, these changes could be caused by an imbalance between PGI2, a 
potent vasodilator and an inhibitor of platelet aggregation, and TXA2, a potent 
vasoconstrictor and a stimulant of platelet aggregation. A deficiency of PGI2 could 
account for endothelial cell injury through impairment of its cytoprotective function, 
whereas a predominance of TXA2 could account for the vasospasm and activation of 
intravascular coagulation (Friedman 1988). It is now well established that a major 
mechanism involved in the pathophysiologic changes of PIH is an alteration of the 
ratio of TXA2 to PGI2, with a change in the direction of TXA2 dominance 
(Friedman 1988; Walsh 1990). The importance of the change of this ratio in PIH has 
been further proved by the studies showing decreased PGI2 biosynthesis preceding 
the development of clinical disease (Fitzgerald et al. 1987) and the reduced incidence 
of PIH produced by low-dosc aspirin treatment (Wallenberg et al. 1986; Wallenberg 
& Rotman 1988; Benigni et al. 1989; Schiff et al. 1989), which can selectively 
suppress the synthesis of platelet TXA2 without inhibiting the production of vascular 
PGI2 (Walsh 1990; Walsh et al. 1992). In addition, it has been demonstrate' that 
urinary excretion of TXB2 metabolites correlates with the severity of PIH (Fitzgerald 
et al. 1990). Considerable attention has been focused on the pathologic role of PGI2 
and TXA2 in PIH and the clinical significance of them.
4.1.2 Unresoloved questions
Although it has been well documented that the changes of PGI2 and TXA2 play an 
important role in the development of pathophysiologic and clinical features of PIH 
(Friedman 1988; Walsh 1990), it remains questionable as to whether PGI2 deficiency 
and/or TXA2 overproduction are a primary change and thus perhaps a cause of PIH, 
or whether they reflect some other, more basic changes, such as an increase in ROS 
which has been known to occur in PIH women and can specifically inhibit the 
synthesis of PGI2 (Higgs & Vane 1983; Wang et al. 1989; Wang et al. 1992; Warso 
& Lands 1983, also see Chapter 3).
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The incidence of PIH in pregnant women is not increased using a high dose of 
inhibitors of prostaglandin synthesis (Dekker 1989; Briggs et al. 1990) and there is at 
least one study suggesting that PGI2 production merely functions as a rescue 
mechanism, especially during periods of ischemia and hypoxia (Spokas et al. 1983). 
On the other hand, another study has shown that a decrease in FGI2 production 
precedes the onset of PIH (Fitzgerald et al. 1987), suggesting that the changes in 
prostaglandin production might play a aetiological role in the development of PIH. 
Furthermore, it is reported that infusion of exogenous PGI2 to PIH women and 
pregnant animals, drastically reduces maternal blood pressure, diminishes platelet 
consumption and increases the uterine blood flow (Clark et al. 1982; Clark & 
Harrington 1982; Fidler et al. 1980; Lewis 1983; Walker et al. 1982).
The cause of the changes of PGI2 and TXA2 production in PIH remains unclear. 
Previous studies designed to assess the direct effects of PIH serum on several 
features of PIH demonstrated that there was a factors) 1, cytotoxic to human 
endothelial cells (Rodgers et al. 1988); 2, mitogenic to fibroblasts (Musci et al. 
1988); 3, stimulating platelet-derived growth factor synthesis (Taylor et al. 1991b); 
4, inducing a selective activation of endothelial cell procoagulant protein production 
CTaylor et al. 1991a). These data strongly suggest that there is a specific circulating 
factor(s) existing in PIH patients and functioning to induce the features of PIH.
4.1.3 Aims of the study
The aim of this study was to determine the production of PGI2 and TXA2 in human 
peripheral blood mononuclear cells (PBMC) and to investigate whether PIH serum is 
relevant to this event The rational for using PBMC instead of umbilical vein 
endothelial cells as the study model was several fold. Firstly, the advanced assay 
systems for prostaglandins have proved that human lymphocytes which are the major 
component of PBMC can produce detectable amounts of prostaglandins (Aussel et 
al. 1987). Secondly, most of previous studies concerning the prostaglandins in PIH 
were carried out on the umbilical vein endothelial cells or placental tissue. The 
production of PGI2 and TXA2 by PBMC has not been examined in PIH. Thirdly, if 
PIH is associated with a specific factor(s) in the serum, the factor must circulate 
systemically rather than being present only in local tissues such as the placenta. The 
prostaglandins are considered to be local mediators, generally exerting their biologic 
effects within a micrometer of their site of synthesis (McCormack et al. 1991). As 
the PBMC are the major functional cells in the circulation, their production of 
prostaglandins is potentially much more important than that produced by other cells.
I l l
Lastly, unlike placenta or umbilical vein endothelial cells, PBMC are available easily 
from the patients with PIH throughout the whole period of pregnancy. Therefore, the 
use of PBMC as the study material is more practical.
4.2 Materials and Methods
4.2.1 Reagents
Fetal calf serum (FCS) was supplied by Northumbria Biologicals Ltd., Cramlington, 
UK. PBS and lymphoprep™ were purchased from Oxoid Limited, England and 
Nyegaard Co., Oslo, Norway respectively.
RPMI 1640 (lOx) was obtained from Gibco, BRL and the culture medium was 
prepared according to the manufacturers instructions. For details see Section 2.2.3 in 
Chapter 2.
The enzymeimmunoassy (EIA) systems for TXB2 and 6-keto-PGFla were 
purchased from Amersham International pic., Amersham, U.K.
4.2.2 Subjects
Three groups of subjects were studied: 1, 16 normotensive pregnant women, age: 
27.3±4.6 (mean±SD) years, gestational length: 34.8±3.8 weeks. 2, 9 PIH women 
without proteinuria, age: 26.6±4.1 (mean±SD) years, gestational length: 35.3±4.2 
weeks. 3, 6 PIH women with proteinuria, age: 25.9±4.1 (mean±SD) years, 
gestational length: 35.1±4.9 weeks. All were primigravidas. The PIH women were 
sampled after diagnosis but before any anti-hypertensive therapy.
PIH is defined as a persistent or recurrent diastolic blood pressure of >90mmHg 
developing during pregnancy after 20 weeks of gestation, and resolving by six weeks 
post partum. Proteinuria is defined as the persistent presence of protein in the urine 
of > + on urine 'dipstick' testing, or >300 mg excreted in 24 hours. The latter 
measurement is preferred where available. Patients who had a history of 
hypertension before the twentieth week of pregnancy were designated as essential 
hypertension, (see Section 1.1.3 in Chapter 1).
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4.2.3 PBMC preparation
Blood was obtained from the three group patients stated above by venipuncture and 
collected into a sterile universal container with 300 units of preservative-free heparin 
(final concentration in blood: 30 units/ml, Leo Laboratories). PBMC were separated 
by density gradient centrifugation using a modification of the method originally 
described by Boyum (Boyum, 1968). Heparinised blood was layered on to an equal 
volume of lymphoprep™ in 15 ml plastic conical tubes (diameter 12mm). 
Following centrifugation at 500 x g for 30 minutes at room temperature (25°C), the 
mononuclear cell bands at the lymphoprep/plasma interface were removed using a 
Pasteur pipette. The bands/cells were washed three times in PBS by centrifugation at 
400 x g for 10 minutes and the cell pellet resuspended in RPMI 1640 containing 
2mM L-glutamine, sodium bicarbonate, penicillin and streptomycin. The cell 
number was assessed in a 10 pi aliquot of cell suspension stained with 90 pi of white 
cell staining solution (2% glacial acetic acid, a few grains of crystal violet in PBS) 
and then counted in a hematocytometer (Improved Neubauer). Their viability, 
checked with trypan blue staining, was routinely higher than 95%.
4.2.4 Serum preparation
Blood was centrifuged at 2000 rpm for 10 minutes and serum was obtained. Serum 
was frozen at -70°C until use.
4.2.5 Cell culture
The modified method described here is originally from that of Jakob et al.(1990). 2 
x 105 PBMC were incubated in 96 well-U-shaped microtitre plates, at 37°C, 5% CO2  
for 48 hours. 62.5 ug/ml of ConA (Sigma Chemical Company Ltd., UK) was added 
at the initiation of the culture. To test the effects of serum on the production of PGI2 
and TXA2 from normal pregnant PBMC, serum was added to cells to give a 
concentration of 10% at the beginning of the culture. After incubation the 
supernatants were obtained and assayed for thromboxane B2 (TXB2) and 6-keto- 
prostaglandin F la  (6-keto-PGFla) levels (the stable metabolites of TXA2 and 
PGI2, respectively). The sample controls consisted of PBMC processed in the same 
manner as those treated with ConA and serum. This control was set up to take 
account of spontaneous release of TXB2 and 6-keto-PGFla. The medium controls 
were tested for medium intereference with the assay system and found to contain 6-
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keto-PGFla and TXB2 concentrations of less than 5% and 4% respectively of the 
concentrations of detected in supernatants of the background PBMC culture.
4.2.6 Measurement of TXB2 and 6-keto-PGFla
The levels of 6-keto-PGFla and TXB2 (the stable metabolites of TXA2 and PGI2, 
respectively) in supernatants were determined by the EIA method, performed 
according to the instructions. Briefly, 50 pi of sample was added to a 96-well plate 
which was coated with donkey anti-rabbit IgG and then 50 pi of rabbit anti-6-keto- 
PGFla or rabbit anti-TXB2 was added. After incubation by shaking at room 
temperature, the samples were reacted with 6-keto-PGFla- or TXB2-horseradish 
peroxidase for 1 hour. The wells were washed four times with wash buffer and then 
150 |il enzyme substrate (TMB) was dispensed into the wells. The reaction was 
stopped by adding 100 pi of 1.0M sulphuric acid and read at 450nm within 30 
minutes. The assay sensitivity, defined as the amount of TXB2 or 6-keto-PGFla 
needed to reduce zero dose binding by two standard deviations was 3.6 pg/ml and 3.0 
pg/ml respectively. The intra and inter-assay variations for TXB2 assays were 2.5% 
and 9.9% respectively and for 6-keto-PGFla 4.5% and 14.8%. The cross-reactivity 
for TXB2 and 6-keto-PGFla was performed with a number of related compounds 
and the results shown in Table 4.1.
4.2.7 Result Adjustment
Serum 6-keto-PGFla levels are lower and TXB2 levels higher in preeclamptic 
women (Friedman 1988). Therefore in those experiments where the effects of serum 
on prostaglandin production are considered the results need to be adjusted according 
to 6-keto-PGFla and TXB2 levels in the serum used. In this experiment 10% serum 
was added to a final volume of 0.2 ml per culture well to give a 0.02 ml of serum per 
well. The determination of serum levels of 6-keto-PGFla and TXB2 showed that 
0.02 ml of serum from preeclamptic women with proteinuria contained 13.78 
(median) pg more TXB2 and 1.36 (median) pg more 6-keto-PGFla than the same 
volume of serum from normal pregnant women and serum from those without 
proteinuria contained 7.54 (median) pg more TXB2 and 1.44 (median) pg more 6- 
keto-PGFla. Therefore, 13.78 for TXB2 and 1.36 for 6-keto-PGFla should be 
subtracted from the results using proteinuric-preeclamptic serum. The same 
principle also applies to the data from using non-proteinuric-preeclamptic serum.
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4.2.8 Statistical Analysis
Since the levels of TXB2 and 6-keto-PGFla are not normally distributed (Moodley 
et al. 1984), their data are expressed as medians and ranges. To determine whether 
comparisons among groups were valid, we first performed a Kruskal-Wallis analysis. 
Where permitted, the two-tailed Mann-Whitney was then used to test statistical 
difference (Siegel & Castellan 1988). All statistical analyses were done by using 
Minitab Statistical Software. A p value of less than 0.05 was considered to indicate 
statistical significance.
4.3 Results
4.3.1 Production of 6-keto-PGFla
Figure 4.1 shows that the production of 6-keto-PGFla from PBMC tended to be 
lower in PIH patients both with and without proteinuria than in normal pregnant 
women (257,218 and 324 pg per 106 cells, respectively), although this did not reach 
the statistical significance (p=0.153 and p=0.054 respectively). There was no 
significant difference between the PIH patients with proteinuria and those without 
proteinuria (p>0.05).
4.3.2 Production of TXB2
Figure 4.2 shows that the concentrations of TXB2 from PBMC were significantly 
higher in PIH patients both with and without proteinuria than in normal pregnant 
women (1397, 1065 and 897 pg per 106 cells respectively and both p<0.01). The 
levels of TXB2 in PIH patients with proteinuria was significantly increased 
compared with those without proteinuria (p<0.05).
4.3.3 Ratio of TXB2 to 6-keto-PGFla
Figure 4.3 shows the change of the ratio of TXB2 to 6-keto-PGFla. This ratio 
reflects the relative concentrations of TXB2 and 6-keto-PGFla. Therefore, its value 
is an index of the relative activity of the opposing stimuli that regulate vascular tone 
and other functions. This ratio was significantly elevated in PIH patients both with 
and without proteinuria compared to that in normal pregnant women (5.30, 5.16 and 
2.46 respectively and both p<0.01). However, there was no significant difference 
between the PIH patients with proteinuria and those without proteinuria (p>0.05).
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Figure 4.1. The production of 6-keto-PGFla in PBMC from women
with PIH and normal pregnant women
PIH with
Proteinuria
n=6
PIH without 
Proteinuria 
n=9
Normal
Pregnancy
n sl6
(207-328)
(161-320)
(166-680)
6-keto-PGF1a (pg/106 cells)
PBMC were stimulated with ConA and incubated for 48 hours. 6- 
keto-PGFla in the supernatants was measured by the method of 
enzymeimmunoassy. The data are represented as the medians with 
the ranges in parentheses.
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Figure 42 . The production of TXB2 in PBMC from women with
PIH and normal pregnant women
PIH with
Proteinuria
n=6
(1030-1510)
PIH without 
Proteinuria 
n=9
Normal
Pregnancy
n*16
680-1075)
(905-1390) *
1600
TXB2 (pg/106 cells)
PBMC were stimulated with ConA and incubated for 48 hours. 
TXB2 in the supernatants was measured by the method of 
enzymeimmunoassy. The data are represented as the medians with 
the ranges in parentheses. Statistical significance is expressed as: 
**p<0.01, compared with nomal pregnant women; +p<0.05 
compared with PIH women with proteinuria.
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Figure 4.3. The ratio of TXB2 to 6-keto-PGFla in women with PIH
and normal pregnant women
PIH with
Proteinuria (4.60-5.73)
ns6
PIH without a.
Proteinuria
n=9
Normal
Pregnancy (1.58-3.78)
n=16
t------------ »------------I
2 4 6 8
TXB2/6-keto-PGF1 a
PBMC were stimulated with ConA and incubated for 48 hours. TXB2 
and PGFla in the supernatants was measured by the method of 
enzymeimmunoassy and the ratio of TXB2 to 6-keto-PGFla was 
calculated. The data are represented as the medians with the ranges in 
paretheses. Statistical significance is expressed as: **p<0.01, compared 
with nomal pregnant women.
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4.3.4 Effect of PIH sera on 6-keto-PGFla and TXB2 production
The effects of sera on the production of 6-keto-PGFla and TXB2 are illustrated in 
Figure 4.4. PBMC from normal pregnant women exposed to sera from normal 
pregnant women release 301 pg 6-keto-PGFla per 106 cells into their conditioned 
media, whereas conditioned media from identical cells treated with serum from PIH 
women with proteinuria contained 223 pg 6-keto-PGFla per 106 cells. Serum from 
PIH women with proteinuria significantly increased the production of TXB2 as 
compared with identical cells treated with normal pregnant sera (1241 vs 844 pg per 
106 cells, p<0.05) or treated with non-proteinuric-PIH serum (1241 vs 950 pg per 
106 cells, p<0.05). However, serum from PIH women without proteinuria did not 
significantly affect either 6-keto-PGFla or TXB2 formation. Cells treated with 
serum from PIH women with proteinuria had a significantly increased ratio of TXB2 
to 6-keto-PGFla, compared to cells treated with sera from either normal pregnant 
women (5.54 vs 2.81, p<0.01) or from PIH women without proteinuria (5.54 vs 3.19, 
p<0.01) (Figure 4.5). Although the ratio of TXB2 to 6-keto-PGFla from cells 
treated with PIH patients without proteinuria tended to be higher than that of cells 
treated with normal pregnant sera (3.19 vs 2.81), this difference did not reach 
statistical significance (p>0.05).
4.3.5 6-keto-PGFla and TXB2 production from PBMC with and without
sera treatment
When production of 6-keto-PGFla and TXB2 from PBMC without serum treatment 
was compared to that with treatment, it was found that TXB2 levels from normal 
pregnant PBMC treated with the serum from PIH women with proteinuria was 
similar to that from proteinuric-PIH PBMC which had not received serum treatment 
(1241 vs 1398 pg per 106 cells, p>0.05). The ratio of TXB2 to 6-keto-PGFla in 
normal pregnant PBMC treated with proteinuric-PIH serum was also similar to that 
of proteinuric-PIH PBMC without serum treatment (5.54 vs 5.30, p>0.05) and was 
significantly higher than that of normal pregnant PBMC without serum treatment 
(5.54 vs 2.46, p<0.01).
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Figure 4.5. The ratio of TXB2 to 6 -k e to -P G F la  after
serum treatment
Treated with serum 
from PH women with 
proteinuria, n -4
Treated with serum 
PH women without 
proteinuria, n -6
Treated with serum 
from normal pregnant 
women, n -5
PBMC were stimulated with ConA and incubated for 48 hours. 
Test sera (10%) were added to cells at the beginning of incubation.
TBX2 and 6-keto-PGFla in the supernatants were measured after
culture and the ratio of TXB2 to 6-keto-PGFla was calculated.
The data are represented as the medians with the ranges in 
parentheses. Statistical significance is expressed as: **p<0.01, 
compared with PBMC treated with nomal pregnant serum; 
++p<0.01 compared with PBMC treated with serum from PIH 
women without proteinuria.
0 2 4 6 8
TXB2/6-keto-PGF1 a
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4.3.6 A comparison of the effect of serum from proteinuric PIH patients on
TXB2 production with that on 6-keto-PGFla production
It was noted that although sera from PIH patients with proteinuria affected both 
TXB2 and 6-keto-PGFla formation, the effects on TXB2 was greater than that on 6- 
keto-PGFla. In order to assess this difference, change rate was calculated as 
follows.
Sample treated Sample treated with 
with PIH serum ~ normal pregnant serum
---------------------------------------------------- X 100%
Sample treated with normal pregnant serum
The results of this showed that when PBMC were treated with sera from PIH patients 
with proteinuria, the change rates of TXB2 is significantly greater than that of 6- 
keto-PGFla (Figure 4.6).
Change _ 
Rate (%)
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Figure 4 .6 . Com parison the effect o f serum  on TXB2
production w ith that on 6 -k e to -P G F la  production
80 i
o
in
6 0 - o
©
13
^  40 -© wD)
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6
SZ
O
2 0 -
6-keto-PGF1 aTXB2
PBMC weie stimulated with ConA in the presence of 10% test sera. After 48-hour
incubation, 6 -keto-PGFla and TXB2 in the supernatants were measured Change
rate was calculated as follows:
Sample treated serum from Sample treated with serum
PIH women with proteinuria from normal pregnant wome
Change Rate (%)=------------------------------------------------------------------ X 1 0 0 %
Sample treated with senm  from normal pregnant women
The data are represented as the medans with the ranges in parentheses. Statistical 
significance is expressed as: **p<0.01, compared with 6 -keto-PGFla.
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4.4 Discussion
In recent years, evidence from maternal plasma, maternal urine, fetal plasma, fetal 
vessels, amniotic fluid and fetoplacental units has supported the concept that PIH is 
associated with a functional imbalance between PGI2 and TXA2 (Friedman 1988; 
Walsh 1990). Using PBMC as a study model, we have also confirmed that changes 
of PGI2 and TXA2 production occur in PIH. The balance between PGI2 and TXA2 
shifted to a dominance of TXA2. In normal nonpregnant women production of PGI2 
is below the threshold for biological activity (Fitzgerald et al. 1981). However, in 
view of its enhanced production in normal pregnancy (Brash et al. 1983), PGI2 may 
regulate blood pressure. Thus, a reduction in PGI2 biosynthesis may play a 
pathophysiological role in PIH through its effects on vascular smooth muscle. In 
addition to PGI2 deficiency, TXA2 overproduction could exaggerate 
vasoconstriction in PIH, because the balance between PGI2 and TXA2, rather than 
either agent alone, may be a factor resulting in vascular dysfunction and thereafter 
hypertension and probably a reduction of uterine and placental blood flow (Lunell et 
al. 1984)
Alternatively, PGI2 and TXA2 may play a role in PIH through their effects on 
platelets. A decreased PGI2 biosynthesis and increased TXA2 production may result 
in increased platelet activation, either systemically or in the uterine vascular bed, 
leading to enhanced vascular tone through release of platelet vasoactive mediator or 
obstruction of the placental vasculature by platelet aggregates (Moncada & Vane 
1979; Lindheimer & Katz 1981; Editorial 1986). Consistent with platelet activation 
in this disease, a decrease in platetlet count, an increase in platelet aggregation and 
an excessive release of beta-thromboglobulin and other platelet factors have been 
observed in patients with PIH (Inglis et al. 1982; O'Brien et al. 1986).
Of primary importance, this study has demonstrated that the sera from PIH women 
with proteinuria contained a factor(s) which could suppress the PGI2 production and 
enhance TXA2 synthesis in PBMC. It is unlikely that this factor(s) is solely 
responsible for the imbalance of PGI2 and TXA2 in PIH as no significant effects 
were observed in the cells treated with sera from PIH patients without proteinuria. 
These patients also showed the changes in prostaglandin metabolism albeit to lesser 
degree than those with proteinuria.
The cause of the imbalance between PGI2 and TXA2 seems to be complicated and 
multifactorial. To date, there are several substances which have been reported to be
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changed in PIH and are also known to affect the production of prostaglandins in 
humans.
The first of them is progesterone. Progesterone is capable of inhibiting PGI2 
production (Walsh 1988) and is found to be increased in PIH placentas (Walsh 
1989). However, as progesterone does not affect TXA2 production and as its 
circulating concentration is not significantly different between normal and PIH 
women (Pedersen et al. 1983), it is unlikely that the effects described here can be 
attributed to progesterone.
The second is reactive oxygen species. It has been reported that the activity of 
reactive oxygen species is increased in PIH (Ishihara 1978; Maseki et al. 1981; 
Wickens et al. 1981; Dekker & Kraagenbrink 1991; Wisdom et al. 1991; Wang et al. 
1992; also see Chapter 3). Increased reactive oxygen species can change the pattern 
of prostaglandin production in favour of TXA2 synthesis (Moncada et al. 1976; 
Salomon et al. 1978; also see Chapter 3). At present, it is not shown that the serum 
factor(s) belongs to reactive oxygen species, but the possibility does remain.
The third is the mitogenic factor(s). The mitogenic factor(s), which was recently 
discovered in the serum from PIH patients by Taylor and his colleagues, has the 
ability to stimulate fibroblasts and is classified as a growth factor (Musci et al. 1988; 
Taylor et al. 1990). It has been documented that the process of activation of cells 
induced by growth factors or mitogens can generate reactive oxygen species (Meier 
et al. 1989). If the reactive oxygen species is overproduced, the imbalance of PGI2 
and TXA2 as stated above would occur. Therefore, there is a possibility that the 
serum factor(s) we have found here is the mitogenic factor(s).
The fourth is lipoxygenase products. Lipoxygenase products have been suggested to 
suppress PGI2 synthesis (Turk et al. 1980) and are known to be increased in PIH 
(Friedman 1988). Since the role of lipoxygenase products on TXA2 production is 
not known, it is unclear at present whether the serum factor(s) is related to them.
The last possibility is a completely new substance which is at present totally unkown 
to us.
The effect of PIH sera on TXA2 formation is much more intense than that on PGI2 
production as it is proved by the calculation of change rate (Figure 4.6). Both PGI2 
and TXA2 are derived from arachidonic acid through the action of cyclooxygenase.
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If the the serum factor(s) described here only affects the level of cyclooxygenase 
then the change rate of PGI2 and TXA2 should be similar. From this point of view, 
the site of action of this serum factor(s) may locate on the levels of TXA2 and PGI2 
synthase rather than on the levels of cyclooxygenase or prostaglandin H synthase. 
This suggestion is similar to that of Satoh et al. (1991) who analysed the TXA2 and 
FGI2 synthesizing activity in PIH and found that TXA2 synthesis was significantly 
increased whereas PGI2 was not
The mechanism leading to the changes in TXA2 and PGI2 in PIH is complicated. 
The serum factor(s) found here can not fully account for such changes, as serum 
from PIH patients without proteinuria failed to exert such an effect It seems that a 
number of factors may work in combination to contribute to the imbalance of TXA2 
and PGI2. In addition to the above four substances, a defective genetic coding for 
TXA2 and PGI2 production should be also considered (Walsh 1990). The 
occurrence of altered prostacyclin biosynthesis long preceding the development of 
PIH clinical signs (Fitzgerald et al. 1987) and the induction of similar pathological 
changes and hypertension in pregnant rats by a diet deficient in polyunsaturated fatty 
acids (McKay et al. 1967) implicate abnormalities in prostanoid formation in the 
genesis of the human disease. Obviously, further and more comprehensive studies 
are needed to extrapolate the mechanism of abnormal prostaglandin production in 
PIH and the present study must be regarded as preliminary.
Several pharmacological approaches to the prevention and treatment of PIH can stem 
from the possible role of PGI2 deficiency and exaggerated TXA2 generation in the 
development of PIH. Firstly, dietary factors (composition of precursor fatty acids, 
antioxidants such as vitamin E) may modify the PGI2 and TXA2 balance (Lands 
1981), but their implication in the synthesis of PGI2 and TXA2 during pregnancy has 
not been thoroughly studied. Secondly, evidence has shown that the infusion of 
exogenous PGI2 increases and inhibition of endogenous PGI decreases the uterine 
blood flow in pregnant animals (Clark & Harrington 1982; Clark et al. 1982). More 
important, preliminary data showed that synthetic PG12, when given intravenously to 
PIH women, significantly reduced maternal blood pressure and platelet consumption 
(Fidler et al. 1980; Walker et al. 1982; Lewis 1983). However, these provocative 
trials need to be confirmed in controlled studies, the performance of which is 
hampered by the knowledge that it may cause a bleeding tendency (Fidler et al. 
1980). Thirdly, besides giving dietary factors and exogenous PGI2, the most 
promising therapeutic intervention in this regard is small doses of aspirin. Low 
doses of aspirin would inhibit TXA2 formation while sparing PGI2 synthesis (Walsh
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1990; Walsh et al. 1992) and have been successful in reducing the incidence of PIH 
and improving the clinical signs in several trials (Wallenberg et al. 1986, Wallenberg 
& Rotman 1988; Benigni et al. 1989, Schiff et al. 1989, Walsh 1990). However, 
large-scale clinical trials are still needed to comfirm the efficacy and safety of this 
treatment protocol in the wide population of pregnant women and to establish the 
precise nature of the relation between the aspirin-induced decrease in the ratio of 
TXA2 to PGI2 and the reduction in the incidence of PIH.
4.5 Conclusions
1. PIH is associated with an imbalance of decreased PGI2 and increased TXA2 
production in PBMC.
2. A factor(s) from PIH patients with proteinuria was discovered to contribute 
to, at least in part, the abnormal pattern of prostaglandin production.
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CHAPTER FIVE EFFECTS OF ANTIHYPERTENSIVE DRUGS
ON ANTIOXIDANTS
5.1 Introduction and aim of the study
The treatment of PIH with antihypertensive drugs is controversial, but methyldopa, 
atenolol, labetalol and calcium-channel blockers all have been used in treatment of 
this disorder (Fuerst 1982; Moietti et al. 1990; Blake & Macdonald 1991). Toxic 
oxygen metabolites such as superoxide anion (0 2'), hydrogen peroxide (H2 O2 ) and 
the hydroxyl radical (OH'), commonly called reactive oxygen species (ROS), have 
been implicated in the development of cardiovascular diseases including PIH 
(Wilson 1990; Krzanowski 1991; Rice-Evans & Bruckdorfer 1992; See Chapter 
three). Furthermore, there is some evidence that there is protection from 
cardiovascular diseases from the administration of nonenzymatic antioxidant agents 
such as vitamin E (Guamieri et al. 1980) and glutathione (Menasche et al. 1986) or 
enzymatic antioxidant agents (Bernier et al. 1989). Therefore, from a therapeutic 
standpoint, it is clearly of great interest to find if antihypertensive drugs have 
favourable effects on ROS scavengers.
The effects of methyldopa on blood pressure is related to the stimulation of a 2- 
adrenergic receptors. It used to be believed that methylnoradrenaline, the metabolite 
of methyldopa, had a weaker action than noradrenaline but in fact its pressor 
properties are hardly less than those of noradrenaline. It is now clear that 
methylnoradrenaline produces its antihypertensive effect by stimulating a 2- 
adrenergic receptors in the brainstem. Such stimulation results in decreased 
sympathetic outflow from the central nervous system (Bobik et al. 1986; Reid 
1988). Atenolol binds with high affinity to ^-adrenergic receptor sites and 
subsequendy blocks the catecholamine stimulation of adenylate cyclase (Lefkowitz 
1976). Labetalol is a ^-blocker with a  ^ adrenoceptor antagonist properties. 0 4 - 
receptor blockade leads to relaxation of arterial smooth muscle and p-receptor 
blockade limits the reflex sympathetic stimulation of the heart and causes peripheral 
blood vessel vasodilation (Gold et al. 1982, Louis et al. 1984). Binding to the a  or P 
receptors can result in changes of cellular signals such as 3'5-cyclic adrenosine 
monophosphate (cAMP) and calcium. Since recent studies have shown that ROS 
activity is associated with cellular signals (Lim et al. 1983, Vercellotti et al. 1991), it 
is possible that these three agents might have antioxidant biochemical properties.
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Published literature has indicated that ^-blockers are able to provide significant 
protection against ROS-mediated sarcolemmal membrane lipid peroxidation (Mak & 
Weglicki 1988), but the literature investigating the relation between ^-blockers and 
antioxidant agents in peripheral blood is limited. Likewise, relatively few studies 
have been considered the effects of methyldopa on ROS or antioxidant agents in 
peripheral blood.
Calcium channel blockers constitute a structually and pharmacologically diverse 
group of organic compounds which share the common action of reducing the 
movement of calcium ions into cells. They have become a widely accepted therapy 
in hypertension and angina pectoris (Cohn & Braunwald 1984; Kiowski et al. 1989). 
Recently, calcium channel blockers have become particularly attractive as possible 
intervention agents in peroxidative damage (Henry 1991; Nayler & Britnell 1991). 
However, the mechanism accounting for their antiperoxidative protection is not fully 
understood.
The aim of the present study was to determine in vitro the effects of atenolol, 
labetalol and methyldopa on antioxidant levels and to see in vitro whether calcium 
channel blockers (nifedipine and nimodipine) exert their antiperoxidative effect by 
changing the levels of antioxidant activity. Six antioxidant markers were 
investigated. They were red cell membrane thiol (MSH), plasma thiol (PSH), red 
cell lysate thiol (LSH), plasma total glutathione (GSHp), lysate total glutathione 
(GSH1) and red cell lysate superoxide dismutase (SOD).
5.2 Materials and Methods
5.2.1 Reagents and Supplies
5,5-Dithio-bis (2-nitrobenzoic acid) (DTNB), ethylenediaminetetraacetic acid 
(EDTA), glutathione, glutathione reductase (type m ), O-dianisidine, riboflavin and 
superoxide dismutase were purchased from Sigma Chemical Company LTD, Dorset, 
England. Sulphosalicylic acid (SSA) was from BDH Chemical Ltd, Poole, England. 
Atenolol was supplied by ICI Pharmaceuticals, Macclesfield, England, labetalol by 
Glaxo and Methyldopa by Merck Sharp and Dohme. Nifedipine and nimodipine 
were supplied by Bayer UK Limited, Berkshire, UK.
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5.2.2 Drug solution preparation
Atenolol (0.1-100 pg/ml), labetalol (0.1-100 jig/ml) and methyldopa (0.1-100 pg/ml) 
were dissolved in PBS. Nifedipine (1-1000 ng/ml) and nimodipine (1-1000 ng/ml) 
were dissolved in PBS containing 0.04% ethanol (ethanol is required to dissolve both 
drugs). All these solutions were shown to have no significant effect on cell viability 
by trypan blue staining. The cell viability was found to be greater than 95%.
5.2.3 Preparation of cells
Heparinized peripheral blood (30 units of heparin/ml) was taken from 14 healthy 
normal subjects (12 females, 2 males, mean±SD age: 33.6±6.8) who had no family 
history of hypertension or autoimmune disease. Peripheral blood was incubated with 
atenolol, labetalol, methyldopa, nifedipine and nimodipine respectively. After 
incubation, RBC and plasma were separated by the centrifugation of peripheral blood 
at 4°C for 10 minutes.
5.2.4 Preparation of RBC lysate
All steps were carried out at 4°C. 1 ml of the RBC pellet was resuspended in 1 ml of 
ice-cold distilled water, mixed and stood in ice for 2  hours. 800 pi of cooled 
absolute ethanol and chloroform mixture (3:5, v/v) was then added and mixed 
thoroughly. Lysate was obtained after centrifugation (For details see Chapter 3)
5.2.5 Assays for antioxidant agents (For details see Chapter 3)
The methods for the assays of SOD and PSH have been previously described by 
Banford et al (1982a, 1982b). LSH activity was measured according to the method 
of Misra and Fridovich (1977), based on the increase in the rate of photo-oxidation 
of O-dianisidine. The glutathione content of the plasma or lysate was measured 
enzymatically at 25’C by the method of Anderson (1985). MSH was measured using 
Ellman's reagent Ellman's reagent can be used to induce an oxidative stimulus on 
the exofacial membrane sulfhydryl group of the human red cell, thus making it a 
chemical probe of the sulphydryl population (Hoey 1987). MSH was calculated by 
the following formula:
nireTjrM c i / m [ES_] x volume x Avogadro's No.MSH(No of thiols/cell) =------------ -—-— — —— —-
number of cells x 1000 x 13600
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5.2.6 cAMP assay
After peripheral blood was treated with atenolol, labetalol and methydopa 
respectively as stated above, plasma was separated and kept in -70°C until assay. 
cAMP was measured using an in-house radio-imunoassay after acetylation of the 
samples with triethylamine/acetic anhydride (2:1). The cAMP antiserum has been 
described previously (O'Reilly et al. 1986). The assay has a detection limit of 30 
pmol/1  and a between-batch coefficient of variation of 10-15% over the working 
range of the assay. All samples were assayed in duplicate and performed by Dr.
W.D. Fraser, Dept of Biochemistry, Liverpool Royal Infirmary, UK.
5.2.7 Statistical analysis
All statistical analyses were made with statistical analysis package for 
microcomputers (Minitab). Effects of atenolol, labetalol, methyldopa, nifedipine and 
nimodipine were analyzed for drug effect by analysis of variance (ANOVA). In 
cases in which a significant ANOVA was demonstrated, a paired Student's t test was 
used to determine which of the data point(s) differed. Results are expressed as mean 
± SD. A p value less than 0.05 was considered to be significant
5.3 Results
5.3.1 Statistical results of effects of antihypertensive drugs on antioxidant
acidvity by ANOVA
0 .1 - 1 0 0  p,g/ml of atenolol, labeltalol and methyldopa and 1 - 1 0 0 0  ng/ml of nifedipine 
and nimodipine were incubated with peripheral blood samples respectively for 1 2 0  
minutes. After incubation, the antioxidant markers were measured. The data were 
subjected to ANOVA to test whether these drugs had effects on antioxidant levels. 
This results were presented in Table 5.1. Atenolol has significant effects on PSH and 
MSH and labetalol has significant effects on PSH only. However these two drugs 
had no effects on other antioxidant markers. Methyldopa, nifedipine and nimodipine 
did not affect any of the parameters tested.
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Table 5.1 ANOVA results of effects of antihypertensive
drugs on antioxidant levels
A.
Atenolol Labetalol Methyldopa
DF* F P DF F P DF F P
PSH 8/45 3.39 0.004 8/45 3.71 0.002 7/41 1.37 0.243
LSH 8/44 1.32 0.260 8/45 1.61 0.148 7/42 0.41 0.893
SOD 7/44 0.88 0.529 7/38 0.76 0.680 7/38 0.42 0.886
GSHp 6/36 0.61 0.722 6/36 1.38 0.249 6/36 1.01 0.437
MSH 8/42 2.96 0.010 8/43 2.15 0.051 7/40 0.13 0.995
*DF is expressed as DF Factor/DF Error.
B.
Nifedipine Nimodipine
DF* F P DF F P
LSH 2/42 0.33 0.718 2/42 0.47 0.629
SOD 2/78 0.86 0.427 2/51 0.11 0.900
GSHI 2/60 3.08 0.053 2/51 2.94 0.062
MSH 2/33 0.69 0.507 2/33 1.27 0.293
*DF is expressed as DF Factor/DF Error.
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5.3.2 Effects of nifedipine and nimodipine on MSH, LSH, GSH1 and SOD 
respectively
Tables 5.2 and 5.3 were the detailed data of antioxidant markers after nifedipine or 
nimodipine treatment Compared to an untreated control group both drugs at the 
concentrations of 1 0 - 1 0 0 0  ng/ml incubated with peripheral blood for 1 2 0  minutes 
tended to increase the levels of the four tested antioxidant agents. However, these 
increases did not reach statistical significance (all p>0.05, t test).
5.3.3 The time course study of effects of nifedipine and nimodipine on 
antioxidant levels
Results are shown in Tables 5.4 and 5.5. 100 ng/ml of both drugs at different 
incubation times (0 - 1 2 0  minutes) had no effect on antioxidant levels.
5.3.4 Effects of atenolol, labetalol and methyldopa on PSH, LSH, SOD, 
MSH and GSHp respectively
As shown in Figure 5.1 A, atenolol at concentrations from 1 to 50 pg/ml and labetalol 
at concentrations from 0.1 to 25 (ig/ml increased PSH levels significantly. The dose 
response curves were bell shaped with maximum effect being detected at a 
concentration of 25 pg/ml for both atenolol and labetalol. As shown in Figure 5. IB 
atenolol and labetalol at various concentrations produced no significant changes in 
LSH levels. Atenolol at concentrations of 1 to 50 ng/ml and labetalol at 
concentrations of 0.1 to 25 ng/ml had significant effects on MSH (Figure 5.1C). 
Atenolol, labetalol and methyldopa showed no effects on SOD activity (Figure 5. ID) 
and GSHp content (Figure 5. IE). There was no significant effect of methyldopa on 
any of the tested antioxidant agents (Figures 5.1A-C,E).
5.3.5 The time course study of effects of atenolol and labetalol on 
antioxidant levehs
Time course studies (Figure 5.2) showed that 25 lig/ml °f atenolol and labetalol 
exerted significant effects on PSH and MSH after 60 to 120 minutes of incubation 
with peripheral blood, but not after 15 and 30 minutes of incubation.
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Figure 5.1. Effects of atenolol, labetalol and methyldopa 
on antioxidant agents
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Peripheral blood was incubated with atenolol (— □— ), labetalol (— A — )
and methyldopa (--- • — ) respectively. After incubation, plasma and red cell
lysate were prepared and antioxidant markers: PSH (A, n=8 ), LSH (B, n=8 ), 
MSH (C, n=8 ), SOD (D, n=8 ) and GSHp (E, n=7) were measured. The data 
are expressed as mean ± SD. Statistical significance of a point versus no 
drug is given by asterisks: *p<0.05, **p<0.01. A. Atenolol and labetalol 
significantly raise the levels of PSH, p<0.004 and p<0.002, ANOVA for 
effects of atenolol and labetalol respectively. C. Atenolol and labetalol 
significantly raise die levels of MSH, p<0.01 and p<0.05, ANOVA for effects 
of atenolol and labetalol respectively.
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Figure 5.2. Changes of antioxidant levels after 
incubation of peripheral blood with 
atenolol, labetalol and methyldopa 
respectively at different times
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Peripheral blood was incubated with atenolol ( — □—  , n=4), labetalol 
(— A—  , n=4), methyldopa ( ■ •  ■ , n=4) and PBS (controls: -  -  O- -  , 
n=4) respectively. After incubation, plasma and red cell lysate were prepared 
and antioxidant markers: PSH (A) and MSH (B) were measured The data are 
expressed as mean ± SD. Statistical significance of a point versus no drug is 
given by asterisks: *p<0.05. A. Atenolol and labetalol significantly affect the 
levels of PSH, p<0.03 and p<0.049, ANOVA for effects of atenolol and 
labetalol respectively. B . Atenolol and labetalol significantly affect the levels 
of MSH, p<0.05 and p<0.012, ANOVA for effects of atenolol and labetalol 
respectively.
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5.3.6 Determination of PSH and MSH in the solution of atenolol and 
labetalol
Solutions of atenolol and labetalol per se at different concentrations were determined 
for PSH and MSH activity in order to find out whether the chemical forms of these 
physiological antioxidant agents exist in the drugs. The levels of PSH and MSH in 
drug solutions were not significantly different from those in phosphate-buffered 
saline solution (PBS) alone (all p>0.05, ANOVA) (Table 5.6).
5.3.7 Additive effect of atenolol and labetalol
An additive effect of atenolol and labetalol on antioxidant agents was observed at 5 
ng/ml of atenolol plus 5 ng/ml of labetalol, but not at 50 ng/ml of atenolol plus 50 
Hg/ml of labetalol (Table 5.7).
5.3.8 Plasma cAMP levels after antihypertensive drug treatment
Following the incubation of whole blood with atenolol (0.1-50 |Xg/ml) 9 labetalol (0.1- 
50 ng/ml) and methyldopa (0.1-50 ng/ml) for 60 and 120 minutes respectively, no 
significant difference in plasma cAMP levels were found in any group (Table 5.8).
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Table 5.6 Determination of PSH and MSH In PBS and a
solution of atenolol (A) and labetalol (B) respectively 
A.
PBS 0.1 1
Atenolol (jig/ml) 
5 10 50 100
PSH (|Xmol/l) 3.4 3.3 3.5 6.0 3.4 6.1 8.0
±1.7 ±1.4 ±1.3 ±2.0 ±1.5 ±1.4 ±2.1
MSH (No.of 1.74 1.72 1.66 1.68 1.76 1.77 1.77
Thiols/Cell X 106)±0.12 ±0.11 ±0.09 ±0.08 ±0.14 ±0.11 ±0.15
B.
PBS 0.1
Labetalol (|ig/ml) 
1 5  10 50 100
PSH (|imol/l) 3.4 8.2 3.6 4.0 10.3 1.1 9.9
±1.2 ±2.9 ±1.5 ±1.8 ±3.6 ±0.8 ±3.1
MSH (No.of 1.74 1.63 1.80 1.69 1.72 1.77 1.74
Thiols/cell X 106)±0.09 ±0.13 ±0.19 ±0.16 ±0.18 ±0.21 ±0.19
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Table 5.7 Effects of atenolol and labetolol
alone or combination of them on PSH and MSH 
A.
PSH MSH
Atenolol 5 ng/ml 455±40 2 2 4±21
Labetalol 5 ng/mi 448±38 232±39
Atenolol
Labetalol
5 ng/mi+ 
5 ng/mi
5 0 6121 254±39
Atenolol io ng/mi 482±40 247±40
Labetalol io ng/mi 473±48 2 3 6±3 9
B.
PSH MSH
Atenolol 50 ng/mi 479±31 229117
Labetalol 50 ng/mi 458±41 255125
Atenolol
Labetalol
50 ng/mi+ 
50 ng/mi
472134 252 30
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5.4 Discussion
In this study, we have shown that when incubated with whole blood, atenolol and 
labetalol at certain concentrations are able to raise the levels of the ROS scavengers: 
PSH and MSH, suggesting that they possess some antioxidant properties. The dose- 
effect curve of atenolol and labetalol on LSH (Figure IB) seems to show that both 
agents can raise the level of LSH. However, statistical analysis demonstrated no 
significant difference. This maybe due to the wide variation of the data. The 
increase in the level of the ROS scavengers could arise from increased production of 
these scavengers or decreased formation of ROS.
Our study has excluded the possibility that atenolol and labetalol per se contain 
chemical forms of PSH and MSH observed in this study because no significant 
difference in the values of these scavengers was found between the solutions of 
drugs and PBS.
Both atenolol and labetalol are ^-blockers, while methyldopa, nifedipine and 
nimodipine, which showed no antioxidant effects in these experiments, are not On 
this basis, it can be inferred that the antioxidant effects of (J-blockers may occur by a 
mechanism involving the -^receptor. One of the major pharmacological mechanisms 
of ^-adrenoceptor blockers is to decrease intracellular cAMP through the 
inactivation of adenosine cyclase (Lefkowitz et al. 1984). Elevation of cAMP levels 
or reduction of adenosine levels has been suggested to increase ROS production in 
other studies (Meltzer et al. 1989; Yukawa et al. 1989). Therefore, it is possible that 
by decreasing cAMP levels and subsequently reducing ROS formation, ^-blockers 
may take the place of the physiological ROS scavengers thus causing the levels of 
PSH and MSH to rise. Since PSH and MSH whose levels are changed in this study 
are not intracellular antioxidants, the measurement of plasma cAMP was chosen to 
test whether plasma cAMP is relevant to the changed antioxidants found here. 
Plasma cAMP levels after administration of fi-blockers (which changed PSH and 
MSH) were not different from that of methyldopa (which did not change PSH and 
MSH). Therefore, the possibility that the changes of PSH and MSH found in this 
study might result from the alteration of plasma cAMP is excluded.
To avoid possible cell activation consequent to the purification procedure (Shappel 
et al. 1990), Blood components has not been purified in this study. By incubating 
the drugs with whole blood, the effects of ^-blockers on ROS were studied. It has 
been documented that blood cells such as lymphocytes can not only produce ROS
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but can also modulate ROS production via cytokines including interferon-y and 
interleukin-2 (Salisbery et al. 1990; Klausner et al. 1991). Therefore, it is also 
possible that the (5-blockers reduce ROS activity by altering cytokine production or 
release. However, the time course of blood cell activation to produce cytokines is 
measured in hours or days (Gupta et al. 1987; Oppenheim et al. 1991). In the 
present experiment, the significant effects of ^-blockers were detectable as early as 
60 minutes after the beginning of incubation. Thus, any change in cytokines, caused 
by the [5-blockers, is unlikely to be the main mechanism by which (5-blockers exert 
antioxidant effects.
It has been reported that the concentration of atenolol in plasma ranges from 0.3 to
2.2 pg/ml (mean value 1.0 pg/ml) and the concentration of labetalol from 0.093 to
0.271 pg/ml (mean value 0.191 ng/ml) (McNeil et al. 1979; Cruickshank 1980). 
Therefore, the clinical concentrations of both agents appear to be the concentrations 
at which the antioxidant activity was found in this study. Concentrations well above 
the range needed clinically to block ^-adrenergic receptors also showed antioxidant 
effects, although their effects did not always increase with drug concentration. At 
concentration 100 |ig/ml no effects were observed. In addition, the data also showed 
that 5 ng/ml of atenolol plus 5 ng/ml of labetalol produced similar effects to those 
observed with 10 ng/ml of atenolol or 10 ng/ml of labetalol (P>0.05), and was more 
effective than 5 ng/ml of atenolol or 5 ng/ml of labetalol alone (p<0.05) (Table 
5.7A). However, 50 ng/ml of atenolol plus 50 ng/mi of labetalol show no such 
additive effects (Table 5.7B). These results support the concept that the effects could 
be due to the interaction of the drugs with specific membrane receptors, probably (5 
receptors.
It is known that the antioxidant mechanisms for conventional chainbreaking agents 
are related to their phenols or aromatic amines which are capable of stabilizing 
trapped radicals (Burton & Ingold 1981). Although the intrinsic chemical properties 
of (5-blockers are quite diverse, they all contain this kind of aromatic resonance rings 
(Connolly et al. 1976). However, it is impossible to attribute the antioxidant effects 
of atenolol and labetalol found in this study to their common structural features of 
aromatic resonance rings, as the calcium channel blockers which also have aromatic 
resonance rings( Mak & Weglicki 1990) showed no antioxidant effects in the present 
experiments.
Mak & Weglicki (1988) and Mak et al. (1989) have demonstrated that (5-blockers 
can interact with the membrane hydrophobic components and subsequently inhibit
149
ROS propagation in the membrane. Concomitantly, they protect the membranes 
against ROS-induced lipid peroxidation. Our study found that atenolol and labetalol 
can exert antioxidant activity either directly or indirectly by raising the levels of ROS 
scavengers PSH and MSH. Although the mechanism responsible for the observed 
effects of P-blockers on ROS scavengers remains to be further elucidated, the 
potential therapeutic significance of these drugs has been deemed to be of scientific 
interest
Jones et al. (1981) have demonstrated that methyldopa stimulates the conversion of 
the primary catalase peroxide complex (the active form of the enzyme) to the 
catalytically inactive secondary catalase peroxide complex, leading them to conclude 
that methyldopa may initiate a ROS process. Using ROS scavengers as indirect 
indexes of ROS activity, our study showed that methyldopa had no significant effects 
on ROS, producing neither augmentation nor reduction of ROS levels.
Previous studies have suggested that the movement of calcium ions is important in 
the coupling of extracellular messages to intracellular response and this process 
results in cell activation (Rasmussen & Goodman 1977; Abbas et al. 1991). It is 
reported that the activation of cells is associated with an increase in the production of 
ROS (Meier et al. 1989) and moreover, the calcium ionophore A23187 has been 
shown to stimulate the formation of ROS (Lim et al. 1983). On the above basis, it is 
seems reasonable to assume that calcium channel blockers such as nifedipine and 
nimodipine may possess the ability to increase antioxidant levels by inhibiting the 
formation of ROS. However, this is not supported by the present study which found 
that neither nifedipine nor nimodipine had any effect on the antioxidant agents 
measured in this study. Although this finding is unexpected, it may suggest that 
calcium is not a major factor contributing to the production of ROS in the present 
test system.
Several studies have claimed that calcium channel blockers possess antiperoxidative 
effects (Henry 1991; Nayler & Britnell 1991). Using an in vitro model of 
sarcolemmal membrane lipid peroxidation, Mak et al. (1990) demonstrated that 
calcium channel blockers significantly protected the cell from death by decreasing 
the levels of superoxide and hydroxyl radicals. This effect was believed to be due to 
the specific structure of aromatic resonance rings in calcium channel blockers rather 
than the blockade of calcium influx as the aromatic resonance rings are capable of 
stabilizing trapped radicals and calcium is omitted in the test system. Therefore, it is 
concluded that calcium channel blockers can directly scavenge the ROS in vitro.
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The data from the present study did not provide any evidence to show that calcium 
channel blockers themselves have a radical scavenging effect, but the possibility that 
they might serve as indirect scavengers by increasing the levels of antioxidant 
activity in vitro is excluded. Very recently, an in vivo study by Ding et al. (1992) 
proved that the calcium channel blocker, isradipine had no effect on ROS. It should 
be noted that these studies on the relation of calcium channel blockers, ROS and 
antioxidant levels were carried out on differejt systems. Therefore, whether or not 
calcium channel blockers possess an antioxidant effect in vitro or in vivo needs to be 
further studied.
The pharmacological serum concentrations of nifedipine and nimodipine have been 
reported to be 47±20 ng/ml and 39±26 ng/ml respectively (Gilman et al. 1990; 
Tartara et al. 1991). These concentrations are well within the range examined by 
this study. Therefore it is concluded that calcium channel blockers at 
pharmacological concentrations or above are unable to increase the physiological 
antioxidant level in vitro. If these drugs have any antiperoxidative effect in vitro, it 
is impossible that that action is due to the elevation of antioxidant levels.
5.5 Conclusions
1, Atenolol and labetalol in vitro possess some antioxidant activity as they can
significantly raise the levels of plasma thiol and membrane thiol.
2, Atenolol and labetalol at lower concentrations tend to have additive effects
on antioxidant agents but at higher concentration do not, suggesting the 
antioxidant property may associated with specific membrane receptors, 
probably P receptors.
3, Calcium channel blockers are unable to elevate the levels of physiological
antioxidant agents in vitro.
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CHAPTER SIX SUPEROXIDE DISMUTASE GENOMIC 
POLYMORPHISM AND GENE 
EXPRESSION
6 .1 Introduction and aim of the study
Superoxide dismutase (SOD) catalyses the dismutation of the superoxide anion into 
oxygen and hydrogen peroxide and is thought to be an important component of the 
cellular defense repertoire against oxidative damage mediated by superoxide radicals 
produced as a by-product of oxygen metabolism (Fridovich 1978; Getzoff et al., 
1983).
In eukaryotic cells, there are two distinct types of SOD (Fridovich 1978; Getzoff et 
al., 1983). The predominant SOD is a soluble cytosolic enzyme containing copper 
and zinc at the catalytic site (CuZn-SOD). The second type is the manganese- 
containing SOD (Mn-SOD) found in the matrix of the mitochondria. The Mn-SOD 
differs substantially from the CuZn-SOD in primary structure (Steinman & Hill, 
1973). Although extracellular SOD, which is similar to CuZn-SOD, has been 
reported, the physiological significance of this type of SOD remains unknown 
(Marklund 1984a). The gene for human CuZn-SOD is on chromosome 21 and that 
for the Mn-SOD on chromosome 6; the chromosomal location for the extracellular 
SOD gene has not yet been reported.
In recent years, increased superoxide formation or lipid peroxidation products have 
been described in patients with pregnancy-induced hypertension (PIH) (Hubei et al., 
1989; Wang et al. 1992; Tsukimori et al. 1993). Decreased antioxidant levels or 
activities including SOD have also been found in this disorder (See Chapter three). 
Therefore, an imbalance between pro-oxidation and anti-oxidation has been 
suggested to be implicated in the pathogenesis of PIH. Considering that PIH is well 
known to be familial and a genetic predisposition has been proposed (Cooper et al., 
1988; Kilpatrick et al., 1989; Amgrimsson et al., 1990), one might speculate that a 
mutation in a critical region of the SOD gene or its abnormal expression could result 
in an alteration of SOD activity. To determine whether reduced SOD activity found 
in patients with PIH is associated with molecular genetic abnormalities, the CuZn- 
SOD genomic DNA and mRNA expression were analysed in the present work.
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6.2 Materials and Methods
Reagents described in this section were supplied by BDH Laboratory Supplies, 
Merck Ltd., UK, unless indicated. The 0.6 Kb P s t  I insert from pSODl, a plasmid 
containing a CuZn-SOD cDNA was kindly supplied by Dr. Y Groner, Weizmann 
Institute of Science, Rehovot, Israel and used as the probe (Lieman-Hurwitz et al. 
1982; Danciger et al. 1986).
6.2.1 Subjects
Eight PIH patients with mean age 27.5±5.0 years and mean gestational age 36.314.2 
weeks were included in the study. Four of these patients had proteinuria, and four 
did not Seven normal pregnant women with mean age 25.216.1 years and mean 
gestational age 36.115.2 weeks and rive normal nonpregnant women with mean age
28.815.3 served as controls.
The diagnosis of PIH was made using the criteria of the American College of 
Obstetricians and Gynecologists (For details see Chapter 1). Briefly, PIH is defined 
as a persistent or recurrent diastolic blood pressure of £90mmHg developing during 
pregnancy after 20 weeks of gestation, and resolving by six weeks post partum. 
Proteinuria is defined as the persistent presence of protein in the urine of ^ + on 
urine 'dipstick' testing, or >300 mg excreted in 24 hours. The latter measurement is 
preferred where available. Patients who had a history of hypertension before the 
twentieth week of pregnancy were designated as essential hypertension.
6.2.2 White cell preparation
30 ml of peripheral blood was collected, and 10 ml was placed in each of three sterile 
conical tubes containing EDTA (1 mg/ml blood) (Pharmacia Ltd., Bucks, UK). 10 
parts EDTA blood were mixed with 1 part 6%(w/v) Dextran 500 and this was left to 
settle. When the white cell band in the upper plasma layer was visible, it was 
transferred to another tube.
6.2.3 Genomic DNA isolation (Darbre 1988; Sambrook et al. 1989)
1. The white cells (from 10 ml of blood) were pelleted by centrifugation at 1000 
x g for 10 minutes and the cell pellet was washed twice with cold PBS. The 
cells were adjusted to a concentration of 5 x 107 cells/ml in TE buffer and
153
mixed with an equal volume of 2x lysis buffer for 30 minutes to lyse the cells 
and nuclei.
2. An equal volume of water-saturated phenol was added to the tube and mixed 
gently by inversion for 10 minutes. This was then centrifuged for 10 minutes 
at 2500 x g to separate the layers.
3. The top phase was transferred to another tube and Step 2 was repeated once.
4. Two volumes of 100% ethanol were added and the tube was inverted several 
times until the solution was thoroughly mixed. The nucleic acid precipitate 
should be visible at this stage.
5. The nucleic acid precipitate was fished out with a glass rod and allowed to air 
dry for a few minutes. The precipitate was then dissolved in 2.8 ml of lx  
lysis buffer.
6. RNase (BRL, Gibco Ltd., UK) was added to a final concentration of 50 
|ig/ml and incubated in a water bath (37°C) for 1 hour.
7. SDS and proteinase K (Boehringer Mannheim GmbH., German) were then 
added to final concentrations of 0.5% and 100 |xg/ml respectively and 
incubated for a further 2 hours in a water bath (55°C).
8. Repeat Step 2.
9. Repeat Step 2 but using phenol:chloroform:isoamyl alcohol instead of water- 
saturated phenol.
10. Repeat Step 4.
11. The DNA was spooled onto a glass rod, allowed to air dry and DNA was then 
put in a microtube in 100-500 |il of TE buffer. This was left at 4°C for some 
days to be dissolved.
12. The absorbance of the DNA at 260 nm and 280 nm was measured, the ratio 
of A2 6 0  to A2 8 0  should be greater than 1.75. A lower ratio is an indication 
that a significant amount of protein remains in the preparation. In this case, 
Steps 7-11 were repeated.
Amount of DNA (jxg/ml) = O.D(260nm) x 50 x dilution factor.
13. Store DNA samples at 4°C.
6.2.4 RNA isolation (Chomczynski & Sacchi 1987)
1. The white cells (from 20-30 ml of blood) were mixed with an equal volume 
of red cell lysis buffer for 15 minutes at room temperature to lyse the 
remaining red cells. The pellets were washed twice with cold PBS and 
sedimented by centrifuging for 10 minutes at 2500 x g.
2. Add 5 ml of prechilled denaturing solution and mix thoroughly by inversion.
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3. Add 0.5 mi of 2M sodium acetate, pH 4.0 and mix thoroughly by inversion.
4. Add 5 ml of phenol:chloroform:isoamyl alcohol mixture, mix by inversion 
and shake vigorously for 10 seconds. Chill on ice for 15 minutes.
5. Transfer this mixture to a 30 ml tube (DEPC-treated) and centrifuge at 10,000 
x g for 20 minutes at 4°C. Either a fixed-angle or swinging bucket rotor may 
be used.
6. Carefully remove the top aqueous phase which will contain the RNA and 
transfer it to a fresh DEPC-treated tube. DNA and proteins will remain in the 
organic phase at the interface. Be careful to avoid taking material from the 
interface.
7. Add an equal volume of isopropanol and incubate the sample at -20°C 
overnight to precipitate the RNA.
8. Pellet the RNA by centrifugating at 10,000 x g for 15 minutes at 4°C.
9. Repeat Steps 2-8.
10. Resuspend the RNA pellet ij 5 ml of denaturing solution and vortex until the 
RNA dissolves.
11. Add an equal volume of isopropanol and precipitate the RNA as described in 
Step 7.
12. Pellet the RNA by centrifugating at 10,000 x g for 15 minutes at 4°C. Wash 
the pellet with ice-cold 75% ethanol and centrifuge as above. A minimum of 
10 ml of 75% ethanol should be used.
13. Dry the pellet in air.
14. Resuspend the RNA in DEPC water.
15. The absorbance of the RNA at 260 nm and 280 nm was measured, the ratio 
of A2 6 0  to A2 8 0  should be greater than 1.70.
Amount of RNA (|ig/ml) = O.D(260nm) x 40 x dilution factor.
16. Store RNA samples at -20°C.
6.2.5 Electrophoresis of DNA through agarose gel (Sambrook et al. 1989)
Agarose (Sigma Chemical Co. ltd., England) was dissolved in E buffer by boiling in 
a microwave oven. The agarose solution was allowed to cool to about 50°C. While 
the gel was cooling, the open ends of the tray were sealed with masking 
(autoclaving) tape. The gel solution was then poured onto the gel tray. Insert the 
comb and leave to set for about 30 minutes. When the agarose had set, the comb and 
the tape were removed and the gel tray was placed under the E buffer in the gel 
electrophoresis tank. 1/10 volume of stop mix was added to each sample. The stop 
mix (1). helps the samples sink into the wells and not float away (Ficoll); (2). stops
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any enzymatic reactions from occurring (EDTA) and (3). tracks the position of the 
sample in the gel (orange G). The gel was run at constant voltage and towards the 
positive electrode. Once the gel had run i.e. the orange dye had reached the end, the 
power pack was switched off and the gel was stained in a solution of ethidium 
bromide (1 mg/L) for 10 minutes. The gel was then viewed over a UV light A 
photograph of the gel was then taken with Polaroid camera using a fast film 
(Polaroid Type 667).
6.2.6 Electrophoresis of RNA through gel containing formaldehyde
1. Prepare the gel by melting the appropriate amount of agarose in water, 
cooling it to 60°C. In chemical hood, add 5x formaldehyde gel-running 
buffer and formaldehyde to give final concentrations of lx  and 2.2 M 
respectively. Mix well and immediately cast the gel. Allow the gel to set for 
at least 30 minutes.
2. Prepare the sample by mixing the following in a sterile microfuge tube:
3. Incubate the samples for 15 minutes at 65°C, and then chill them on ice. 
Centrifuge the samples for 5 seconds to deposit all of the fluid in the bottom 
of the microfuge tubes.
4. Add 2 pi of sterile, DEPC-treated formaldehyde gel-loading buffer.
5. Before loading the samples, prerun the gel for 5 minutes at 5V/cm and then 
immediately load samples into the lanes of the gel.
6. Run the gel submerged in lx  formaldehyde gel-running buffer at 3-4V/cm. 
When the bromophenol blue has migrated approximately 8 cm the gel can be 
used for photography and blotting. A representative RNA gel photograph is 
shown in Figure 6.1.
(Sambrook et al. 1989)
RNA (up to 30 jig)
5x formaldehyde gel-running buffer
formaldehyde
formamide
4.5 pi
2.0 pi
3.5 pi
10.0 pi
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Figure 6.1 RNA Electrophoresis
A representative electrophoresis of RNA through agarose gel 
containing formaldehyde is shown. Each lane was load with 10 |ig 
of RNA. The gel was stained with ethidium bromide.
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6.2.7 DNA polymorphisms
In order to make genes easier to study, DNA needs to be cut into mangeable 
fragments by enzymes isolated from bacteria called restriction endonucleases. 
Plasmid DNA is usually digested with 1 unit enzyme/p.g DNA. Enzyme activity is 
defined as the amount of enzyme required to cut lambda DNA. For genomic DNA it 
is normal to use about 2 units enzyme/}!g DNA. Reaction volume is about 1 |Xg in 10 
|il for plasmid DNA and normally 1 p,g DNA in 5 |xl final volume for genomic DNA. 
Restriction enzyme EcoRI (BRL, Gibco Ltd., UK) was used for digesting genomic 
DNA in this experiment
1. Calculate what volume correspond to 1 mg DNA.
2. Set up a reaction mix containing
lOx buffer 1/10 of final volume
DNA volume equivalent to 1 |xg
EcoRI 2 units
Sterile dH20  to make the volume to 5 |il
3. Incubate at 37°C for 1 hour for plasmid DNA or 4 hours (or overnight) for
genomic DNA.
4. After incubation, add at least 1/10 volume stop mix and run on a gel as
described in section 6.2.5. A representative genomic DNA gel photography 
is shown in Figure 6.2.
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Figure 6.2 DNA Electrophoresis
Kb
-0.60
-0.87 
-1.08
-1.35
-2.03
-2.32
-4.36
-6.56
-9.42
-23 .13
Lane 1 2 3 4 5
A representative ethidium bromide stained agarose gel containing 
genomic DNA that has been completely digested with the 
restriction endonuclease, EcoRI (lanes 1-3). Each lane was load 
with 6 |ig of DNA sample. Lanes 4 and 5 are ///^ //-d ig es te d  
lambda-DNA marker and HaelI I-digested phi X174-RF DNA 
marker respectively. Sizes are in kb.
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6.2.8 Transfer of DNA and RNA from agarose gels to solid support
6.2.8.1 Southern blotting for DNA transfer (Southern 1975)
1. Soak the gel in denaturing buffer for 1 hour.
2. Wash the gel with dH20  briefly and immerse it in neutralizing buffer for 
another 1 hour.
3. Put the gel on transfer apparatus (Figure 6.3). Now cover all edges of the gel 
using four pieces of clingfilm, tucking excess under the tray but taking care 
not to cover any areas of the gel.
4. Cut a piece of nitrocellulose (Amersham International pic. UK) to the same 
size as the gel, wet it in dH20  and then transfer to 20x SSC for at least 5 
minutes.
5. Place nitrocellulose on top of the gel. Using a pipette, roll out any air 
bubbles between the nitrocellulose and the gel.
6. Briefly wet a piece of Whatman 3MM filter paper (Whatman International 
Ltd., England) which had been cut to the size of the gel and place it on the 
nitrocelluse. Again remove any air bubbles between the 3MM paper and the 
gel.
7. Place a dry piece of Whatman 3MM filter paper on top and then paper towels 
(about 8 cm). On the top of the pile place a weight (about a kilogram). 
Leave overnight
8. Disassemble blot the next day. Carefully mark positions of wells. Remove 
nitrocellulose, place it betwen glass plates and bake in a vacuum oven at 
80°C for 2 hours. The filter may then be stored until required.
9. Stain the gel with ethidium bromide and look at under UV illumination to 
ensure that all the DNA has transferred.
6.2.8.2 Northern blotting for RNA transfer (Sambrook et al. 1989)
1. Soak the gel for 20 minutes in 0.05 N NaOH and then rinse the gel in DEPC- 
treated water.
2. Soak the gel for 45 minutes in 20x SSC. Then carry out Steps 3-9 as 
described in section 6.2.8.1.
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6.2.9 Preparation and labelling of probes
6.2.9.1 Small scale plasmid preparation (Sambrook et al. 1989)
1. Single colonies are removed from the antibiotic-containing plates using a 
sterile cocktail stick and placed in 10 ml of L Broth.
2. Incubate at 37°C overnight on an orbital shaker.
3. Spin 500 x g 4°C, discard the supernatants.
4. Add 200 pi cold Solution I, votex well.
5. Add 400 pi fresh Solution n, mix by inversion and leave on ice for 5 minutes.
6 . Add 300 pi cold solution HI votex gently and leave on ice for 5 minutes.
7. Transfer to a microtube and spin 13,000 x g for 5 minutes.
8 . Remove supertanants to a fresh microtube and add approximately 600 pi
chloroform/phenol (1:1). Votex well.
9. Spin 13,000 x g for 5 minutes and transfer top phase to another microtube.
10. Add 600 pi iso-propanol and allow to stand 5 minutes at room temperature or 
in ice for 30 minutes.
11. Spin 13,000 x g for 5 minutes and discard the supernatants.
12. Wash the pellet with cold 75% ethanol and allow the pellet to dry in the air 
for 1 0  minutes.
13. Add 50 pi TE buffer containing DNAase-free pancreatic RNase (20 pg/ml, 
BRL, Gibco Ltd., UK). Votex briefly and store at -20°C.
6.2.9.2 Isolation of fragment from low melting agarose gels for random 
priming (Parker & Seed 1980; Struhl 1985)
1. Digest plasmid (pSODl) DNA with restriction emzyme, Pst I (BRL, Gibco 
Ltd., UK) (see section 6.2.7). Pst I  is known to cut out the CuZn-SOD 
fragment (600 bp) (Lieman-Hurwitz et al., 1982; Danciger et al., 1986).
2. Run sample on 0.8% low melting point agarose (Sigma Chemical Co. Ltd., 
England) gel.
3. Stain the gel with ethidium bromide (see section 6.2.3) and examine gel 
briefly on a transilluminator. A photograph was taken as this stage and it 
showed that there was a band at 600 bp (Figure 6.4).
4. Cut out the band (600 bp) using scalpel into a pre-weighed 1.5 ml microtube.
5. Add sterile distilled water at a ratio of 2 ml/g of the gel.
6 . Melt the gel by boiling the tube for 10 minutes.
7. Store DNA/agarose mixture at -20°C until use.
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Figure 6.4 Digestion of pSODl plasmid DNA and
siza analysis
Lane 1 2 3 4 5
bp
-23130
-9416 
-6557
-4361
■
-2322 
-2027
-1353
-1078
-872
-603
pSODl plasmid DNA was isolated by the method of small scale 
plasmid preparation. 5 }ig of plasmid DNA was applied to 0.8% low 
melting point agarose gel and run at 32V for 4 hours. Lane 1: 
undigested plasmid DNA Lane 3: plasmid DNA was digested by 
restriction enzyme Pst /. There was a band at 600 bp in length which 
contained the CuZn-SOD insert. Lane 4: lambda DNA/Hind III 
fragments (molecular weight marker). Lane 5: phi X174 RF DNAJHae 
III fragments (molecular weight marker).
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6.2.9.3 Labelling by Random Priming (Feinberg & Vogelstein 1983,1984)
1. Set up reaction as follows:
Oligonucleotide reaction mix 10 pi
BSA (Sigma Chemical Co. Ltd., England) 2 pi
a-3 2 P-dATP(Amersham International pic., UK) 2.5 pi 
Klenow fragment 2 units
DNA/agarose mixture* 20 pi
Sterile dH20  add to 50 pi
Incubate at room temperature in a lead pot overnight 
* this mixture needs to be boiled for 10 minutes and kept at 37°C (in water 
bath) for at least 1 0  mins before use.
2. Terminate the reaction by addition of 50 pi oligonucleotide stop mix.
3. The incorporated dNTPs was separated from the unincorporated
triphosphates by passing through a 7 cm Sephadex G-50 (DNA Grade,
Pharmacia LKB, Sweden) column equilibrated with 1 x CB, 0.02% (w/v)
SDS.
4. Collect incorporated dNTPs in a tube and leave it on ice.
6.2.10 Preparation of denatured salmon sperm DNA (Sambrook et al. 1989)
Salmon sperm DNA (type II sodium salt, Sigma Chemical Co. Ltd., England) was 
dissolved in 0.5 M NaOH at a concentration of 10 mg/ml and boiled for 30 minutes. 
When it cooled glacial acetic acid was used to adjust pH to 6.0. This mix solution 
was then diluted 2 fold and precipitated with 2 volumes cold ethanol at -20°C 
overnight The precipitation was obtained by centrifuging at 10,000 x g 4°C for 5 
minutes and dissolved in sterile water at a concentration of 10 mg/ml. The OD2 6 o of 
the solution was then determined and the exact concentration of the DNA was 
calculated as follows.
Denatured salmon sperm DNA (pg/ml)=OD26o x dilution factor x 50
6.2.11 Hybridization with labelling probe and autoradiograph (Sambrook et 
al. 1989)
1. The filter was placed in heat-sealable polyethylene bag with 25-30 ml of
prehybridization/hybridization mix and the air bubbles in the bag was 
removed as much as possible. The bag was placed in a shaking water bath at 
6 8 °C for at least 1 hour.
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2. Boil the labelling probe for 10 minutes immediately before use and plunge it 
into ice.
3. The bag was carefully opened by cutting a hole near the top and the labelling 
probe was added to the solution in the bag. The solution was then mixed 
thoroughly.
4. Hybridization was carried out overnight at 6 8 °C in the shaking water bath.
5. When hybridization was complete the filter was removed from the bag and 
washed quickly with 300 ml of washing solution (pre-heated to 6 8 °C) for 5- 
10 minutes. Wash was repeated 3 more times.
6 . The filter was blotted dry between 2 pieces of 3MM Whatman paper, then 
placed on a dry 3MM Whatman paper and covered with clingfilm.
7. The filter was put into an X-ray cassette and coverd with a X-ray film (Kodak 
XAR 5) in the dark. The film was exposed overnight at -70°C and developed 
the next day.
6.2.12 Solutions used in molecular genetic work
1. 0.05% DEPC water
Add DEPC to cfi^O, leave at room temperature overnight and then autoclave.
2. 20 x Denhardts 
0.4% Ficoll
0.4% Polyvinylpyrrolidone (PVP)
0.4% Bovine serum albumin (BSA)
Filter through 0.45 |im filter.
3. 20 x SSC, pH 7.4 
0.3 M Sodium citrate
3.0 M Sodium chloride
4. lx  lysis buffer 
0.05 M Tris, pH 7.9 
0.5 mM EDTA
10 mM Sodium chloride
5. 2x lysis buffer 
0.1 M Tris, pH 7.9
1.0 mM EDTA
20 mM Sodium chloride 
4% SDS
6 . 5x Formaldehyde gel-running buffer 
0.1 M MOPS (pH 7.0)
40 mM Sodium acetate 
5 mM EDTA (pH 8.0)
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7 10 x column buffer, pH to 5.0 with glacial acetic acid
3 M sodium chloride 
0.1 M sodium acetate 
0.2% (w/v) SDS
8 . CSB buffer
42 mM Sodium citrate 
0.83% N-lauryl sarcosine 
0.2 mM b-mercaptoethanol
9. Denaturing solution (for Southern blotting)
0.5 M Sodium hydroxide
1.5 M Sodium chloride
10. Denaturing solution (for RNA isolation)
25g Guanidine thiocyanate (4M final) (Fluka AG, Switzerland) 
33ml CSB buffer
Mix throrough until components are completely dissolved.
11. E buffer, pH 8.2 with glacial acetic acid 
40 mM Tris
20 mM Sodium acetate 
1 mM EDTA
12. Formaldehyde gel-loading buffer 
50% Glycerol
1 mM EDTA (pH 8.0)
0.25% Bromophenol blue
13. L Broth, pH 7.2, for 1000 ml:
10 g Tryptone
5 g Teast extract 
5 g Sodium chloride
1 g Glucose
14. Neutralising solution, pH 7.4 (for Southern blotting)
1 M Tris
2 M sodium chloride
15. Oligonucleotide reaction mix 
Solution A
Solution B 
Solution C 
in ratio 100:250:150.
16. Oligonucleotide stop mix 
20 mM sodium chloride 
20 mM Tris, pH 7.5
2 mM EDTA 
0.25% (w/v) SDS
15. Phenol:chloroform:isoamyl alcohol
Mix at the ratio of 25:24:1 
Store at 4°C
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16. Prehybridization/hybridization mix (for DNA)
5x SSC
4x Denhardts
10% Dextran sulphate (Sigma Chemical Co. Ltd., England)
0.1% SDS
0.1% Sodium pyrophosphate (PPi)
100 |ig/ml Denatured salmon sperm DNA (see section 6.2.8)
17. Prehybridization/hybridization mix (for RNA)
5xSSC
4x Denhardts 
0.1% SDS
0.1% Sodium pyrophosphate (PPi)
100 |Ag/ml Denatured salmon sperm DNA (see section 6.2.8)
18. Proteinase K (Fungal)
Make up a 10 mg/ml solution in lx  lysis buffer + 0.05% SDS and store at - 
20°C.
19. Red cell lysis buffer, pH 7.4
155 mmol/L Ammonium chloride (NH4 CI)
10 mmol/L Patassium hydrogen carbonate (KHCO3)
100 |imol/L Na2 -EDTA
20. Ribonuclease A (RNase A) (BRL, Gibco Ltd., UK)
Make up a 10 mg/ml solution, boil for 5 minutes and store at -20°C.
21. Sephadex SP-50
4 g SP-50
1 0 0  ml 1 x column buffer 
0.2% (w/v) SDS
22. Solusion I (for plasmid DNA preparation)
50 mM Glucose
25 mM Tris (pH8.0)
10 mM EDTA (pH8.0)
23. Solution II (for plasmid DNA preparation)
0.2 N NaOH
1% SDS
24. Solution HI (for plasmid DNA preparation)
5 M Potassiou Acetate 60 ml
Glacial acetic acid 11.5 ml
Water 28.5 ml
The resulting solution is 3 M with respect to potassium and 5 M with respect 
to acetate.
25. Solution A (for random primer labelling of DNA)
1 ml solution O
18 |il P-mercaptoethanol 
5 ill 100 mM dCTP (BRL, Gibco Ltd., UK)
5 ill 100 mM dTTP (BRL, Gibco Ltd., UK)
5 til 100 mM dGTP (BRL, Gibco Ltd., UK)
Store at -20°C.
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26. Solution B, pH 6 . 6  with 4 M NaOH (for random primer labelling of DNA) 
2 M Hepes titrated (Sigma Chemical Co. ltd., England)
27. Solution C (for random primer labelling of DNA) 
Hexadeoxyribonucleotides dissolved in TE at 90 OD units/ml.
28. Solution O, pH 8.0 (for random primer labelling of DNA)
1.25 M Tris
0.125 M magnesium chloride
29. Stop mix, pH 8.1
15% Ficoll (Sigma Chemical Co. Ltd., England)
0.2 M EDTA 
0.01% (w/v) Orange G
30. TE buffer, pH 8.0 
10 mM Tris-HQ 
1 mM EDTA
31. Washing solution 
2xSSC
0.1% SDS 
0.1% PPi
6.2.13 SOD activity assay
SOD activity in red blood cells was determined by a photochemical augmentation 
method described by Misra and Fridovich (1977) (For details see Chapter 3). 
Briefly, 1 ml of red cell pellet was resuspended in 1 ml of ice-cold distilled water, 
mixed and put in ice for 2  hours. 800 |il of cooled absolute ethanol and chloroform 
mixture (3:5, v/v) was then added and mixed thoroughly. Lysate was obtained after 
centrifugation. All steps were carried out at 4°C. The SOD activity was then 
assayed based on the increase in rate of photo-oxidation of 0 -dianisidine.
6.2.14 Statistical analysis
Data are expressed as mean ± S.D., with differences between groups being assessed 
by Student's t test
6.3 Results
The SOD activity was significantly decreased in patients with PIH as compared to 
either normal pregnant women (p=0.036) or normal nonpregnant women (p=0.017) 
(Table 6.1). There was no difference between the normal pregnant women and 
normal nonpregnant women (p=0.37).
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Genomic DNA from white cells of the eight women with PIH was treated with 
endonuclease (EcoRI) and hybridized to a CuZn-SOD probe. Representative 
experiments are shown in Figure 6.5. The frequencies of the 5.26 and 0.74 Kb 
fragments did not differ between patients with PIH and the control groups as all three 
groups showed all of these bands. There was also no difference between PIH 
patients with proteinuria and those without However, there seems to be an extra 
band in lane 7 whose size is close to 5.26 Kb. This patient was known to be 
complicated with asthma and nephrotic syndrome.
Figure 6 . 6  shows the Northern blot analysis of RNA isolated from white cells. The 
RNA was hybridized to a cDNA probe of CuZn-SOD. A band, estimated (by the 
0.24-9.5 Kb RNA Ladder) to be 0.67 Kb, was detected. This is similar size of the 
CuZn-SOD mRNA in human cells reported by others (Lieman-hurwitz et al. 1982; 
Sherman et al. 1984; Delabar et al. 1987). The results obtained in the Northern blot 
experiments were quantified by the densitometry on a Microcomputer Imaging 
Device (Imaging Research INC., Canada). No significant changes in expression of 
the CuZn-SOD gene was found between the patients with PIH and controls (p>0.05). 
There was also no difference in CuZn-SOD gene expression between PIH patients 
with proteinuria and those without
Table 6.1. SOD activity In patients with PIH and 
controls
n SOD (|imol/L) P*
PIH 8 37.0±7 .1
Normal pregnancy 7 44.114.5 0.036
Normal nonpregnancy 5 47.015.5 0.017
* Compared with PIH.
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Figure 6.5 Southern blot analysis of DNA
Kb
9.42-
6.56-
4.36-
m  * * *  *"*1
2.32-
2.03-
1.35-
1.08-
0.87-
0.60-
Lane 1 2 3 4 5 6 7 8 9
Southern blot analysis of genomic DNA from white cells of PIH patients 
(lane 3-7), normal pregnant women (lane 8, 9) and normal nonpregnant 
women (lane 1, 2). DNA was digested with restriction enzyme EcoRI and 
the filter was hybridized using a human CuZn-SOD probe. The 
frequencies of 5.26 and 0.74 kb fragments did not differ between PIH 
patients and the control groups.
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Figure 6.6 Northern blot analysis of RNA
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Northern blot analysis of RNA from white cells of PIH patients 
(n=7), normal pregnant women (n=7) and normal nonpregnant 
women (n=5). Blots were hybridized with a human CuZn-SOD 
probe. The intensities of autoradiographic images were quantified 
by the Microcomputer Imaging Device. The upper panel shows the 
autoradiography of a representative experiment. The graph 
represents the mean ± SD of the independent experiments.
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6.4 Discussion
The assay for SOD in this study is based on the property that SOD can increase the 
rate of the aerobic photo-oxidation of dianisidine, sensitized by riboflavin (Mira and 
Fridovich 1977). Although this assay is convenient, reproductive and free of serious 
interferences, it can not indicate the type of SOD. It could be both CuZn-SOD and 
Mn-SOD. However, the SOD measured in the present experiment is the SOD in 
peripheral red blood cells, this type of SOD is considered to be the CuZn-SOD as the 
mature red blood cells contain no mitochondria (Lewis 1989), which is home of Mn- 
SOD (Fridovich 1978; Getzoff et al. 1983). Therefore the decreased SOD activity 
found in this study model should correspond to CuZn-SOD.
CuZn-SOD is a major SOD in mammalian tissue. A decreased CuZn-SOD activity 
in PIH is not surprising because the disease has been associated with increased 
superoxide production and lipid peroxidation (Hubei et al. 1989; Wang et al. 1992; 
Tsukimori et al. 1993). Superoxide is known to exert a hypertensive effect by 
changing the pattern of prostaglandin production (Wang et al. 1992; also see 
Chapter 4), inactivating the endothelium-derived vascular relaxing factor 
(Gryglewski et al. 1986), and directly contracting smooth muscles (Katusic & 
Vanhoutte 1989). Conversely, injection of SOD has been shown to have a 
hypotensive effect (Nakazono 1991).
The inheritance of a low CuZn-SOD activity has been documented in some human 
diseases such as amyotrophic lateral sclerosis (Rosen et al. 1993). There is 
increasing evidence to show that a genetic factor plays a role in the pathogenesis of 
PIH (Cooper et al. 1988; Kilpatrick et al. 1989; Amgrimsson et al. 1990), but a 
study of the genetic aspects of antioxidant enzymes in PIH has not been investigated 
before. Although it is reasonable that there could be a link between the low SOD 
activity and the its gene mutation or defective expression, this possibility seems 
unlikely in the present study as both the DNA and mRNA related to CuZn-SOD in 
PIH did not differ from that in normal pregnancy and normal nonpregnant women. 
However, one patient (lane 7 in Figure 6.5) with the exception. An extra band whose 
size is close to 5.26 Kb appeared in this patient Since this PIH patient was also 
suffering from asthma and nephrotic syndrome at time of sampling, whether this 
possible extra band was relevant to asthma or/and nephrotic syndrome remains to be 
further studied. It is possible that some women with PIH may be like the PIH patient 
suffered from asthma and nephrotic syndrome and show abnormalities of the SOD 
gene whereas others may not.
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It is known that hydrogen peroxide, a product of SOD itself, can effectively 
inactivate CuZn-SOD enzyme by a Fenton-type reaction of H jO j with Cu++ at the 
centre of the enzyme, forming a reactive intermediate that destroys an essential 
liganding histidine residue (Blech & Borders 1983; Marklund 1984b). Hydrogen 
peroxide is mainly metabolized by a selenium-dependent glutathione peroxidase at 
the expense of glatathione (GSH) (Sinclair et al. 1990). A dietary lack of selenium 
has been suggested to contribute to a high incidence of PIH (Lu et al. 1990) and, 
furthermore, lower GSH levels occurred in patients with PIH (see Chapter 3). In 
ad'ition, activation of cells, especially white blood cells, is known to induce 
hydrogen peroxide formation (Cumutte et al. 1987; Klockars & Savolainen 1992). 
Neutrophils and mononuclear cells also appear to be activated in PIH (Greer et al. 
1991; also see Chapter 2). Therefore, it is likely that increased hydrogen peroxide 
levels may result in the decreased SOD activity in PIH. A number of cytokines such 
as TNF and IL-1 have been reported to affect SOD activity in vitro (White et al. 
1989). However, so far, their state in PIH is not known. Finally, the SOD deficiency 
can also occur at some time during the course of its protein synthesis.
Although the SOD activity in white cells has not been measured in this study, it can 
be inferred that its activity may be also lower in PIH patients. The increased activity 
of white cells in PIH patients (Greer et al., 1991; also see Chapter 2) favors 
formation of hydrogen peroxide, which is a powerful chemical to inactivate SOD 
(Blech & Borders, 1983; Marklund, 1984b). And there is also a study which 
indicates that SOD activity in while cells is parallel to that in red cells (Feher et al. 
1988).
In the absence of size abnormality of both mRNA and major structural 
rearrangements in genomic DNA, it is likely that the decreased SOD activity may be 
a secondary phenomenon which develops during the course of the disease, though 
whether there are subtle changes such as microdeletion/insertion or point mutation 
needs further investigation. Finally, it needs to be mentioned that absence of a 
genetic abnormality in CuZn-SOD does not exclude the possibility of a genetic 
induced deficiency of other antioxidant enzymes or proteins.
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6.5 Conclusions
This study seems to indicate that there is not a genetic cause for the decreased SOD 
(CuZn) activity in PIH, suggesting that decreased SOD activity is an acquired 
phenomenon which occurs in the development of PIH.
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CHAPTER SEVEN PIH AND ESSENTIAL HYPERTENSION
7.1 Introduction and Aim of the Study
Hypertension in pregnancy is defined as a blood pressure of 140/90 mmHg or greater 
on two separate occasions. There are several possible causes of high blood pressure 
during pregnancy (Table 7.1). Among them, PIH and essential (chronic) 
hypertension are the most common. Although both PIH and essential hypertension 
in pregnant women have similar clinical phenomena, it is important to distinguish 
between them because they have different aedological and pathophysiological 
mechanisms and thus require different treatments.
PIH is a placental disease. Its pathological features and clinical signs and symptoms 
disappear soon after delivery (Roberts 1984) and it can develop in abdominal and 
molar pregnancy (Page 1939; Rote 1985). All these suggest that the placenta is a 
vital factor in the pathogenesis of this disorder. It has been thought that immune 
system, ROS and eicosanoids contribute significantly to the aetiology of PIH (See 
Chapters 2 ,3,4).
The cause of essential hypertension is unclear. Alterations in systemic 
hemodynamics, the renal handling of salt and water, the renin-angiotensin- 
aldosterone system, sympathetic activity, genetic mechanisms and diet have all been 
implicated to varying degrees in the pathogenesis of essential hypertension. 
Although considerable attention has been focused on these elements, there is some 
evidence suggesting that in many forms of experimental as well as human essential 
hypertension, alterations in ROS and the immune system may have a role in the 
development of the disease.
As these two diseases have similar clinical features and some similar 
pathophysiological changes, it was the aim of this study to determine whether they 
show differences in the levels of antioxidant agents and in the immune system. This 
kind of study has not previously been carried out in hypertension during pregnancy.
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Table 7.1 Causes of hypertension In pregnancy*
1. Pregnancy-induced hypertension
2. Essential hypertension
3. Renal disease
Renal artery stenosis
Chronic pyelonephritis
Acute and chronic glomerulonephritis
Polycystic renal disease
4. Adrenocortical hyperfunction
Cushing's syndrome 
Hyperaldosteronism 
Congenital adrenogenital syndromes 
(17-and 11-hydroxylase defects)
5. Pheochromocytoma
6. Hypo- and hyperthyroidism
7. Hypercalcemia
* Adapted from Swartz et al. (1981).
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7.2 Materials and Methods
7.2.1 Subjects
Three groups of sujects were enroled in this study. Group 1, 38 normotensive 
pregnant women; Group 2, 34 women with PIH; Group 3, 5 pregnant women with 
essential hypertension. The demographic characteristics of the study population are 
detailed in Table 7.2.
7.2.2 Diagnosis
The diagnosis of essential hypertension in pregnancy is usually based on any of the 
following findings (Hughes 1972):
1, A history of hypertension before pregnancy.
2, Persistent blood pressure elevations of at least 140 mmHg (systolic) or 90
mmHg (diastolic) before the 20th week of gestation.
3, Evidence of persistent hypertension beyond the 42nd day postpartum.
PIH was defined by the standard recommended by American College of 
Obstetricians and Gynecologists. Specifically, hypertension was defined as the 
presence of a blood pressure of 140/90 mmm Hg or more. Preoteinuria was defined 
as excretion of >300 mg of urinary protein/24 hours or £ + on urine 'dipstick' testing 
(For details see Chapter 1).
7.2.3 Peripheral blood mononuclear cells (PBMC) preparation and red blood cell
(RBC) lysate preparation
Blood was obtained by venipuncture and collected into a universal containing 300 
units of preservative-free heparin (for 10 ml of blood). A total of 60 ml of blood was 
obtained. PBMC were obtained by density gradient centrifugation using a 
modification of the method originally described by Boyum (1968) (For details see 
Chapter 2). RBC were disrupted by distilled water and lysate was extracted by using 
absolute ethanol and chloroform mixture (For details see Chapter 3).
7.2.4 Mitogenic activity assay
Briefly, PBMC were prepared in RPMI1640 containing 10% heat inactivated human 
serum and made up to a concentration of lxlO6  cells/ml for PHA and ConA and
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2x10  ^ cells/ml for PWM. All mitogens were obtained from Sigma Chemical 
Company and used at optimal concentrations. PHA was used at 10 pg/ml; ConA at 
100 pg/ml and PWM at 200 fig/ml. Cells were grown for 72 hours and 1 jtCi of 3 H- 
thymidine (TRK418, Amersham) was added to each well for the final four hours of 
incubation. The cells were harvested using a Dynatech cell harvester and the 
incorporated tritiated thymidine was measured by a beta counter(LKB) (For details 
see Chapter 2).
7.2.5 IL-2 production
IL-2 containing supernatants were obtained by culturing PBMC at 4 x 106  cells/ml in 
the presence of PHA (Wellcome) for 48 hours at 37 °C in 5% 0 0 ^ 5 %  air.
A murine IL-2-dependent cell line, HT-2 (a gift from Cetus Corporation) was used in 
a bioassay to assess IL-2 production. Reciprocal dilutions of the IL-2 containing 
supernatants were carried out in a microtitre plate. 1.5 x 104  HT-2 cells were added 
to each of the reciprocal dilutions in triplicate. The cells were cultured at 37 °C in 
5% CC>2/9 5 % air for 20 hours. 1 |iCi of 3 H-thymidine (TRK418, Amersham) was 
then added to each of the wells and the plates were incubated for a further 4 hours. 
The cells were harvested by MicroMate™ 196 Cell Harvester (Packard Instrument 
Company, CT, USA) onto glass fibre paper. The 3 H-thymidine incorporation was 
determined by a computer-programmed Matrix 96™  Direct Beta Counter (Packard 
Instrument Company, CT, USA). For quantitation of activity (units) in unknown 
samples, a curve was plotted for the percentage of maximum counts versus the 
dilutions for each of the samples/standards and then test results were compared with 
standard curve (For details see Chapter 2).
7.2.6 Immunoglobulin production and assay
The ability of B cells to secrete IgG and IgM in culture medium was determined. 
PBMC were made up to lxlO6  cells/ml in RPMI-1640 containing 10% FCS and 
cultured for 7 days in presence or absence of PWM(1:250 dilution). The amount of 
immunoglobulins in culture medium was measured using an ELISA assay as 
described in Chapter 2.
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7.2.7 Antioxidant agent assay (For details see Chapter 3)
The methods for the measurement of superoxide dismutase (SOD) and plasma thiol 
(PSH) have been previously described by Banford et al (1982a, 1982b). Lysate thiol 
(LSH) level was measured according to the method of Misra and Fridovich (1977), 
based on the increase in the rate of photo-oxidation of O-dianisidine. The 
glutathione content of the plasma (GSHp) was measured enzymatically at 25°C by 
the method of Anderson (1985). Red cell membrane thiol (MSH) was measured by
using Ellman's reagent Ellman’s reagent can be used to induce an oxidative stimulus
on the exofacial membrane sulphydryl group of the human red cell, thus making it a 
chemical probe of the sulphydryl population (Hoey 1987). MSH was calculated by 
the following formula:
r A. , , / [ES"] x volume x Avogadro's No.MSH(No of thiols/cell) =-±— J - - -number of cells x 1000 x 13600
7.2.8 Statistical analysis
Results and data are expressed as mean±SD. Statistical comparisons between groups 
were carried out by Student's t test Correlations between parameters were 
determined by univariate linear regression and the Pearson coefficient of correlation. 
A p value of less than 0.05 was considered significant
7.3 Results
7.3.1 Mitogenic activity
Figure 7.1 shows mitogenic activity. There was no significant difference in any of 
the four parameters tested between normal pregnant women and women with 
essential hypertension. However, compared to both normal pregnant women and 
women with essential hypertension, PBMC from patients suffering from PIH showed 
enhanced 3H thymidine uptake when stimulated by PHA (both p<0.01). Since the 
mean systolic blood pressure in patients with essential hypertension was significantly 
lower than in those with PIH (Table 7.2), the question arises whether the different 
mitogenic activity was due to the different blood pressure levels found in these two 
groups. A paired Student's t test was perfomed to see if these differences still exist 
after their blood pressure was matched for. Five PIH patients with 137.6±7.3 
(mean±SD) mmHg of systolic blood pressure were compared to five essential
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hypertensive patients with 136.6±5.9 mmHg of systolic blood pressure. After match, 
there was no significant difference in blood pressure between the two groups. The 
results showed that PHA-induced mitogenic activity was still lower in patients with 
essential hypertension than in those with PIH (62146±35593 vs 108870±47291 cpm, 
n=5, p<0.05).
7.3.2 IL-2 activity
IL-2 activity in patients with PIH (26.9±8.6 units/ml) was higher than in normal 
pregnant women (23.3±7.4 units/ml) or in pregnant women with essential 
hypertension (22.1±9.9 units/ml), however, a significant difference was found only 
between PIH and normal pregnancy (p<0.01) not between PIH and essential 
hypertension (p=0.093) (Figure 7.2).
7.3.3 Immunoglobulins
The amount of immunoglobulins (IgG and IgM) produced by PWM mitogen- 
stimulated PMBC is shown in Figure 7.3. IgG production in both PIH women and 
women with essential hypertension was significantly higher than that in normal 
pregnant women (both p<0.05). The levels of IgG were not significantly different 
between women with PIH and those with essential hypertension. IgM production 
was not different between the three groups.
7.3.4 Antioxidant levels
The results for antioxidant activity are presented in Table 7.3. In patients with PIH, 
the levels of PSH were significantly reduced compared with normal pregnant 
women. The levels of LSH in pregnant women suffering from essential hypertension 
were much lower than those in normal pregnant women and PIH women. After 
blood pressure in both patient groups was matched for, the levels of LSH in PIH 
patients were 395±89 pmol/L which was still higher (p<0.05, paired Student's t test) 
than that in patients with essential hypertension (222±87 p.mol/L). There was no 
significant differences in other antioxidant markers between the three groups.
7.3.5 Correlation
No significant correlation was found between blood pressure (systolic and diastolic) 
and any of the parameters tested in the investigated groups.
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Figure 7.1 Lymphocyte activity
Q  Essential hypertension 
□  PIH
|  Normal pregnancy
Continuing
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Figure 7.1 continuing
□  Essential hypotension 
E2 PIH
■  Normal pregnancy
0 1 2  3 4
c pmx I O-3
PBMC were incubated for 72 hours in the presence of 
mitogens (A, PHA, ConA and PWM) or in the absence of 
mitogens (B). The data are represented as mean ± SD. 
Statistical significance is expressed as: **p<0.01, compared 
with normal pregnant women; ++p<0.01 compared with 
women with PIH.
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Figure 7.2 IL-2 activity
■  N o r ma l  p r e g n a n c y
□  PIH
□  E s s e n t i a l  h y p e r t e n s i o n
IL-2 containing supernatants were obtained by culturing 
PBMC in the presence of PHA for 48 hours. IL-2 activity 
was determined by a bioassay using HT-2 cells, an IL- 
dependent cell line. The data are represented as mean of 
samples with standard deviation. Statistical significance is 
given by asterisk: *p<0 . 0 1  compared with normal pregnant 
women.
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Figure 7.3 Production of immunoglobulins by lymphocytes
500 1000
IgG (ng/ml)
1500
250 
IgM (ng/ml)
500
□  Essential hypertension
□  PIH
■  Normal pregnancy
Immunologlobulins were secreted from PBMC stimulated by PWM 
after 7 day incubation. IgG and IgM were measured by ELISA. 
The data are represented as mean ± SD. Statistical significance is 
expressed as: *p<0.05 compared with normal pregnant women.
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7.4 Discussion
Although PIH and essential hypertension have the most important clinical feature in 
common, that is, high blood pressure, the cause of these conditions remains unclear. 
Recently, it has been suggested that a disorder of the endothelial cells may play an 
important role in the regulation of blood pressure and hence contribute to the 
development of both diseases in some similar and/or different ways (Tesfamariam & 
Halpem 1988; Koga et al. 1989; Roberts et al. 1989; Pinto et al. 1991).
Endothelial cells, which lie between the circulating blood and vascular smooth 
muscle cells, are a rich source of prostacyclin and other endothelium-derived 
relaxing factors (EDRF) (Moncada et al. 1977; Luscher 1988). The control of 
vascular function by the endothelium, however, proved to be more complex than 
anticipated as the cells not only release different vasodilator substances but also 
mediate contraction of the underlying vascular smooth muscle. Endothelium- 
dependent contractions are known to be elicited by a number of substances such as 
arachidonic acid, thrombin, acetylcholine, nicotine, norepinephrine and physical 
stimuli (quick stretch and pressure) (DeMey & Vanhoutte 1982; Harder 1987; 
Katusic et al. 1987; Katusic et al. 1988; Shirahase et al. 1988). Recently, 
immunological factors and antioxidant factors have also been suggested to mediate 
endothelial functions in several ways.
Activated polymorphonuclear leukocytes, monocytes and lymphocytes can adhere to 
endothelial cells and damage them by generating toxic substances such as ROS. In 
this microenvironment, the production of cytotoxic products derived from the 
metabolism of molecular oxygen, including superoxide anion, hydrogen peroxide, 
hydroxyl anion and hypochlorous anion, inevitably leads to an increase in vascular 
permeability and myocyte damage and a decrease in vasodilator substance (such as 
PGI2) production by the endothelium. Cytokines are mediators of the complex 
bidirectional interactions between leukocytes and vascular cells. Cytokines 
produced by activated lymphoid and mononuclear phagocytes elicit a complex 
spectrum of responses in endothelium. IL-1 is able to induce PGI2 production from 
endothelial cells (Rossi et al. 1985) and IL-1, IL-2 and TNF can cause endothelial 
cells to become markedly adhesive for leukocytes and lymphocytes (Cavender et al. 
1986; Cotran 1987). Furthermore, it has been documented that IL-2 therapy could 
prevent the development of hypertension and lower blood pressure to normotensive 
levels in hypertensive rats, though conflicting reports existed (Tutde & Boppana 
1990).
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In the present study, lymphocyte mitogenic activity and IL-2 production were found 
to be increased in patients with PIH but not in patients with essential hypertension, 
suggesting that in the pathogenesis of these two diseases cellular immunological 
factors may only be associated with the former but not with the latter.
It is well known that ROS can damage endothelium and conversely, antioxidants can 
prevent endothelial injury from ROS (For details see Chapter three). A decreased 
levels of antioxidants may indicate that the balance between pro-oxidation and anti­
oxidation is shifted to the former. Both PGI2 and EDRF are readily degraded by 
ROS (Prabha et al. 1990). In the present, series evidence of reduction in antioxidant 
levels was found in both PIH and essential hypertension though the types of 
antioxidants involved were somewhat different The levels of PSH was decreased in 
PIH while LSH remained unchanged. In contrast, the levels of PSH was unchanged 
and LSH was decreased in essential hypertension. The levels of GSH and MSH 
were similar in both diseases. Although the mechanisms underlying these differing 
changes is unknown, the findings indicate that antioxidant/ROS factors could be 
relevant to the development of hypertension in both diseases.
A common finding in patients with PIH or essential hypertension is an elevated level 
of IgG production. However, the significance of this change may be different for 
these two diseases. As elevated levels of autoantibodies to trophoblast antigens, 
amniotic glycoprotein, placental and renal antigens, and endothelial cells are evident 
in PIH (Rappaport et al. 1990; Sibai 1991) and increased lymphocyte mitogenic 
activity and IL-2 production have been found in PIH, the higher IgG production may 
reflect an increased B cell function in PIH and therefore represent the involvement of 
the humoral components of the immune system in the pathogenesis of PIH. In 
essential hypertension, there is evidence to suggest that elevated levels of IgG are 
secondary to vascular damage since immunologlobulin levels were highest after a 
vascular event (Kristensen & Soiling 1983). However, elevated immunoglobulin 
levels were also found in patients with essential hypertension who had not 
experienced a vascular pathology (Suryaprabha et al. 1984). Therefore, the 
possibility that humoral immunological factors are involved in the onset of essential 
hypertension cannot be excluded.
It has been reported that the levels of serum IgG correlated positively with blood 
pressure in essential hypertension (Kristensen 1978). However, no significant 
correlations were found between blood pressure and any immunological or
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antioxidant markers in this study. Therefore it is possible that there is no direct 
causal link between blood pressure elevation and the immunological or antioxidant 
factors tested in this study.
7.5 Conclusions
Although both PIH and essential hypertension in pregnant women have similar 
clinical features, the mechanisms underlying them are different Immunological 
factors might be involved in the pathogenesis of PIH, but it is unlikely that this is the 
case of essential hypertension. Antioxidant changes are seen in both diseases.
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CHAPTER EIGHT FINAL DISCUSSION
This study like other previous ones suggests that the cause of PIH is multifactorial. 
The immune system changes, ROS, eicosanoids and genetic factors all may have a 
role in the development of this disorder.
The occurrence of PIH in abdominal and molar pregnancies indicates that uterine 
and fetal factors are not required (Page 1939; Rote 1985). Two areas of direct 
contact between the mother and fetus are thus located: the syncytiotrophoblast, 
bathed by maternal blood, and the extravillous cytotrophoblast within the decidua. 
Trophoblastic cells are heterogeneous. They express paternal antigens, and these 
antigens can elicit a graft rejection response (Toder et al. 1982; Foglia et al. 1986). 
Furthermore fetal antigens may circulate in the maternal circulation as early as the 
18th week of gestation (Beer 1988). On the other hand, trophoblast supernatant can 
suppress mononuclear cell transformation (Silver et al. 1990). The ability of the 
first-trimester trophoblast to inhibit maternal T-cell proliferation and the balance 
between the fetal antigenic load and maternal blocking antibodies may contribute 
directly to fetal survival and it is also believed that they may play an important role 
in triggering the abnormal immunological characteristics seen in PIH, such as an 
increased cellular immunity and an excess production of autoantibodies (For details 
see Chapter 2).
Because immunological responses are determined genetically, genetic predisposition 
also appears to be one of the major contributing factors to the development of PIH 
(Kilpatrick et al. 1987 & 1989a; Amgrimsson et al. 1990). A delicate balance 
between the maternal immune responses and the fetal genotype may regulate the 
process of trophoblastic invasion that is necessary for normal placentation. A 
disturbance in this balance by either maternal or fetal factors may preclude the 
normal hypertrophy of placental arteries in synchrony with the growing uterus (poor 
placentation) (Robertson & Khong 1987; Roberts et al. 1989). Under these 
circumstances, stretching and tension on the placental artery will produce lesions of 
the arterial wall, initiating biochemical maladaptations in the maternal vasculature. 
These changes include a decreasing PGI2 production, platelet aggregation and 
overproduction of TXA2 (Friedman 1988). Other maladaptational changes involve 
the renin-angiotensin-aldosterone system and the kallikreikinin system (Hanssens et 
al. 1991). These changes would be followed by placental hypoxia, leading through a 
chain of events to the development of PIH.
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Endothelial cell injury and altered endothelial cell function play an important role in 
the pathogenesis of PIH. The damaged vascular endothelium expresses antigens that 
make these cells themselves an immunological target Antibodies to human vascular 
endothelial cells are present in PIH (Rappaport et al. 1990). Binding of these 
antivascular endothelial cell antibodies and immune complexes to resting endothelial 
cell monolayers may be involved in altered PGI2 secretion, increased platelet 
adherence, activation of the complement cascade, and disruption of the monolayers. 
A cytotoxic circulating factor also contributes to human endothelial cell injury 
(Rodgers et al. 1988). In addition, mitogenic activity is increased in predelivery 
blood obtained from PIH patients (Musci et al. 1988). It has been hypothesized that 
this increase in mitogenic or growth factor activity was a result of the direct release 
of mitogens from injured endithelial cells or from platelet activation by perturbed 
endothelium (Musci et al. 1988; Taylor et al. 1990).
Reactive oxygen species (ROS) and antioxidants may establish the link between the 
immunological mechanisms and the injury of endothelial cells in PIH. 
Immunological maladaptation can result in placental hypoxia and activation of 
leukocytes both of which are capable of inducing ROS formation and reducing 
antioxidant ability (Babior 1978; Flamm et al. 1978; Granger et al. 1981; Kogure et 
al. 1982; Marietta 1989). In addition, the active arachidonic acid metabolism seen in 
PIH is also a promoting factor in ROS production (Miyamoto et al. 1976; Ogino et 
al. 1978). The ROS are well known to be cytotoxic to cells by oxidative conversion 
of membrane unsaturated fatty acids and damaging protein and nucleic acid (Wolff 
et al. 1986; Wispe & Roberts 1987; Schraufstatter et al. 1988). In PIH, both the 
immunological maladaptation and the hypoxic environment occur subsequently in 
the placental vascular bed and thus set the stage for the imbalance of increased ROS 
formation and damaged antioxidant levels which lead to the endothelial cell injury. 
Increased ROS can also (1), change the pattern of prostaglandin production in favour 
of TXA2 synthesis (Moncada et al. 1976; Salomon et al. 1978; Wang et al. 1992; 
also see chapter 3 & 4); (2), inactivate EDRF (Gryglewski et al. 1986); (3), cause a 
decrease in endothelin levels (Dekker et al. 1991). Although, it is believed that 
increased ROS formation results from immunological abnormalities and placental 
hypoxia, other mechanisms may also have a role to play. The normal CuZn-SOD 
gene structure and expression indicates that reduced SOD activity may not be 
primary event (see Chapter 6 ). However, this does not exclude the possibility that 
genetic factors may associated with other antioxidant agents. Indeed, the incidence 
of PIH is higher in a Norwegian family in whom there is a failure of the NADH 
ubiquinone oxidoreductase step in the mitochondrial electron chain (Torbergsen et
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al. 1989), still giving a suggestion that there could be a genetic factor in imbalance of 
ROS and antioxidants found in PIH.
Hypothesis
Extensive moiphological and physiological changes take place in the uteroplacental 
vasculature which is necessary for the development of hemochorial placentation, 
characteristic of human pregnancy. A low-resistance, low-pressure, high-flow 
placental vascular system is therefore developed (Ramsey & Donner 1980). These 
vascular changes are thought to be induced by the interaction of the fetal-derived 
trophoblasts with maternal tissues at the time of implantation. In PIH, 
immunological maladaptation results in poor placentation in which the endovascular 
system remains a non-pregnant architecture and fail to dilate (Robertson & Khong 
1987). The proposed abnormal maternal immunological activity and the placental 
hypoxia may induce an imbalance of increased ROS formation and decreased 
antioxidant levels. ROS are probably produced by various leukocytes and other local 
cells and they can not only impair endothelial cells but also directly cause 
vasoconstriction (Gryglewski et al. 1986; Katusic & Vanhoutte 1989). The antigens 
on the damaged endothelial cells may be attacked by the immune system. Such 
alterations can cause the imbalance of increased TXA2 production and decreased 
PGI2 formation, damage other vasodilators such as EDRF and endothelin, and 
probably lead to the release of lipoxygenase products. These changes, in turn, result 
in the clinical and laboratory signs of PIH (Figure 8.1).
As the story unfolds, it is becoming apparent that endothelial dysfunction is the final 
common pathway in the aetiology and pathogenesis of PIH. However, there are 
some critical questions remain to be answered. What is the exact role of the 
trophoblasts in PIH? Does a genetic factor have a role to play in the development of 
PIH? What is the nature of the special circulating factor(s) in PIH? And where do 
they come from? Definitive studies of this disorder are urgently needed if we wish 
to diminish this leading cause of maternal morbidity and mortality, intrauterine 
growth retardation, and perinatal morbidity and mortality.
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